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Abstract 
Dietary supplementation with fibre has been shown to ameliorate features of the metabolic 
syndrome and inhibit malignant growth in certain types of cancer. These effects have been 
linked to short-chain fatty acids (SCFA), mostly acetate. However, the ubiquitous role of 
SCFAs in metabolism, combined with a short tissue half-life and the non-targeted nature of 
oral and peripheral administrations make achieving phenotypically relevant levels of SCFA 
by standard delivery techniques challenging and limit their therapeutic potential. Liposomal 
encapsulation of a therapeutic agent overcomes these issues by protecting against 
degradation, increasing circulation time and passively targeting both the liver and tumour 
tissue.  
 
In this research project, I have designed a bifunctional liposome formulation to transport 
SCFA, monitored their distribution and uptake utilising visualisation by MRI, PET/CT and 
fluorescence microscopy. These bifunctional liposomes were useful for effectively 
encapsulating small molecules within their aqueous core, which in this case was acetate, 
and capable of acetate delivery into cells while also being amenable to cellular imaging. I 
have shown that preferential delivery of liposome encapsulated acetate (LITA) nanoparticles 
to key sites of metabolic control provide beneficial therapeutic effects in animal models of 
both obesity and cancer. Chronic administration of LITA nanoparticles in an obeseogenic 
model led to a significant reduction in adiposity, intrahepatocellular lipid, inflammatory tone 
and genetic indication of a decrease fatty acid synthesis in the liver. Application of LITA in a 
murine xenograft model caused an inhibition of tumour growth in three colorectal cancer cell 
lines: HT-29, HCT116 p53+/+ and HCT116 p53-/-. The mechanisms for these two outcomes 
are not fully defined; however cellular energy homeostasis of both scenarios was restored. 
These results indicate that LITA nanoparticles can be used to improve multiple metabolic 
pathways, in vivo. 
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1.1 Introduction 
Cellular metabolic dysregulation is a central premise in the development of many chronic 
diseases including obesity and cancer [1,2]. Central to this effect appears to be the 
mitochondrion, either through decline in function or simply a reduction in number and 
mitochondrial mass [3,4]. These effects compromise not only the metabolic fluxes 
associated with these cellular organelles, but also appears to affect the ability of cells to 
manage changes in redox and reactive oxidation species (ROS) production [5, 6]. Due to the 
increased rates of obesity and corresponding problems associated with metabolic 
disequilibrium, there is an urgent demand for interventional therapeutic strategies. The 
desired response to an obese state is typically focused on diet and exercise, however these 
have been shown to be unsustainable in the long-term [7]. Although bariatric surgery has 
arisen as a potential long-term solution to the obesity problem, it is not applicable to the 
general population, it is costly and not without clinical complications [8]. Recently, there has 
been renewed interest in the potential of metabolic engineering, through the use of small 
molecules, to achieve metabolic retransformation of abnormal cells and tissues [9-11]. 
However, making sufficient and sustained metabolic impact though such methods can be 
difficult, since a suitable small molecule(s) needs to be identified and an appropriate mode of 
delivery. This clearly requires a new approach if we are to tackle the challenge of metabolic 
dysregulation in vivo. 
 
1.2 The obesity pandemic 
Obesity is a major growing health concern affecting people in both developed and 
underdeveloped nations. Estimates from the World Health Organization in 2010 stated that 
1.5 billion adults today (around 35% of the world’s population) are thought to be overweight 
or obese. Obesity occurs because of a positive energy balance, whereby over nutrition 
exceeds the energy expenditure [12].  
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A key feature of obesity, the metabolic syndrome (MS), represents a common clinical 
condition in countries with high incidence of obesity and western dietary patterns [13]. MS is 
a cluster of medical disorders that, when simultaneously occurring, increase the risk for 
developing type II diabetes, insulin sensitivity, elevated triglyceride levels, cardiovascular 
disease, hypertension, lipotoxicity, inflammation and some types of cancer [12,14].  
 
 
Energy homeostasis is the multi-system balance in energy intake by feeding and energy 
expenditure by physical activity, basal metabolic rate and adaptive thermogenesis [15]. 
Energy intake is primarily partitioned towards homeostatic energy expenditure with excess 
nutrients being stored in the form of triglycerides (TGs) in white adipose tissue (WAT). In 
some circumstances this deposition of TGs extends to ectopic tissue including liver, 
pancreas and skeletal muscle [16].  
 
1.3 Adiposity  
Modern Western lifestyle is associated with chronic exposure to excess intake of 
carbohydrates and lipids and reduced physical activity [17]. Following digestion, lipids are 
stored as neutral triglycerides in cells known as adipocytes which increase in size in 
response. In a balanced environment, TG storage during energy intake is offset by fat 
mobilisation during fasting or situations with elevated energy demands [18-21]. However, in 
an obese state the storage of TGs is the predominant behaviour of adipocytes. One of the 
primary compensatory responses, to obesity-induced excess TG storage, is the enlargement 
of adipocytes (hypertrophy). When hypertrophic adipocytes exceed their fatty acid (FA) 
storage capacity, lipids are then stored in other tissues leading functional impairment [22].  
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 Adipocytes are an important component of adipose tissue which also contains connective 
tissue, nerve fibres, vascular cells, lymph nodes, immune cells fibroblasts and preadipocytes 
[23]. Adipose tissue not only responds to sensory signals from traditional hormone systems 
but also expresses and secretes factors with important endocrine functions [24]. Adipose 
tissue is divided into specific regional depots with differences in structural organisation, 
cellular size and biological function [25]. The specific location and distribution of adipose 
tissue within the body is an important factor when defining the health risks of obesity.  
 
 
1.3.1 Differential Roles of Fat Depots 
In humans, body-fat can be found throughout the body and although its constitutive cells 
(adipocytes) are the same across the body, body-fat appears to be arranged in distinctive 
depots, with location-specific functions, yet working in coordination with each other [26-28]. 
A list of body-fat depots identified in humans includes subcutaneous, internal, gluteofemoral, 
‘visceral’, intermuscular and pericardial [29]. It should be noted that there are numerous 
subdivisions of body-fat, with some scientists basing their classification purely on anatomical 
location; with others insisting that body-fat depots should be classified solely on metabolic 
basis [30, 31]. What is important to note is that there is large variability in body-fat 
distribution across the human population and that this confers different effects on metabolic 
health. 
 
1.3.1.1  Subcutaneous adipose tissue 
Subcutaneous adipose tissue (SAT) is found underneath the skin in the femerogluteal 
regions, back and anterior abdominal wall and interspersed in skeletal muscle [32]. SAT is a 
key depot for fat storage in periods of excess energy intake and energy supply in periods of 
fasting, starvation, or exercise. SAT also appears to act as a buffer during intake of dietary 
lipids, thereby protecting other tissues from lipotoxic effects [33].  
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1.3.1.2  Visceral adipose tissue  
Visceral adipose tissue (VAT) is located in the abdominal cavity and surrounds the internal 
organs. VAT is highly associated with disturbances to lipid metabolism, insulin resistance, 
diabetes, inflammation, hypertension and cardiovascular disease [34, 35]. VAT mass 
correlates with the development of insulin resistance, while total or subcutaneous tissue 
does not [36-38].  
 
1.3.1.3  Intra-hepatocellular fat 
Intra-hepatocellular fat is located within the liver and is deposited when triglycerides, derived 
from circulating FAs upon insulin resistance (IR)-induced dysregulation of peripheral 
lipolysis, accumulate in the liver cells [39]. Accumulation of lipids leads to a reversible 
condition known as fatty liver and may be accompanied by progressive inflammation, 
fibrosis, cirrhosis and hepatocellular carcinoma [40].  
 
 
1.3.1.4  Brown adipose tissue 
The largest region of brown adipose tissue (BAT) is found in the upper back region of 
rodents (interscapular). In humans, small areas are found in the thorax region 
(supraclavicular) and abdomen [41]. The primary function of BAT is to generate body heat in 
a nonshivering form. There are indications that the nonshivering heat generation provided by 
this depot plays a role in the development of obesity [42]. Although adult humans possess 
only a small percentage of BAT compared to WAT has been shown to be negatively 
correlated to obesity. Active BAT is known to be able to increase energy expenditure, thus 
the possibility to pharmacologically increase BAT amount or activity would be a potential 
treatment for obesity [43, 44].  
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1.3.2 Monitoring of adipose tissue 
There are a number of methods for estimating relative body adiposity, of which measuring 
the body mass index (BMI; weight divided by height squared) is the gold standard and most 
widely used. There is a strong correlation between BMI and overall bodyweight, however a 
substantial number of publications report limitations to this technique when taking athletes 
and different ethnic groups into consideration [45-47]. Another method of estimating overall 
obesity is through the method of waist circumference, which is commonly used as a proxy of 
abdominal obesity [48-50]. These indirect methods of body composition analysis cannot 
determine the distribution profile of visceral adipose tissue, thus the need to accurately 
phenotype an individual is carried out by non-invasive imaging techniques. These common 
techniques, such as magnetic resonance imaging (MRI) and magnetic resonance 
spectroscopy (MRS), enable the measurement of regional adipose content, in addition to 
liver, pancreatic and muscle fat can be obtained [51].  
 
 
1.4 Liver Metabolism  
The liver is the metabolic centre of the body and is located between the absorptive surfaces 
of the gastrointestinal tract where it performs a key role in many pathways involved with 
nutrient homeostasis such as carbohydrates, lipids and proteins [52-55]. It is also the main 
detoxifying organ and the only site where molecules such as bile, clotting factors and other 
serum proteins are synthesised [56]. The central role of the liver in controlling carbohydrate 
and lipid homeostasis makes it particularly vulnerable to the effects of the overall metabolic 
state of the body [57].  
 
 
The liver governs energy homeostasis by its ability to metabolise glucose, fatty acids and 
controlling overall lipid circulation. During periods of fasting, an adequate supply of glucose 
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to the tissues is orchestrated by the liver through breakdown of glycogen stores within 
hepatocytes (glycogenolysis) and de novo synthesis (gluconeogenesis) [58]. In the fed state 
glucose is derived principally from the diet stimulating insulin release, which in turn promotes 
glucose uptake by different tissues, inhibits liver gluconeogenesis and lipolysis in adipose 
tissue. In some physiological conditions, free fatty acids (FFAs) released from adipose tissue 
are known to contribute to central and peripheral insulin resistance through their 
accumulation in skeletal muscle and liver. Additionally, there are fat-derived signals, 
including tumour necrosis factor-α (TNF-α), resistin and adiponectin, which modulate insulin 
sensitivity and fatty acid metabolism in muscle and liver [59]. This complex system to control 
lipid and glucose homeostasis is shown in Figure 1.1. 
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Figure 1.1 The central role of the liver in Glucose and Lipid Homeostasis 
An overview of the central role of the liver in energy homeostasis. Glucose derived from diet 
(intestine) or endogenous sources (liver) stimulates insulin secretion, promoting glucose 
uptake by skeletal muscle and fat. Glucose uptake opposes hepatic glycogenolysis and 
gluconeogenesis, and inhibits fat lipolysis. Free fatty acids liberated from adipose tissue (via 
lipolysis) contribute to insulin resistance in skeletal muscle and liver. Additional fat-derived 
signals, including TNF-α, resistin and adiponectin, modulate insulin sensitivity and fatty acid 
metabolism in muscle and liver. Green arrows depict an increase in activity, whereas the red 
arrows depict a decrease in activity. Figure from Evans R et al., 2004. 
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1.4.1 Altered liver function in the obese state 
Hepatic metabolism helps maintain nutrient homeostasis throughout the body. The individual 
steps in hepatic metabolism are orchestrated by a delicate interplay of hormones, nuclear 
receptors, intracellular signalling pathways and transcription factors (Figure 1.6). 
Dysregulation of nutrient metabolism is a key step during the process of chronic liver disease 
that induces an inflammatory state, cellular damage, and impaired hepatic insulin signalling 
leading to insulin resistance. Insulin resistance causes an increase in lipolysis and failure to 
supress glycolysis and gluconeogenesis in the liver. Furthermore, increased uptake of FAs 
and glucose causes progressive deposition of triglycerides leading to hepatic steatosis [60]. 
De novo lipogenesis (DNL) further contribute to hepatic steatosis [61], and hepatocytic lipid 
accumulation predisposes to overproduction of ROS, endoplasmic reticulum (ER) stress and 
lipotoxicity [62-64]. Fabbrini et al. have further suggested that increased liver fat is an 
independent indicator of multi-organ insulin resistance and postulate that the observed 
relationship between increased visceral fat and metabolic disease is essentially a 
confounding factor due to the correlation between visceral and liver fat [65]. More recently, 
Magkos et al. have shown that increased adiposity, without an increase in liver fat, does not 
cause abnormalities in adipose tissue, skeletal muscle and hepatic insulin sensitivity, or very 
low-density lipoprotein (VLDL) metabolism [66]. 
 
 
Intra-hepatocellular lipid content (IHCL) is an accumulation of lipid within the hepatocytes 
thus increasing the availability of fatty acids and inflammatory adipokines to the liver. In turn, 
the resulting accumulation of IHCL is associated with metabolic syndrome risk factors and 
progress to the more severe liver diseases such as non-alcoholic fatty liver disease 
(NAFLD). NAFLD is the most common liver disease in Western society [56, 67] and is 
characterised by lipid accumulation within hepatocytes and may progress to non-alcoholic 
steatohepatitis (NASH), the extreme form of NAFLD and is regarded as a major cause of 
cirrhosis of the liver [68]. These triggers of inflammation in the liver can however be 
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positively modulated by the anti-inflammatory markers. One in particular, adiponectin, has 
been shown to lower adiposity in liver [69, 70]. 
 
 
In order to investigate the effects of obesity, a robust model must be established in vivo. 
Recent studies have shown that diet-induced-obesity (DIO) murine models can provide a 
good platform for the study of NAFLD and NASH [71]. Rodents fed on high fat diet have 
increased inflammation, oxidative stress and lipogenesis and also display a increase in 
adiponectin concentrations, which then progress to insulin resistance, obesity, steatosis, 
steatohepatitis and fibrosis [71]. In a study by Xu et al., high fat feeding of animals caused 
elevated concentrations of glucose, insulin, FFAs, TGs, TNF-α and finally liver steatosis [72].  
 
1.4.2 Monitoring of Liver Fat 
Measurement of ectopic fat, especially liver fat, has become an important goal in light of the 
previous discussion. The lipid content of the liver can be evaluated by a number of invasive 
and non-invasive methods [73]. Until recently, needle biopsy, in combination with electron 
microscopy and oil staining, was the most commonly used technique and considered the 
golden standard for monitoring lipid accumulation in the liver. This technique has limited 
application in tissues such as the heart and pancreas and has practical and ethical issues 
even when applied to the liver, making it incompatible with longitudinal studies as it can 
cause bleeding and inflammation. Today, the advent non-invasive imaging techniques, 
including computerized tomography (CT), magnetic resonance spectroscopy (MRS) have 
revolutionized the study of ectopic fat. Both MRI and MRS allow for a fast and reproducible 
quantitative measurement of adipose tissue and ectopic fat, including the liver, pancreas, 
heart and skeletal muscle (Figure 1.2). Whereas MRI provides quantitative information about 
adipose tissue, 1H MRS has become the gold-standard for assessing lipid content of liver 
[51,74, 75].  
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Figure 1.2 Localisation and monitoring of Ectopic Fat Accumulation 
Measurement of fat content by 1H-magnetic resonance spectroscopy. Transverse magnetic 
resonance images were taken through the abdomen to identify the liver and pancreas, and 
the lower leg to identify soleus and tibialis muscles. Voxels were placed in the organ of 
interest avoiding bone, blood vessels and obvious fatty streaks. 1H-magnetic resonance 
spectra were obtained in approximately 2 min from (a) the liver, (b) pancreas and (c) soleus 
muscle. Figure from Thomas EL et al., 2012. 
 
 
1.4.3 Lipotoxicity and Inflammation 
Lipotoxicity is a metabolic condition that results from excess FFA accumulation in non-
adipose tissue and has a harmful effect on the organelles within the cell, particularly the 
mitochondria, reducing their capacity to orchestrate lipid metabolism [76]. 
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Chronic inflammation is widely observed in the obese state and commonly has many 
elevated markers of inflammation [24]. One recent study conducted by Zhang et al. in mice 
showed that consuming a high fat diet (HFD) induces an inflammatory response that 
precedes the development of obesity; however, by pharmacologically preventing this 
inflammatory response, there was a protection against weight gain [77].  
 
In addition to being a storage site for triglycerides, adipocytes produce and secrete a number 
of these markers of inflammation and endocrine hormones, such as leptin, adiponectin, 
resistin, TNF-α and interleukin-6 (IL-6) [78]. Adipocytes regulate both hormonal (such as 
insulin) and sympathetic (such as adrenergic) stimulation [79]. Adipose tissue has also been 
shown to have macrophage infiltration as a result of obesity [80]. Figure 1.3 shows the pro- 
and anti-inflammatory adipokines released by adipose tissue in healthy and obese states 
[81]. 
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Figure 1.3 Modulation of Adipose Tissue with Obesity 
Adipose tissue changes its morphology with increased obesity which can be categorised into 
three distinct phenotypic groups; lean with normal metabolic function, obese with mild 
metabolic dysfunction and obese with full metabolic dysfunction. As obesity develops 1) the 
adipocytes gets bigger due to increased storage of triglycerides, 2) the number of 
macrophages increases, 3) the vasculature decreases relative to tissue size and 4) anti-
inflammatory adipokines are replaced with pro-inflammatory adipokines. In obese adipose 
tissue with full metabolic dysfunction crown like structures are seen which are macrophages 
circling around the necrotic adipocytes. Figure from Ouchi et al., 2011. 
 
 
1.4.4 Mitochondria 
Mitochondria are double-membrane bound organelles that play a critically and relevant role 
in energy homeostasis, metabolism, apoptosis, regulation and cell viability [82]. Mitochondria 
are prominently responsible for generating most of the chemical energy utilised by cells 
known as adenosine triphosphate (ATP), through respiration, and to regulate cellular 
metabolism [83]. The primary set of reactions involved in ATP production is collectively 
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known as the tricarboxylic acid cycle (TCA cycle) or the Krebs cycle. In addition to ATP 
production, mitochondria maintain key metabolic processes such as lipolysis, glycolysis, fatty 
acid β-oxidation, ketogenesis and fatty acid synthesis. Figure 1.5 shows an overview of the 
numerous mitochondrial pathways involved in energy homeostasis. In addition, the 
mitochondria generate intermediates for biosynthesis and reactive oxygen species (ROS) 
that serve as a secondary messenger to mediate signal transduction and metabolism. This 
balance is maintained through normal mitochondrial function matching oxidative 
phosphorylation (OXPHOS) and dissipation of the proton gradient [84].  
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Figure 1.4 Bioenergetic Functions of Mitochondria 
This simplified diagram displays the critical bioenergetic circuitries that mitochondria host. 
These pathways include the tricarboxylic acid (TCA) cycle, or Krebs cycle, glycolysis, 
oxidative phosphorylation, the urea cycle, β-oxidation, and ketogenesis. Mitochondrial 
compartmentalisation provides optimal microenvironment for these and other biosynthetic 
and catabolic pathways to coincide. Several intermediate reactions and all transporters have 
been omitted for clarity. Figure adapted from Gulluzzi, Lorenzo et al., 2012.  
 
 
Several characteristics make mitochondria a very unique organelle. One such example is the 
variable concentration of mitochondria present in specific tissue types. In particular, BAT has 
a high concentration of mitochondria per lipid droplet, in order to maintain body heat, which 
makes the tissue itself appear brown [85]. The mitochondria are also densely populated in 
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liver cells, due to the greater demand for ATP [86]. Mitochondrial content of otherwise similar 
cells can vary substantially and can affect the central function of the cell through the 
prominent role of energy production. Observations that the number of mitochondria in 
adipose tissue from obese people is reduced, suggests that impaired mitochondrial activity 
could cause a predisposition to obesity. In addition, studies have shown that mitochondria 
biogenesis is also altered in obesity [87].  
 
Given the diverse array of unique metabolic functions centralised in the liver, an energy 
imbalance could cause impairment of mitochondrial function. One consequence of hepatic 
lipid accumulation, or “fatty liver”, is increased mitochondrial fat oxidation without 
compensatory electron transport chain activity, leading to “stressed” mitochondria and the 
production of ROS [88]. These events are thought to play a pivotal role in the subsequent 
development of inflammation and lipotoxicity, creating an aberrant cellular environment 
which contributes to NASH, hepatic fibrosis and cirrhosis [63]. 
 
In summary, it is widely accepted that the liver is a central organ in lipogenesis, 
gluconeogenesis and cholesterol metabolism and that these functions can be considerably 
compromised in obesity. As observed recently, a variety of pathological conditions 
highlighted the importance of metabolic functions within the liver. An increase in the 
prevalence of obesity and the metabolic syndrome promotes pathophysiological changes 
that cause NAFLD and may lead to cirrhosis and NASH. Alteration in insulin response, beta-
oxidation, lipid storage and transport, autophagy and an imbalance of inflammatory markers 
are held accountable for these changes. Figure 1.6 shows the key metabolic pathways that 
regulate hepatic metabolism, specifically, the cross talk between lipid metabolism and 
mitochondria and in both the healthy and unhealthy state. 
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Figure 1.5 Hepatic Lipid Metabolism in Health and Disease 
In a healthy hepatocyte (A) free fatty acids (FFA) are actively taken up by various fatty acid 
(FA) transporters under the control of insulin and nuclear receptor signalling and are 
oxidized in the mitochondrially, providing ATP for the TCA cycle. Under fatty liver conditions 
(B) increased peripheral lipolysis, upregulation of fatty acid transporters, an increase in de 
novo lipogenesis (DNL) and a reduction in mitochondrial β-oxidation promote fatty acid 
toxicity and the release of reactive oxidation species. This leads to the induction of 
hepatocyte apoptosis, the invasion of activation of inflammatory cells and fibrogenesis. 
Figure from Bechmann et al., 2012.  
 
 
1.5 Dietary Fibre and Obesity 
The World Health Organization has suggested that a diet consisting of a high level of 
indigestible carbohydrates could improve the health state of an individual by weight loss or 
improving overall health [89]. Dietary patterns that include fruit, vegetables and whole grains 
are recommended. Carbohydrates can be classified into two main groups; digestible 
(A
)  
(B
) 
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(soluble) or indigestible (insoluble, or resistant) depending where in the gastrointestinal track 
they are digested[90]. Dietary intervention studies have shown that a diet consisting of high 
levels of indigestible carbohydrates reduces blood glucose levels, body weight and body fat 
content [91]. Increased dietary fibre consumption have also been associated with a reduction 
in cancer occurrences, specifically colorectal cancer [92-94]. Early observations concerning 
the metabolic differences between cancer and normal cells were made by Otto Warburg, 
who showed that cancer cells are inherently dependent on glycolysis for production of 
chemical energy [95]. There is now mounting evidence that this increased glycolysis results 
from the influence of multiple molecular pathways, including adaptive responses to the 
hypoxic tumour microenvironment, oncogenic signalling, and mitochondrial dysfunction[96-
98]. The glycolytic phenotype offers growth advantages to cancer cells by resisting 
apoptosis, and facilitating tumour spread and metastasis [99]. It has been suggested that 
microbial fibre fermentation maybe important in relation to fibre intake and colon cancer 
prevention[100]. Thus, the inverse relationship between dietary fibres and the development 
metabolic syndrome and some forms of cancer raises interest into the bioactive components 
of dietary fibres [101-104]. The mechanisms responsible for this observation are still unclear, 
however several modes of action have been proposed [105-107]. One such mechanism that 
has attracted particular attention in recent years is the potential role that some of the by-
products of the fermentation of the resistant dietary fibre, principally the short-chain fatty 
acids, may have on metabolic dysfunction in the liver and adipose tissue [108-111] . 
 
 
1.5.1 Short- Chain Fatty Acids 
Short-chain fatty acids (SCFA) are a sub-group of fatty acids that are produced by the 
microbiota in the colon and the distal small intestine from resistant starch (RS), dietary fibre 
and other low-digestible polysaccharides during fermentation. Microbial fermentation of 
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these dietary products yields three main SCFA: acetate, propionate and butyrate as 
significant end products [112, 113]. Their molecular structure is shown in Figure 1.6. 
 
 
 
 
 
Figure 1.6 Molecular Figure Structures of Short- Chain Fatty Acids 
The three main short-chain fatty acids fermented by the microbiota in the colon: acetate, 
propionate and butyrate. Figure from Al-Lahham et al., 2010. 
 
  
The rate of fermentation of fibre varies according to type and food source; e.g. fibre derived 
from grains is fermented much more slowly and less completely than that from fruits and 
vegetables [114]. The ratio of SCFA produced by fermentation may vary, depending on the 
source and type of dietary fibre. In the large intestine the concentrations of acetate, 
propionate and butyrate is approximately 60, 20 and 20 mmol/kg [115]. SCFAs produced in 
the colon are absorbed by colon mucosal cells, play a significant role in maintaining the 
normal physiological function of the colonic mucosa, normal bowel function and prevent 
pathology through their actions in the lumen and on the colonic musculature and vasculature 
and through their metabolism by colonocytes [116]. After SCFAs are absorbed by the colonic 
mucosa, they pass through the colonic wall and are absorbed and transported via the portal 
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vein to the liver, and the fraction not absorbed is distributed into the general circulatory 
system to other organs and tissues for metabolism [117]. 
 
 
The concentration of SCFA in peripheral circulation is directly correlated with the intake of 
resistant starch [118]. SCFAs have been shown to have effects in different parts of the body. 
Butyrate has been shown to be the preferred energy source of the colonocytes, over 
propionate and acetate, in a ratio of 90:30:50 [119, 120]. Acetate and propionate are also 
utilised by colonocytes; remaining propionate and acetate is metabolised in the liver, with 
some acetate consumed by peripheral tissues, where they are substrates for 
gluconeogenesis and lipogenesis [121, 122]. 
 
 
The mechanism by which SCFA is absorbed in the lumen is unknown. The effects of SCFA 
in the intestinal lumen are potentially induced via the activation of specific receptors and/or 
via absorption in epithelial cells. In 2003, two research groups independently identified that 
SCFAs with 1-6 carbons atoms, such as acetate, propionate and butyrate are a natural 
ligand of the G-protein-coupled receptor 41 and 41 (GPR41 and GPR43) [123, 124]. Both 
receptors decrease adenylyl cyclase concentrations in cells and increase Ca+2 
concentrations. The receptors exert their functions by coupling with Gi/o and/or Gq; GPR41 
with Gi/o and GPR43 with both. It has also been shown that acetate is less potent to GPR41 
than propionate and butyrate and GPR43 is activated similarly by the three SCFAs [123]. 
Figure 1.7 provides an overview for SCFA uptake and absorption. 
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Figure 1.7 Short- Chain Fatty Acid Uptake and Absorption 
Complex carbohydrates, such as dietary fibre that are resistant to amylase digestion, are 
metabolized by the colonic microbiota to oligosaccharides and monosaccharides and then 
fermented to short-chain fatty acid end-products, mainly acetate, propionate and butyrate. 
Short-chain fatty acids are absorbed in the colon, where butyrate provides energy for colonic 
epithelial cells, and acetate and propionate reach the liver and peripheral organs, where they 
are substrates for gluconeogenesis and lipogenesis. In addition to being energy sources, 
short-chain fatty acids control colonic gene expression by inhibiting the enzyme histone 
deacetylase (HDAC) and metabolic regulation by signalling through G-protein-coupled 
receptors (GPCRs), such as GPR41 or GPR43. Figure from Tremaroll & Backhed, 2012. 
 
 
Over the last two decades, the principle role of SCFA has evolved from a culprit in the 
pathogenesis of carbohydrate-induced diarrhoeas to a pluripotent benefactor of multiple 
epithelial functions. These beneficial metabolic effects include post-prandial satiety, 
reductions in fat mass, inflammation, stabilisation of blood glucose levels and thus 
improvements in insulin sensitivity [125-128]. Once absorbed, SCFAs are metabolized at 
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three major sites in the body: 1) cells of the caecum-colonic epithelium that use butyrate as a 
major substrate for maintenance-energy; 2) liver cells that metabolize residual acetate and 
propionate used for gluconeogenesis; and 3) muscle cells that generate energy from the 
oxidation of residual acetate [129]. In addition, 50% to 70% of acetate is also taken up by the 
liver and VAT and in response increases insulin sensitivity. Figure 1.8 shows an overview of 
the numerous physiological processes affected by SCFA uptake. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic representation of the effects of short-chain fatty acid  
SCFA are produced by the fermentation of undigested food by the colonic microbiota, 
passes the gut epithelium into the peripheral system and reduces the production and the 
release of FA from VAT and liver. Potentially this leads to an inhibition of inflammation and 
therefore to insulin sensitivity. As a result of SCFA influences of the production of hormones 
by VAT and liver, the endo-, para- and auto-crine and neuronal pathways (via vagus and 
splanchnic nerves) are initiated to reduce food intake and to influence other metabolic 
effects. Figure adopted from Al-Lahham et al., 2010. 
 SCFAs 
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1.5.2 Acetate Formation and Metabolism 
Acetate is critical to all forms of life and is the most common building block for biosynthesis, 
playing a central role in cellular metabolism. When bound to coenzyme A, it is fundamental 
to the metabolism of carbohydrates and fats. Unlike longer-chain carboxylic acids (FAs), 
acetate or acetic acid do not occur naturally in triglycerides. Acetyl-CoA functions as 
intermediate in both the synthesis and breakdown of many organic molecules. Particularly in 
the mitochondria, acetyl-CoA is used to fuel the TCA cycle, which is a fundamental energy 
producing pathway in all aerobic organisms as well as producing the essential building block 
for biosynthesis of many molecules including FA and nucleotides [130]. Figure 1.9 shows the 
complex involvement acetate has is numerous pathways and functions. 
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Figure 1.9 Metabolic pathways for acetate via acetyl-CoA 
Different pathways by which acetate is utilised; the pyruvate- acetaldehyde- acetate pathway 
has vital roles in acetyl-CoA production. Mitochondrial acetyl-CoA supplied from the 
mitochondrion-associated pyruvate dehydrogenase complex or β-oxidation is used to 
replenish the mitochondrial tricarboxylic acid (TCA) cycle. Therefore, mitochondrial acetyl-
CoA is essential in the production of energy sources for the survival and normal growth of 
cells. cytosolic acetyl-CoA is an essential building block for the biosynthesis of fatty acids 
and numerous secondary metabolites. Acetyl-CoA carboxylase mainly controls fatty acid 
synthesis via malonyl-CoA production from cytosolic acetyl-CoA. Acetyl-CoA synthetase 
(ACS1 and ACS2) are highlight for Acetly-CoA converstion points. Figure from Lee, 
Seunghoon et al., 2011. 
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1.5.3 Epigenetic modifications 
Epigenetic modifications play a key role in the regulation of gene expression, the process by 
which information stored in a gene is used to synthesise a functional gene product [131]. 
Epigenetic modification can occurs at many levels (and forms) in the genome and 
associated components, from methylation of DNA to acetylation of histone proteins. The 
introduction of an acetyl group, most commonly in the form of acetyl-CoA, into a molecule is 
known acetylation. Acetylation occurs as a co- or post-translational modification of proteins, 
in particular histones. Histone acetylation is one mechanistic by which genetic transcription 
can be modulated, causing the chromatin on the DNA to expand. In turn, a deacetylation can 
take place, preventing gene transcription encouraging a balance. This equilibrium between 
acetylated and deacetylated states of histones is governed by two different sets of enzymes: 
histone acetytransferase (HATs) and histone deacetylase (HDAC) respectively [132]. Figure 
1.10 shows a simplified diagram of epigenetic mechanisms. 
 
 
Many small molecules have been identified as potential HDAC inhibitors (HDACi) [133, 134], 
one of these is the SCFA butyrate [135, 136]. Apparently the inhibitor activity of butyrate is 
not only important from a nutritional aspect[137] but may also have the potential to 
profoundly influence cell differentiation, proliferation and motility and inducing cell cycle 
arrest and apoptosis [138].   
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Figure 1.10 Schematic diagram of histone acetylation and deacetylation 
DNA winds around histone proteins and are acetylated by histone acetyltransferase (HATs), 
shown in teal, which causes the strands to loosen allowing for gene expression due to the 
presence of acetyl-CoA. Deacetylation of the histone proteins is caused by histone 
deacetylase (HDAC), which is shown in pink. Figure adopted from Yoshida, M et al., 2008. 
 
 
1.6 Obesity and cancer   
Obesity is an established risk and progression factor for many cancers, including breast 
[139] and colon cancer [140-142]. Multiple hormones, growth factors, cytokines, insulin, 
leptin and other mediators associated with the metabolic perturbations of the obese state 
enable crosstalk between macrophages, adipocytes, endothelial cells, other 
microenvironmental components, and epithelial cells. As shown in Figure 1.11, these 
obesity-associated factors contribute to cancer-related processes (including growth 
signaling, inflammation, vascular alterations, and several pathways associated with tumour-
initiating cell enrichment, invasion, and metastasis) [143, 144]. In particular, the relationship 
between obesity and colorectal cancer (CRC) has been a subject of interest as the 
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prevalence of obesity continues to increase [145, 146]. The presumptive link between 
obesity and CRC remains challenging, as other confounding factors may influence the 
development of CRC; however CRC is thought to be an obesity-related cancer and is 
therefore a reasonable line of cancer to use in this study. 
 
 
Figure 1.11 Metabolic Deregulation and Cancer 
Mechanistic overview of key biological mechanisms which correlate between obesity criteria 
and increased cancer risk. Figure from Hursting, S et al., 2012. 
 
1.6.1 Metabolic deregulation 
The relationship between obesity-related metabolic stresses and cancer are now well 
accepted. In 2000, Weinberg proposed, a series of six complex elements necessary for 
tumour development. These include uncontrolled cell growth, angiogenesis, replicative 
immortality, sustained proliferative signalling, evading growth suppressors and activating 
invasion and metastasis  [147]. Recently, altered cellular energy metabolism has re-emerged 
as a hallmark of cancer, leading to newfound efforts are directed at exploiting these 
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differences as biomarkers and therapeutic targets [148]. Understanding the relationship 
between metabolites in the tumour environment will advance the ability to characterise, treat 
and potentially prevent cancers and other diseases that have not been approached from the 
metabolic perspective. 
 
 
1.6.2 Warburg Effect 
The concept that tumours are metabolically different has grown to encompass other cellular 
pathways, such as fatty acid oxidation, glutamine metabolism and lipid biogenesis [149]. 
Fatty acid synthesis and lipid biogenesis are particularly active in proliferating cells due to 
synthesis of cell membranes [150]. This increased demand is, in part, met by an altered 
metabolic programme known as the “Warburg Effect” [95, 151]. This reliance of cancer cells 
on aerobic glycolysis was proposed in the 1920s by Otto Warburg, which led him to be 
awarded the Nobel Prize, despite the fact that for the next few decades it was mostly ignored 
by researchers working in the field of cancer. In recent years we have seen a renewed 
interest on the ‘Warburg Effect’, becoming a catalyst for investigations attempting to explain 
the biological relationship between cellular metabolites and cancer [152-154]. The alteration 
in tumour metabolism reflects a switch from oxidative phosphorylation to glycolysis, resulting 
in excess pyruvate and lactate production (Figure 1.12). This characteristic metabolic profile 
provides an opportunity to distinguish cancer cells from normal cells, a phenomenon that has 
been successfully exploited by the use of PET [155]. 
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Figure 1.12 Schematic representation of the Warburg Effect 
This figure outlines the differences between oxidative phosporylation, anaerobic glycolysis 
and aerobic glycolysis in normal and cancerous tissue. In the left panel the figure shows the 
normal, non-profilerating tissues generate pyruvate via glycolysis in the presence of oxygen. 
Essential for this process, oxygen is required for the final electron acceptor to completely 
oxidise glucose. When oxygen is limited, as in the right hand panel, cells redirect the 
pyruvate generated by glycolysis away from mitochondrial oxidative phosphorylation by 
generating lactate. This generation of lactate during anaerobic glycolysis allows glycolysis to 
continue (by cycling from NADH back to NAD+), but results in minimal ATP production when 
compared to oxidative phosporylation. Mitochondria maintain some level of oxidative 
phosphorylation in both cancer and normal cells, though aerobic glycolysis is less efficient 
than oxidative phosporylation for generating ATP (~36 mol ATP: 2 mol ATP). In normal 
proliferating cells, ~10% of the glucose is diverted into biosynthetic pathways upstream of 
pyruvate production. Figure from Heiden et al., 2009. 
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1.6.3 Randle hypothesis 
The interaction between glucose and fatty acid metabolism has been examined from a 
number of angles. The Randle cycle was proposed more than 30 years ago as a mechanism 
whereby products of lipolysis (fatty acids and ketone bodies) would inhibit glycolysis in 
normal cells to maintain stable ATP production [156, 157]. According to this mechanism, 
abundant acetyl-CoA causes feedback inhibition of pyruvate dehydrogenase and increases 
the level of TCA intermediates, specifically citrate, to inhibit phosphofructokinase, both of 
which reduce the rate of glycolysis (Figure 1.13). Although it has been pointed out that the 
Randle cycle has only been persuasively demonstrated in vitro, under the condition that 
intracellular glucose is fixed, the fatty acids availability is variable [158]. 
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Figure 1.13 Schematic diagram of the Randle cycle 
The Randle cycle demonstrates the interaction between glucose uptake, metabolism and 
consequent inhibition and effects of fatty acid oxidation on the inhibition of glucose 
utilisation. Glucose enters the cell and the reaction of glycolysis drives the carbon atoms to 
pyruvate where they are oxidised at acetyl-CoA (shown in red). The fate of acetyl-CoA is 
complete oxidation in the TCA cycle or return to the cytosol via citrate for conversion back to 
acetyl-CoA and subsequent long-chain fatty acid via malonyl-CoA. The synthesis of malonyl-
CoA is catalyzed by acetyl-CoA carboxylase (ACC) and once produced will inhibit the import 
of long-chain fatty acyl-CoAs (LCFacyl-CoA) into the mitochondria via inhibition of carnitine 
palmitoyltransferase 1 (CPT-1). This effectively blocks the oxidation of fatty acids leading to 
increased triacylglyceride synthesis. 
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1.6.4 SCFA effects on select pathways 
Supplementation with dietary fibre has been shown to amend features of the metabolic 
syndrome and attenuate malignant growth in certain cancers, in particular colon cancer [159, 
160]. Oxidation of SCFA, particularity acetate, is the initial step in the TCA cycle, a 
fundamental energy producing pathway in all aerobic organisms. Oxidative phosphorylation 
generates the majority of energy required for cellular function in normal differentiated cells. 
In contrast, cancer cells rely primarily on aerobic glycolysis; a metabolic shift termed the 
Warburgh effect that comprises attenuation of energy production via mitochondrial beta-
oxidation [152]. In malignant cells, the inhibition of glucose uptake and metabolism by 
products of SCFA breakdown is thought to preferentially inhibit aerobic glycolysis and 
supress the uncontrolled cellular proliferation [161, 162].  
 
As previously introduced, the ubiquitously expressed HDACs family are part of a 
transcriptional co-repressor complex that influences various tumour suppressor genes, 
making HDAC inhibitors (HDACi) an important emerging class of chemotherapeutic agents 
[163]. The interest in HDACi is due to studies, specifically in butyrate, which show 
deregulated expression in pathological states such as cancer through the modulation of 
histones via acetylation [164, 165]. These complex modifications result in a characteristic 
pattern of acetylation which allows access of transcription factors and other regulatory 
proteins to certain DNA sequences but prevents access to others [166]. 
 
 
Studies investigating the diverse range of cancer inducing agents have led to the hypothesis 
that initial mitochondrial dysfunction results in biochemical and genetic deviations associated 
with malignancy. Exploiting pathways that link cellular energy metabolism and regulation of 
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gene expression is a promising therapeutic approach for the treatment of various disease 
states, including both obesity and cancer [161].   
 
1.6.6 Limitations of SCFA in obesity and cancer paradigms 
Supplementation with dietary fibre has been shown to improve features of the metabolic 
syndrome and attenuate malignant growth in certain cancers [137, 159]. Food sources of 
dietary fibres can act by changing the nature of the contents of the gastrointestinal tract by 
changing how other nutrients and chemicals are absorbed [167]. To achieve the desired 
phenotypic changes described here, the amount of dietary fibres required by consumption 
would be higher than physiologically possible. In addition, there are disadvantages of 
consuming a diet high in fibre, including significant intestinal gas production, bloating and 
potential constipation [168]. Fibre supplementation may be similarly beneficial, however the 
consumption of large qualities can also lead to gas, bloating and discomfort [169]. Thus, 
consuming enough indigestible carbohydrates to have a positive impact on health can be 
difficult, and may therefore not be sustainable for the general population. 
 
 
Current evidence regarding the underlying mechanisms of SCFA, specifically acetate, is 
unclear. Exogenous acetate delivery has demonstrated inconsistent effects on weight gain, 
mitochondrial function and markers of lipogenic and lipolytic activity in both human and 
rodent models [126, 170]. This ambiguity may arise from the ubiquitous role acetate plays in 
cellular metabolism, combined with the non-targeted nature of oral and peripheral 
administration [125, 171]. In addition, the adversely low pH of acetate and its rapid clearance 
from the circulation limit its therapeutic potential when administered systemically [172]. The 
therapeutic limitations of SCFA also extend to cancer models, however are thwarted by a 
short half-life and first-pass hepatic clearance [173].  
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1.7 Liposomal nanoparticles 
Drug delivery systems are being exploited to circumvent some of the non-ideal properties of 
free drug administration and provide better control over the pharmacokinetics of the 
encapsulated drug relative to free drugs. Nanoparticles have many advantages in cancer 
therapy with the small size which can enter tumour vasculature via the enhanced 
permeability and retention effect (EPR) whilst offering a long circulation half-life and 
prolonged exposure time of tumour tissue to anticancer agents [174]. Specifically, liposomes 
have drawn increasing interest due to their ability to delivery drugs in the optimum dosage 
range. The quantification of exact number of drugs being delivered via liposomal carriers has 
seldom been investigated.  
 
Liposomes are vesicles which have become a commonplace within technology of all sectors 
and specialities. The industrial applications of liposomes include drug delivery vehicles in 
medicine, adjuvants in vaccination, signal enhancers/carriers in medical diagnostics and 
analytical biochemistry, solubilizers for various ingredients as well as support matrix for 
various ingredients and penetration enhancer in cosmetics [175, 176]. Liposomal 
encapsulation of therapeutic agents addresses a number of current drug delivery issues by 
improving bioavailability, extending treatment effects and reducing dosing [177]. 
 
1.7.1 Principles of liposomes 
Liposomes are composed of lipid constituents, with hydrophobic head groups and 
hydrophilic tails groups (Figure 1.14). When hydrated, the lipids aggregate together to form 
self-assembled bilayer vesicles, similar to a membrane, which encloses an aqueous 
compartment. This aqueous cavity has traditionally been used as drug delivery vehicles by 
encapsulating water soluble molecules in order to improve drug pharmacokinetics [178-180]. 
Liposomes are typically characterised by their size, shape and lamellarity. The application of 
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liposomes can dictate the combination or choice of lipids incorporated and the preparation 
process in order to formulate a particle for a specific purpose. 
 
 
 
 
Figure 1.14 Basic liposome structure 
A schematic of the structure of a liposome; a spherical vesicle that is comprised of lipid 
constituents with hydrophobic head groups and hydrophilic tails groups. The core of a 
liposome is aqueous which allows for encapsulation of molecules of interest. Figure from 
Encyclopaedia Britannica, Inc, 2007. 
 
1.7.2 Liposome structure 
The bio-distribution of liposomes is dependent on many factors including, formulation 
composition, liposome size, surface charge, concentration of constitute lipids, route of 
injection and the total volume injected in vivo. Formulation composition of a liposome can 
determine the rigidity or fluidity of the membrane by using particular phospholipids. Size is 
an important factor for in vivo application, affecting clearance and distribution, with 
liposomes larger than 100µm being unsuitable for therapeutic use due to uptake by 
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macrophages [180]. Zeta potential is a measure of liposomal stability, whereby the surface 
charge enables particles to repel each another and prevent agglomeration [181-183]. 
 
 
1.7.3 Liposome delivery 
 Liposomes can specifically or nonspecifically absorb onto the cell surface. Liposomes can 
also fuse with the cell membrane, and release their contents into the cell cytoplasm, or can 
be destabilized by certain cell membrane components when adsorbed on the surface 
Liposome can undergo the direct or transfer-protein-mediated exchange of lipid components 
with the cell membrane or be subjected to a specific or nonspecific endocytosis. In the case 
of endocytosis, a liposome can be delivered by the endosome into the lysosome [184]. 
 
 
For in vivo applications and prolonged circulations of liposomes, the liposome bilayer is 
frequently coated with the neutral polymer polyethylene glycol (PEG), which is routinely used 
in the modification of the physiochemical properties of a liposome in order to minimize the 
bioadhesion and immunological response [185, 186]. The incorporation of PEG into the lipid 
membrane increases the hydration of the liposome which makes them unrecognizable to 
macrophages and significantly prolongs their circulation half-life. Without a PEG layer, 
liposomes are also extremely prone to uptake by the reticuloendothelial system (RES), a 
class of cells of the immune system that take up particular substances in the defence against 
foreign bodies [187, 188]. It has been shown that liposomes bearing a surface decorated 
with the neutral hydrophilic PEG polymer benefit from prolonged circulation times with half-
lives reported from 2 to 24 hours in rodents, and as high as 45 hours in humans [189]. The 
presence of PEG molecules on the liposome surface results in the exclusion of other 
macromolecules from the outer layer by occupying the space immediately adjacent to the 
vesicles through its flexible chain and forms a protective layer which reduces the liposome 
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recognition by opsonins in the blood [190, 191]. These liposomes are referred to as sterically 
stabilised or “stealth” liposomes, due to the inhibition of both electrostatic and hydrophobic 
interactions of plasma components with the liposome bilayer. 
 
 
1.7.2 Tumour specific liposomal delivery 
In 1974, Gregoriadis et al. first proposed liposomes for delivery of cancer therapeutics [192] . 
Since then liposomes based therapeutics have found their way into clinical application and 
are often a therapeutic tool of choice given their numerous advantages as pharmaceutical 
carriers. There are numerous studies using liposomes as drug delivery systems in cancer 
therapy which have had a success in patient response. One such example has been 
achieved by formulations such as Doxil® which consists of a liposome formulation 
encapsulating the anti-cancer drug doxorubicin and has been approved for metastatic breast 
cancer [193, 194]. 
 
 
This process involves the complex interplay of a range of specialised cells, growth factors, 
signalling molecules and regulatory elements. It has been shown that potential therapeutics 
of 30kDa and above are able to accumulate in tumour tissue due to the EPR effect [195]. 
This effect coined by Maeda in 1989, shown in Figure 1.15, describes a tumour endothelium 
vasculature, which due to its “leakiness” allows the penetration of macromolecular particles 
through to tumours[196]. 
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Figure 1.15 Schematic of tumour by nanoparticles via Enhanced Permeation and 
Retention (EPR) effect  
Normal tissue does not have endothelial gaps wide enough to allow for macromolecules or 
nanoparticle agents to leak into the extracellular tissue lining blood vessels. Tumour tissue 
has a disrupted endothelial layer, allowing of larger particles to “seep” into the tumour 
extracellular domain. Figure from Prakash, S. et al., 2011. 
 
As mentioned previously a relatively high level of PEG was incorporated into the lipid bilayer, 
which achieves prolonged and sustained drug delivery. These lipids retain the biocompatible 
‘stealth’ effect, thus an increase in the PEG lipid can thereby increase the blood half-life and 
can achieve delivery to a tumour in vivo [197, 198].  
 
 
Liposome 
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1.8 Imaging Modalities for in vivo Studies 
In addition to the encapsulation of drugs within a liposome, equipping the particle with 
contrast generating agents for imaging allows for powerful image-supervised drug delivery. 
The application of nanotechnology platforms to imaging has opened up opportunities for the 
use of multifunctional nanoparticles systems in the study of metabolic disorder detection and 
therapy. This process has been made possible through the use of specific particles that can 
be tracked, monitored and their distribution quantified. Molecular imaging techniques make 
use of modalities which cover a range of frequencies from the electromagnetic spectrum. 
More recently even the use of multiple modalities in combination has been used. Figure 1.16 
shows a sample of the now numerous imaging modalities that can be utilised for molecular 
imaging, each with their own advantage and disadvantage [199]. The most commonly used 
techniques in molecular imaging are magnetic resonance imaging (MRI), optical imaging and 
nuclear imaging (positron emission tomography (PET)) [200]. 
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Figure 1.16 Summary of imaging modalities  
Each modality has particular characteristics, advantages and disadvantages which are 
highlighted in the figure. CT, computed tomography; PET, positron emission tomography. 
 
 
1.8.1 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is a powerful non-ionising, non-invasive imaging tool, 
with high tissue contrast, making it ideal for longitudinal studies on the same subject, which 
why it is widely used in pre-clinical and clinical studies. MRI, unlike nuclear imaging 
techniques such as PET, is relatively insensitive but it has better spatial resolution and can 
be used repeatedly on the same subject without any adverse effects. The vast majority of 
MRI is based upon the manipulation of a particular nuclei, most commonly hydrogen, in a 
magnetic field. This constant magnetic field is usually produced by a super-conducting 
magnet, a tightly wound wire through which an electric current is passed. Producing this 
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current requires a huge amount of energy, thus the wire is maintained at -270°C with liquid 
nitrogen and helium [201]. 
 
 
Once a sample containing water is placed within this strong external magnetic field, almost 
all of the hydrogen nuclei begin in spin, or precess, in a gyrating fashion around the 
magnetic moment, termed B0, and line up parallel or anti-parallel to the direction of the 
magnetic field. The frequency at which the hydrogen nuclei precess is termed the Lamour 
frequency and is directly proportional to the local magnetic field strength. The higher the field 
strength of the magnet, measured in Tesla (T), the more protons align with the field. 
 
 
Encapsulated within the MRI scanner, three variable gradient magnets alter the magnetic 
fields along the x, y or z axes. The gradient magnets alter the main magnetic field on a very 
local level allowing “slicing” in any direction to take place within the sample. The MRI 
machine creates a unique magnetic field for each voxel (a volumetric unit within an MRI 
scanned section) and therefore a unique Lamour frequency.  
 
 
 In order to generate an MRI image, a radiofrequency (RF) coil placed around the region of 
interest is used to deliver an RF pulse. This pulse, applied at the appropriate Lamour 
frequency, perturbs precessing hydrogen nuclei, flipping them into the plane perpendicular to 
B0, also referred to as the transverse plane). After the RF pulse, the precessing nuclei relax 
and recover to the longitudinal plane while decaying in the transverse plane. The longitudinal 
and transverse magnetizations occur simultaneously but are two completely different 
processes. The recovery/relaxation along the longitudinal plane is referred T1 recovery, 
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whereas relaxation in the transverse plane is referred to T2 recovery. The dissipation of 
energy in the form of T1 and T2 within each voxel is recorded by the RF coil and the 
scanner’s computer manipulates this data via complex Fourier transformation, generating an 
MRI image. [202, 203]. 
 
 
1.8.1.1 Gadolinium Contrast Agent 
MRI contrast agents are routinely used in clinical diagnosis as they provide reliable means to 
improve image contrast. One of the most commonly used contrast agent, Gadolinium (Gd), 
consists of a paramagnetic metal core, which is complexed into a strongly chelating ligand. 
Incorporating gadolinium complexes into liposome membranes yields paramagnetically 
labelled liposomes which significantly enhance proton relativity and are therefore MRI visible 
[204-206]. 
 
 
1.8.2 Computed Tomography 
The computed tomography (CT) system is formed from an X-ray source and detector. The 
subject is placed between the source and the detector which acquires a series of 
projections. These projections are then used to generate a three dimensional image, with the 
contrast generated from the difference absorption of the X-rays through different tissues. CT 
can produce very high resolution images, however is limited by lack of soft tissue contrast 
[207]. For this reason, CT is not routinely used as an imaging tool alone but often used in 
combination with other imaging techniques such as position emission tomography [199]. 
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1.8.3 Positron Emission Tomography 
In Positron Emission Tomography (PET) imaging, radioisotopes decay emitting a positron 
and neutrino. The positron is annihilated when it comes in contact with an electron emitting 2 
anti-parallel γ-rays. The energy of the γ-rays emitted is 511keV and detected almost 
simultaneously by an array of detectors surrounding the subject and this allows the 
localisation and quantification of the radioisotope in the subject [208]. The radioisotopes 
used in PET imaging include, but not limited to, 18F and 11C. One main application of PET is 
tumour imaging together with 18Fluorodeoxyglucose (18F-FDG), which is taken up by 
metabolically active cells and following phosphorylation by glucokinase is trapped inside 
allowing for activity to be measured [209, 210]. 
 
 
1.8.4 Fluorescence microscopy 
In fluorescence imaging, the properties of certain molecules known as fluorochromes, are 
exploited for their ability to fluoresce. Fluorescence is the ability to absorb energy from an 
external excitation light of a particular wavelength and to re-emit the light at a longer 
wavelength and lower energy, which can be detected by ultrasensitive cameras. 
Fluorescence techniques, mainly fluorescence microscopy, have been routinely used in vitro 
and ex vivo applications in molecular and cellular biology. This has been extended into non-
invasive in vivo imaging [211]. Fluorescence imaging using excitation in the visible range 
(400-600nm) has been widely used in vitro and ex vivo, it is limited in vivo by the penetration 
depth of excitation light (1-2mm) [212]. 
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1.9   Aims and Objectives 
The work contained in this thesis focuses on the design, evaluation and implementation of a 
liposomal formulation for the in vivo delivery of acetate in animal models of obesity and 
cancer. I hypothesis that cellular metabolic dysfunction can be re-engineered in vivo by the 
targeted delivery of acetate. In chapter 2, I explore the potential of preferential delivery of 
liposome encapsulated acetate (LITA) nanoparticles by utilising this liposome as a viable 
delivery vesicle for acetate. This consists of a panel of potential liposome formulations, 
tested and characterised to determine the ideal vehicle for acetate. Short- and long-term 
biodistribution assessment was carried out by means of histological techniques, MRI and 
18F-FDG-PET/CT. This delivery system aimed to address many of the issues associated with 
the delivery of small molecule to target organs in obesity and cancer murine models. 
 
The metabolic potential of liposomal encapsulated acetate (LITA) nanoparticles was 
assessed in multiple in vivo models, examining a wide range of metabolic outcomes. In 
chapters 3 and 4 I employed the developed SCFA encapsulated vector in animal models of 
both obesity and malignancy. Chapter 3 examines the effects of LITA in an obesogenic 
background to determine how acetate delivery could change the landscape of the obese 
state in vivo. Metabolic, phenotypic, molecular and epigenetic analysis was carried out to 
determine the effects of the LITA nanoparticle. Chapter 3 also explores the short term effects 
of metabolic response to the LITA nanoparticle in vivo in a non-obese state. Chapter 4 
examines the effects of LITA upon delivery to three independent colon cancer tumour 
models in vivo. Analysis of tumour growth and metabolism was determined by calliper and 
bioluminescence activity, as well as the use of molecular analysis. Significant changes in 
tumour size were observed with LITA treatment, together with marked changes in epigenetic 
markers. The potential of preferential delivery of the LITA nanoparticles to key sites of 
metabolic control will provide beneficial therapeutic effects in animal models of both obesity 
and cancer. 
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Chapter 2 
Formulation and Characterisation of 
Liposomal Encapsulation of Acetate 
(LITA) 
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2.1 Introduction  
 
As described in Chapter 1, supplementation with dietary fibre has been shown to ameliorate 
features of the metabolic syndrome and attenuate malignant growth in certain cancers [159, 
160]. Component carbohydrates are fermented by the microflora of the large intestine, 
producing short-chain fatty acids (SCFA), such as acetate, propionate and butyrate [159]. 
Acetate is a key metabolic intermediate in several ubiquitous cellular processes and has 
multiple beneficial effects [125]. 
 
 
 In order to avoid the harmful side effects of pure acetate administration [115] or volume of 
dietary consumption [159], a safe and effective method of delivery is required. A nanoparticle 
delivery system was resolved to be the solution to this problem, specifically the liposome. 
Liposomal encapsulation of therapeutic agents addresses a number of these issues by 
improving bio-availability, extending treatment effects and reducing dosing [177]. This 
chapter is intended to confirm that a liposome is a multi-purpose, artificially prepared vesicle 
composed of a lipid bilayer which can be loaded with small molecules, such as acetate. 
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2.1.1 Aims of Studies 
 
 
To formulate and characterise a nanoparticle that has the capacity to encapsulate the 
short chain fatty acids: acetate, butyrate and propionate. This will develop a novel 
delivery system of short-chain fatty acids with the capacity to tailor the design of the 
nanoparticle to target organs of interest.  
 
To assess the bio distribution over time and in real time of the nanoparticle in vivo. 
This will help to develop a profile of distribution in vivo and can determine the effectiveness 
of delivery of the acetate encapsulated liposome.   
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2.2 Methods 
2.2.1 Materials 
2.2.1.1 Lipids 
The cationic lipid incorporated into the liposomal bilayer was CDAN (N1-
cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine, C35H64N4O2). One isoform of CDAN 
used in this study is DDAB (Dimethyldioctadecylammonium, C38H80NBr). DSPC (1,2-
distearoyl-sn-glycero-3-phosphocholine, C44H88NO8P) was added for membrane structure. 
Two isoform of DSPC was also tested: DOPE(1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine, C41H78NO8P) and DLPC (1,2-dilauroyl-sn-glycero-3-phosphocholine, 
C32H64NO8P). The lipid used to increase blood-half life and bioavailability within in vivo 
circulation was 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (ammonium salt) (DSPE-PEG2000). The helper lipid cholesterol (3β-Hydroxy-5-
cholestene, 5-Cholesten-3β-ol, C27H46O) was included in order to increase fusogenicity and 
stability of the liposomal lipid bilayer. One isoform of cholesterol was also testsed, DC 
cholesterol (3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride, 
C32H57N2O2Cl). To increase transfection efficiency of the liposome DOPE-Rhodamine (1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl), 
C68H109N4O14PS2) was included, which also carried a fluorescence label to allow ex vivo 
histological corroboration. For in vivo MRI visualisation of the liposomes, the formulation 
included a second label containing the lipid gadolinium (III) or Gd.DOTA.DSA (2-[4,7-bis-
carboxymethyl-10-[(N,N-distearylamidomethyl-N′-amidomethyl]-1,4,7,10-
tetraazacyclododec-1-yl], C55H109N6O8Gd). All lipids were stored as stock solutions in the 
anhydrous organic solvent chloroform (CHCl3) at -20oC. All chemicals were of analytical 
grade or best available grade and purchased from Sigma-Aldrich (Dorset, UK) or Avanti 
Polar Lipids (Alabaster, USA). The structures of the primary lipids introduced in the 
formulations of the liposome can be seen in Figure 2.1. Accessory lipid structures are found 
in Appendix I.   
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A) DSPC                
B) CDAN                
C) DSPE-PEG2000      
D) DOPE-Rhodamine B     
E) Cholesterol                      
F) Gd.DOTA.DSA         
Figure 2.1 Chemical structures of the lipids incorporated into the liposomal bilayer 
These chemical structures represent the lipids used to formulate the described liposomes. 
Lipids included (A) DSPC, (B) CDAN, (C) DSPE-PEG2000, (D) DOPE-Rhodamine B, (E) 
Cholesterol and (F) Gd.DOTA.DSA (Gadolinium). 
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2.2.2 Study 1: Liposome Preparation and Formulation 
 
2.2.2.1 Lipid incorporation 
In order to determine the ideal liposome formulation for this study, a number of variable lipids 
and molarity components were tested. Liposomes were formulated with a defined molar ratio 
of individual lipids based on the desired in vivo application (Table 2.1). Appropriate volumes 
of each lipid stock were placed in a 5mL round bottom flask and the solvent slowly removed 
in vacuo at 30°C using a rotary evaporator (Bucchi, UK) until all liquid was completely 
evaporated to ensure production of an even lipid film [213].  
 
2.2.3 Study 2: Short-Chain Fatty Acid Encapsulation   
 
2.2.3.1 Liposomal encapsulation of acetate and dialysis  
The lipid film following rotary evaporation was re-hydrated with either the membrane 
impermeable control buffer 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
(4mM, NaCl 135mM, pH 6.5) or the short-chain fatty acid (SCFA) (1M, CH3COOH, pH 2.0). 
The first SCFA tested was acetate; following the establishment of a robust formulation and 
protocol, butyrate and propionate were tested. In order to form liposomes of an appropriate 
size of 100nm, the resulting solution was sonicated using a sonicating water bath (Grant 
Instruments, Cambridge, UK), for one hour at 30ºC in the dark, The pH of the liposomal 
suspension was determined by a pH measurement device (Camlab Ltd., UK) and was 
adjusted to 7.0 by the addition of sodium hydroxide (NaOH, pH 12.0) or hydrochloric acid 
(HCL, pH 2.0) (Sigma-Aldrich, UK). The formulated liposomes with encapsulated SCFA or 
HEPES then required a dialysis process to filter any excess material from the external 
liposome environment. To achieve this, formulated liposomes were transferred into the 
Float-A-lyzer G2 (Spectrum labs, USA). The column was then suspended into a beaker of 
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100mL sterile deionised water on a stir plate and set to the slowest speed for 18 hours. 
Water was replaced every 4-5 hours to ensure the external environment of the liposome was 
clear of any impurities, as displayed in Figure 2 [214].  
 
 
Figure 2. 2 Illustration of the Float-A-lyzer G2 column  
Dialysis column used to filter the liposomal nanoparticles after formulation to rid any 
impurities from the solution, which is not encapsulated within the liposome. The filer and 
placed into a beaker of 100mL sterile deionised water on a stir plate and set to the slowest 
speed. The red colour in the column represents the nanoparticle solution.  
 
 
2.2.4 Study 3: Liposome Characterisation 
 
2.2.4.1 Liposome sizing and stability confirmation 
Quality control of the liposome was carried out to ensure particles were fully formulated and 
filtered; the size and stability of the particles were determined after each formulation using a 
Zetasizer Nano ZA (Malvern Instruments Ltd, UK), which is an automatized light scattering 
instrument commonly used to measure the size of liposomal nanoparticles. Particle sizing 
was evaluated by measuring the average liposomal hydrodynamic diameter (nm). Particle 
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stability was evaluated by measuring the polydispersity index (PDI), which represents the 
purity in the liposomal solution as a result of the dialysis process. All measurements were 
taken in triplicate and at 25°C. The preparation and filtration protocol used in this study were 
adapted from previous liposomal studies and a commercially available filtration system.  
 
2.2.4.2 1H NMR spectroscopy of encapsulated acetate in liposomes 
To confirm and ensure encapsulation of acetate within the liposomes had occurred, NMR 
was carried out on the particles immediately following formulation of the LITA particle, 
described above using formulation 1 from Table 2.1. Albumin (4g) was added to the LITA 
solution, as the molecule is too large to enter the liposome.  
 
1H NMR spectra was acquired on a Bruker Biospin scanner (Bruker, USA) with a 5mm 
inverse mode BBI probe at the following parameters: 500.13MHz, sweep width 12ppm 
(6009Hz), data points 32k, acquisition time 2.726 seconds, relaxation delay 3 seconds 
(overall recycle delay 5.726 seconds), pulse width 6µs (corresponding to a 55 degree pulse), 
64 averages and temperature of 298K. The free induction decay (FID) signal was apodized 
to reduce noise and fourier transformed. The obtained spectra were baseline corrected, 
referenced and integrated using the Mest-ReC software (Santiago, Spain).  
 
2.2.4.3 1H NMR spectroscopy quantitation of encapsulated acetate in liposomes  
1H NMR spectroscopy was carried out to quantitatively identify the encapsulated SCFA 
concentration in 200ul (LITA formulation, as previously described in 2.2.1). To act as a 
reference peak, lactate (5.2mg) (Sigma-Aldrich, UK) was added to 200µL of liposomes. The 
SCFA encapsulated liposomes and lactate solution were combined in a chilled 50mL conical 
tube and placed into a freeze drier (BOC Edwards, USA) overnight at -20ºC. Once solution 
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was in freeze-dried form, the crystals were resuspended in 1.0mL deuterium oxide (D2O) 
and analysed with 1H NMR spectroscopy. Parameters for 1H NMR scan were described 
previously in 2.2.2.1. Baseline correction was carried out using a spline function and peaks 
were integrated for relative quantification of acetate. 
 
2.2.5 Study 4: Liposomal Bio Distribution and in vivo Optimisation 
 
2.2.5.1  Ex vivo liposomal detection using fluorescence microscopy imaging 
For in vivo monitoring and imaging of the liposomes three methods were applied to examine 
bio-distribution at different stages. For visual identification and in vivo optimisation of the 
liposomes within the organ at a determined time point, fluorescence microscopy was carried 
out using the LITA-Rhd nanoparticle (Table 2.2, formulation A). For quantitative identification 
of the liposomes within the organ at a determined time point, MRI was carried out using the 
LITA-Gd nanoparticle (Table 2.2, formulation B). In order to monitor the liposomal bio-
distribution in real-time, PET/CT was applied using the LITA nanoparticle (Table 2.2, 
formulation 3) and encapsulating the radioactive isotope [18F]FDG.   
 
2.2.5.1.1 Histological evaluation of LITA-Rhd at differing concentrations of acetate and 
peripheral injection comparison 
In order to determine the ideal in vivo dosage and injection method of the liposomes, a 
number of ex vivo bio-distribution studies were executed using histological methods to 
positively identify the presence of the liposome in organs of interest. WT male C57BL/6 mice 
were used for all histological studies. Four different concentrations of acetate were 
encapsulated; 100µM, 1mM, 10mM and 1M as well as control HEPES using formulation A, 
LITA-Rhd (Table 2.2). Animals received a single 200µL injection either intraperitoneally (i.p.) 
or intravenously (i.v.) at each concentration and culled at 2hr (n=4/group). The organs of 
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interest were frozen on dry ice immediately after sacrifice and either continued onto 
histological evaluation or stored at -80ºC. Organs of interest such as the liver, kidneys, heart, 
brain, spleen and lungs were cut into 7µm sections using a Cryostat (Leica, UK) and cell 
membranes were stained with the DNA nuclear stain, 1µL 4',6-diamidino-2-phenylindole 
(DAPI). Microscopy images of the organs of interest were obtained using an Olympus 251 
(Soft Imaging Solutions GmbH, Germany). Three different filters were used to confirm 
liposomes presence. A red filter identified the rhodamine embedded into the lipid bi-layer. A 
green filter identified any background noise and a blue filter used ultraviolet (UV) light to 
identify the DAPI stain thus confirming the liposomes were in fact being identified within 
tissue.  
 
2.2.5.1.2 Histological evaluation of LITA-Rhd at differing time points after injection 
In order to determine the ideal in vivo delivery of liposomes to organs of interest over time, 
WT male C57BL/6 mice received a single 200µL injection intraperitoneally (i.p.) at and culled 
at 2, 16, 24 and 48 hours post injection of LITA-RhD (Table 1). Organs of interest such as 
the liver, spleen, kidney, lungs, heart, brain, muscles, and pancreas were evaluated using 
the same protocol as described in 2.2.4.1.1 (n=4/group). 
 
2.2.5.2 In vivo liposome detection using MRI and T1 measurements 
To monitor bio distribution of liposome accumulation in vivo at a particular time point, LITA-
Gd (Formulations B) and LITA (Formulation C) from Table 1 were used in this study. Both 
sets of liposomes were encapsulated with acetate (1M); the only difference in groups was 
the lipid composition. Formulation B, LITA-Gd contained Gadolinium (Gd), which is an MRI 
contrast agent which when taken up by the tissues decreases the relaxation time of the 
tissue therefore increasing the signal from the tissue. Formulation C, LITA, contained no 
gadolinium and was used as a control liposome. 
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Animals were anesthetized with 4-3% isoflurane oxygen mix, placed in a birdcage coil and 
maintained at 2-2%. A breathing pad was used to monitor the breathing rate and a rectal 
probe for the body temperature which was maintained at 37ºC.  
 
Following shimming on the water signal of the whole mouse, a scout image was obtained. 
This was used to plan the axial slices covering the whole animal. An array of a fast spin echo 
sequence with TR 8500msec, TEeff 20msec, ETL 8, k zero at 2, FOV 50x50 mm2, matrix 
256x256, one average, 40 slices of 2mm thickness, with TI 50, 100, 500, 1000 and 
5000msecs was obtained. Array of 5 TI image volumes was 22 minutes with the total scan 
time per animal about 30 minutes. Animals were then recovered in a heating box. 
 
After the baseline scan was finished animals received 200µL of acetate liposomes either 
with or without Gd, intraperitoneally. The scans were repeated 2, 16, 24 and 48 hours post-
injection. For each time point and each TI, signal intensities were measured in ROIs placed 
in the following organs, liver, brain, heart, fat and kidney using Image J. These were fitted 
into the equation 1 to determine the T1 values using Graphad Prism.  
 𝑌=𝑎𝑏𝑠 [M0 × (1+e8500/T1-2eTIT1)] 
 
Equation 2.1 T1 values were averaged as mean ± SEM. Unpaired t-test was carried out 
for statistical analysis. 
 
2.2.5.3 Real-time biodistribution assessment by PET/ CT fusion 
Positron Emission Tomography (PET) and x-ray Computed Tomography (CT) were used in 
combination to monitor liposomal bio-distribution in real-time and in vivo. Images acquired 
from both PET and CT were taken sequentially in the same imaging session and combined 
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into a single superposed (co-registered) image. Liposomes were formulated (as described in 
3.1.1) using formulation C, LITA and encapsulated with fluorodeoxyglucose ([18F]FDG). The 
volume administered was 200µL in order to monitor the exact dosage given during the study. 
The encapsulation of [18F]FDG was calculated to ensure at the end of the required filtration 
time, there would be an activity of 10 MBq per dosage. Once formulation was completed, 
200µL (10 MBq) [18F]FDG encapsulated liposomes were injected into the mice either 
intraperitoneally (i.p.) or intravenously (i.v.). 
 
Immediately following injection of liposomes, mice were anesthetized with 2-2.5% isoflurane 
1/min oxygen and placed prone into the scanner. Once the animal was placed into the 
scanner, a CT scan without contract was performed which lasted 10 minutes and the PET 
scan followed immediately. During the scan animals were maintained at 1-2% isoflurane-
oxygen mix and body temperature maintained at 37ºC. 
 
 Images of entire body of the mouse were acquired using a 30-minute acquisition program. 
The micro PET/CT (Siemens) scanner operates in a 3-dimensional volume imaging 
acquisition mode. The CT had an X-ray source of 80kVp and 500µA with an exposure time 
of 200ms and isotropic resolution of 103µm. The scan consisted of 3 bed positions with a 
20% overlap. Small animals were laser aligned at the centre of the scanner field of view 
(FOV) for subsequent imaging. To minimize any errors between PET and CT, mice were 
scanned in a chamber, which kept positioning to minimal errors [215]. 
 
Images were analysed using Inveon Research Workplace Version 3, the software provided 
by Siemens. The PET data acquired were list-mode data then sorted into 3D sonograms 
with a span of 3-ring difference of 79 and converted into 2D sonograms by Fourier rebinning. 
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Images with matrix size 128x128, pixel size 0.776mm2 and slice thickness 0.796mm were 
reconstructed from the 2D sonogram by 2D filtered back projection using a ramp filter with a 
nyquist frequency of 0.5. Dynamic framing was used in reconstruction with 20 3s frames, 8 
30s frames, 5 60s frames and 10 300s frames. All regions of interest (ROI) were defined on 
fused PET/CT images to ensure reproducible positioning and accuracy. Reconstructed PET 
images were registered onto the CT images and ROIs were drawn on the desired organs 
using the CT images. PET signals on the desired ROI were obtained over the scan period. 
The intensity of [18F]FDG uptake was quantified using the mean standard uptake value 
(SUV) over the desired ROI by Equation 2 and expressed as area under the curve (AUC). 
 
SUV= Regional radioactivity (MBq/kg)/ (Injected radio activity (MBq)/ body weight (g)) 
 
Equation 2.2 Standard Uptake Value (SUV) to obtain uptake of [18F]FDG from PET/CT 
acquired image 
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2.3 Results 
2.3.1 Study 1: Liposome Preparation and Formulation 
First objective was to determine an ideal liposome formulation that would encapsulate 
acetate. To do this, both the lipid type and molarity percentage incorporated into the 
liposome were tested. The foundation of the liposome was selected to contain four primary 
lipids: DSPC, cholesterol, DSPC-PEG2000 and CDAN. From those lipids, I tested substitute 
lipids to determine the best formulation for a LITA nanoparticle. Following the lipid selection, 
molarity percentage differences were tested. Table 2.1 shows the 14 different liposome 
formulation variables (n=3/group).  
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Table 2.1 Percentage molar and lipid components of potential liposome formulations  
Formulation variables of liposomes generated to produce the most stable and appropriately 
sized liposome which will encapsulate acetate for in vivo delivery. 
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Once the formulation and rehydration was carried out, liposomes were sized. Sizes of the 
formulated liposomes were determined by using a Zetasizer Nano (Malvern, UK). Size is 
expressed in nanometers (nm) and the difference in size within the liposome solution is 
expressed as the poly distribution index (PDI). Figure 2.3 shows two diagrams that show the 
size distribution of the liposome solution before (Figure 2.3 A) and after (Figure 2.3 B) 
dialysis via the Float-A-Lyzer. This comparison of sizing confirms that after dialysis is carried 
out all the excess material, unformed lipids and any other unwanted material is cleared from 
the liposome solution and is appropriately sized and purity for in vivo application. The green 
and red colour recordings in each graph refer to technical replicates to confirm sizing 
reproducibility. Once this method was developed, it was applied to the panel of liposome 
variables to quantitatively assess each formulation. 
 
DSPC was substituted with isoform lipids: DOPE, DLPC (carbon 12) and DLPC (carbon 20) 
(Figure 2.4 A-C). DOPE, DLPC (C12) and DLPC (C20) lipids formulated a bit below than the 
desired 100mn. The molarity of DSPC was tested at 10% and 50% molarity to determine 
stability and formulation abilities (Figure 2.4 D-E). Both molarity percentages formulated 
appropriate, especially 50% DSPC where the average size 100mn; however 10% DSPC 
averaged well below that.  
 
Cholesterol was substituted with the isoform lipid, DC cholesterol (Figure 2.5 A), which 
formulated slightly smaller than the target 100mn however had a precise range of size. The 
molarity of cholesterol was tested at 10% and 50% molarity to determine stability and 
formulation abilities (Figure 2.5 B-C), neither of which formulated properly and had an 
excess of lipids in the solution which did not form into liposomes.  
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DSPE-PEG2000 was substituted with isoform lipids of varying PEG length but at the same 1% 
molarity: DSPE-PEG500 and DSPE-PEG10000 (Figure 2.6). A shorter PEG length formed a 
liposome of appropriate size; however a longer PEG chain caused a formulation size below 
the ideal 100mn.  
 
CDAN was substituted with the isoform lipid, DDAB (Figure 2.7), which was unable to 
formulate a liposome. The molarity of CDAN was tested at 10% and 50% molarity to 
determine stability and formulation abilities (Figure 2.10). At 10% CDAN the formulated 
liposome size was too small, from 10-120nm; whereas 50% CDAN formulated the correct 
average size however had too high a range. Out of all the formulation tested, Formulation 1 
had the most exact sizing profile at 100mn. A quantitative summary of these formulates is 
shown in Table 2.2. 
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Figure 2.3 Liposomal nanoparticle profiles before and after dialysis 
 Size distribution of LITA nanoparticles (A) before and (B) after filtration in the Float-A-Lyzer. 
The x-axis is the size distribution of the particles measured in the solution and the y-axis is 
the intensity of the particles. This particular formulation is notated as Formulation 1 in Table 
2.1. The green and red colour recordings refer to technical replicates.   
 
 
 
 
A) 
B) 
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Figure 2.4 Size of liposomes after formulation and dialysis- target lipid: 1,2-distearoyl-
sn-glycero-3-phosphocholine (DSPC) 
The LITA-nanoparticle was formulated and sized by varying DSPC lipid of either:  (A) DOPE, 
(B) DLPC (C12) or (C) DLPC (C20). Liposomes were formulated at varying molarities of (C) 
10% or (D) 50% DSPC.  
 
 
 
 
 
 
(A) DOPE 
(A) DLPC (C12) (C) DLPC (C20) 
(D) 10% DSPC (E) 50% DSPC 
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Figure 2.5 Size of liposomes after formulation and dialysis- target lipid: 3β-Hydroxy-5-
cholestene, 5-Cholesten-3β-ol (cholesterol) 
The LITA-nanoparticle was formulated and sized by varying the cholesterol lipid of (A) DC 
cholesterol. Liposomes were formulated at varying molarities of either (B) 10% or (C) 50% 
cholesterol. 
(A) DC cholesterol  
(B) 10% cholesterol  
(C) 50% cholesterol  
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Figure 2.6 Size of liposomes after formulation and dialysis- target lipid: 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-
PEG2000) 
The LITA-nanoparticle was formulated and sized by varying the cholesterol lipid of either (A) 
DSPE-PEG500 or (B) DSPE-PEG10000. Both formulations were had the same 1% molarity 
incorporated into the liposomes. 
 
 
 
(A) DSPE-PEG500 
(B) DSPE-PEG10000 
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Figure 2.7 Size of liposomes after formulation and dialysis- N1-
cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine lipid (CDAN) 
 
The LITA-nanoparticle was formulated and sized by varying the cholesterol lipid of (A) 
DDAB. Liposomes were formulated at varying molarities of either (B) 10% or (C) 50% 
CDAN. 
(A) DDAB 
(B) 10% CDAN 
(C) 50% CDAN 
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Table 2.2 Quantitative summary from formulation with varying molarities and 
incorporated lipids 
A panel of lipids and varying molarities were incorporated into numerous liposome 
formulations, filtered through dialysis and measured for characterisation of each formulation. 
This lipid selection was from each foundation lipid selected to incorporate into the liposome: 
DSPC (Figure 2.4), cholesterol (Figure 2.5), DSPC-PEG2000 (Figure 2.6) and CDAN (Figure 
2.7). The formulation with the best performance was Formulation 1. 
 
Lipid Lipid variation Size (nm) 
Formulation 1 DSPC (32); Chol (35); DPSE-
Peg2000 (1); CDAN (32) 
80-110 
DSPC DOPE 35-80 
 DLPC (C12) 35-150 
 DLPC (C20) 30-110 
 10% DSPC 15-100 
 50% DSPC 30-110 
Cholesterol DC Cholesterol 25-45 
 10% Cholesterol 20-1000 
 50% Cholesterol 20-160, 1000+ 
DSPE-PEG2000 DSPE-PEG500 50-150 
 DSPE-PEG10000 35-80 
CDAN DDAB 2.4x104 
 10% CDAN 100-300 
 50% CDAN 
 
20-200 
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2.3.2 Study 2: 1H NMR Spectroscopy of Encapsulated Acetate in Liposomes 
1H NMR spectroscopy was performed to confirm the encapsulation of acetate within 
liposomes and determine the resulting concentration. Firstly, a baseline scan of pure acetate 
solution (4mM) was carried out and a visible acetate peak was observed at 2.03ppm (Figure 
2.8, A). The acetate signal suppressor molecule, albumin (4g), was added to the liposome 
solution and the same scan was repeated. The 1H NMR signal from acetate was completely 
suppressed; (Figure 2.8, B). This established a model to confirm the encapsulation of 
acetate within the liposome. The nanoparticle, specified as Formulation 1, underwent a 
baseline scan and a visible acetate peak was observed at 2.03ppm (Figure 2.9, A). Addition 
of albumin reduced the acetate signal significantly (Figure 2.9, B). The albumin bound to the 
acetate present in the solution which was external of the liposomes, thus the internal acetate 
could be measured and quantified. 
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Figure 2. 8 1H NMR spectra of acetate with added albumin 
1H NMR spectra of (A) 4mM acetate solution and (B) 4mM acetate solution with 4g of 
albumin. The highlighted green boxes are expanded sections of the spectra from 4.5 to -
0.5ppm; the peak for acetate is normally observed at 2.03ppm.  
 
A) 
B) 
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Figure 2.9 1H NMR spectra of acetate encapsulated liposomes with added albumin 
1H NMR spectra of (A) LITA solution and (B) LITA solution with albumin added (4g). 
Trimethylsilyl propionate (TSP) provides a reference at 0ppm. The highlighted green boxes 
are expanded sections of the spectra from 4.5 to -0.5ppm; the peak for acetate is normally 
observed at 2.03ppm.  
 
 
 
 
 
A) 
B) 
94 
 
2.3.3 Study 3: Liposome Characterisation 1H NMR Spectroscopy to Determine 
Encapsulated Acetate Concentration 
Once a formulation was determined, the amount of acetate encapsulated was measured. 
Figure 2.10 shows the 1H NMR spectra of 200µL LITA nanoparticles formulated with 1M 
acetate and the composition of Formulation 1 for a baseline profile. Figure 2.11 shows the 
same 1H NMR spectra following the addition of sodium lactate (5.2mg) added in prior to 
being freeze-dried.  
 
Based on the integrated peak of lactate and acetate, the concentration of acetate in 200µl 
was determined to be 52.9µg (4.41mM). Each liposomal particle was calculated to contain 
4.41×10−14mmol of acetate, based on the concentration of nanoparticles in a known 
concentration of liposome solution (1011 in 1mL). 
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Figure 2.10 1H NMR spectra of LITA formulated with 1M acetate 
1H NMR spectra exhibits the fingerprints of 200µL of LITA (1M). Peak at zero is the 
reference peak; the peak at 2.03ppm is acetate. 
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Figure 2.11 1H NMR spectra of LITA nanoparticles and sodium lactate 
1H NMR spectra of freeze-dried LITA nanoparticles encapsulated with 1M acetate and 
added sodium lactate (5.2mg) to act as a reference. Peak at zero is the reference peak; 
peak at 1.3ppm is sodium lactate whereas the peak at 2.03ppm is acetate. Values 
underneath the peaks (shown in red) are the calculated integrals of the peaks 
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2.3.3.1 Liposome characterisation 1H NMR spectroscopy to determine encapsulated acetate 
concentration of formulation candidates 
Once a protocol was developed and confirmed to identify acetate concentration 
encapsulated within the liposome, this same method was applied to the 13 other liposome 
formulations to determine the best candidate for in vivo application (n=3). For formulation 
specifics, refer to Table 2.1.  
 
DSPC was substituted with isoform lipids: DOPE, DLPC (carbon 12) and DLPC (carbon 20), 
which encapsulated a varying range of acetate per formulation (Figure 2.12 A-C). DOPE and 
DLPC (C12) encapsulated approximately the same amount of acetate (1mM), whereas 
DLPC with a higher carbon chain (C20) encapsulated only half that amount of acetate 
(0.58mM). The molarity of DSPC was tested at 10% and 50% molarity and had differing 
encapsulation concentrations; 10% of DSPC contained 4.19mM whereas 50% contained 
0.51mM of acetate (Figure 2.12 D-E).  
 
Cholesterol was substituted with the isoform lipid, DC cholesterol (Figure 2.13 A), which 
failed to encapsulate a detectable amount of acetate. The molarity of cholesterol was 
formulated with 10% and 50% molarity (Figure 2.13 B-C). The liposome embedded with 10% 
cholesterol into the lipid bilayer encapsulated 2.79mM of acetate, whereas 50% cholesterol 
failed to encapsulate a detectable amount of acetate. 
 
DSPE-PEG2000 was substituted with isoform lipids of varying PEG length but at the same 1% 
molarity: DSPE-PEG500 and DSPE-PEG10000 (Figure 2.14). A shorter PEG length failed to 
formulate a liposome which had a detectable amount of acetate; however a longer PEG 
chain caused the high amount of encapsulated acetate found in this study (6.13).  
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CDAN was substituted with the isoform lipid, DDAB (Figure 2.15 A), which detected a trace 
of acetate encapsulated within the liposome (0.03mM). The molarity of CDAN was tested at 
10% and 50% molarity (Figure 2.15 B-C); at 10% CDAN the formulated liposome 
encapsulated 1.28mM of acetate, whereas 50% CDAN encapsulated a minimal 0.04mM of 
acetate. Out of all the formulation tested, Formulation 1 had the second highest amount of 
acetate encapsulated within the liposome (4.41mM). A quantitative summary of these 
formulates is shown in Table 2.3. 
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Figure 2.12 Acetate encapsulated within the liposomes and measured by 1H 
MRS - target lipid: 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) 
The LITA-nanoparticle was formulated and sized by varying DSPC lipid of either:  (A) DOPE, 
(B) DLPC (C12) or (C) DLPC (C20). Liposomes were formulated at varying molarities of (C) 
10% or (D) 50% DSPC.  
 
(A) DOPE 
(B) DLPC (C12) (C) DLPC (C20) 
(D) 10% DSPC (E) 50% DSPC 
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Figure 2.13 Acetate encapsulated within the liposomes and measured by 1H MRS - 
target lipid: 3β-Hydroxy-5-cholestene, 5-Cholesten-3β-ol (cholesterol) 
The LITA-nanoparticle was formulated and sized by varying the cholesterol lipid of (A) DC 
cholesterol. Liposomes were formulated at varying molarities of either (B) 10% or (C) 50% 
cholesterol. 
 
 
 
 
(B) 10% 
cholesterol  
(C) 50% 
cholesterol  
(A)  DC cho lesterol  
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Figure 2.14 Acetate encapsulated within the liposomes and measured by 1H MRS – 
target lipid: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- 
methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) 
The LITA-nanoparticle was formulated and sized by varying the cholesterol lipid of either (A) 
DSPE-PEG500 or (B) DSPE-PEG10000. Both formulations were had the same 1% molarity 
incorporated into the liposomes. 
 
 
 
(A) DSPE-PEG500 
(B) DSPE-
PEG10000 
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Figure 2.15 Acetate encapsulated within the liposomes and measured by 1H MRS - 
N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine lipid (CDAN) 
The LITA nanoparticle was formulated with varying the cholesterol lipid of (A) DDAB and 
varying molarities of either (B) 10% or (C) 50% CDAN, and amount of acetate encapsulated 
measure.  
 
 
(A) DDAB 
(B) 10% CDAN 
(C) 50% CDAN 
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Lipid Lipid variation 
Acetate 
encapsulated 
(mM) 
Formulation 1 DSPC (32); Chol (35); DPSE-
PEG2000 (1); CDAN (32) 
4.41 
DSPC DOPE 1.70 
 DLPC (C12) 1.02 
 DLPC (C20) 0.58 
 10% DSPC 4.19 
 50% DSPC 0.51 
Cholesterol DC cholesterol 0.00 
 10% Cholesterol 2.79 
 50% Cholesterol 0.00 
DSPE-PEG2000 DSPE-PEG500 0.00 
 DSPE-PEG10000 6.13 
CDAN DDAB 0.03 
 10% CDAN 1.28 
 50% CDAN 0.04 
 
Table 2.3 Quantitative summary of acetate encapsulated within the liposomes and 
measured by 1H MRS  
A panel of lipids and varying molarities were incorporated into numerous liposome 
formulations, filtered through dialysis and measured for characterisation of each formulation. 
This lipid selection was from each foundation lipid selected to incorporate into the liposome: 
DSPC (Figure 2.12), cholesterol (Figure 2.13), DSPC-PEG2000 (Figure2.14) and CDAN 
(Figure 2.15). The formulation with the highest amount of acetate was with DSPE-PEG10000. 
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2.3.3.2 Liposome characterisation spectroscopy to determine encapsulated acetate 
concentration of formulation parameters  
From the previous characterisation experiments carried out examining various liposome 
formulations, one was chosen (Formulation 1, encapsulated with 1M acetate) which had the 
ideal size, stability and acetate encapsulated. Moving forward, this formulation was applied 
with varying concentrations of acetate in order to determine maximum capacity of payload 
within the liposome.  
 
LITA was formulated with varying ranges of acetate was hydrated and measured by 1H NMR 
to determine acetate potential dosage in one administration of 200µl. LITA nanoparticles that 
were hydrated with 1mM encapsulated a total of 0.62mM (Figure 2.16). LITA nanoparticles 
that were hydrated with 10mM encapsulated a total of 0.30mM (Figure 2.17). LITA 
nanoparticles that were hydrated with 100mM encapsulated a total of 0.84mM (Figure 2.18). 
LITA nanoparticles that were hydrated with 10M encapsulated a total of 0.12mM (Figure 
2.19). 
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Figure 2.16 LITA nanoparticle characterisation- size and payload formulated with 1mM 
acetate 
LITA nanoparticle was formulated as previously described and rehydrated with 1mM acetate. 
(A) Size and stability were measured revealing a stable nanoparticle. (B) Encapsulated 
acetate was 0.62mM. 
 
 
 
A) 
B) 
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Figure 2.17 LITA nanoparticle characterisation- size and payload formulated with 
10mM acetate 
LITA nanoparticle was formulated as previously described and rehydrated with 10mM 
acetate. (A) Size and stability were measured revealing a stable nanoparticle. (B) 
Encapsulated acetate was 0.30mM. 
 
 
 
 
A) 
B) 
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Figure 2. 18 LITA nanoparticle characterisation- size and payload formulated with 
100mM acetate 
LITA nanoparticle was formulated as previously described and rehydrated with 100mM 
acetate. (A) Size and stability were measured revealing a stable nanoparticle. (B) 
Encapsulated acetate was 0.84mM. 
 
 
 
A) 
B) 
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Figure 2.19 LITA nanoparticle characterisation- size and payload formulated with 10M 
acetate 
LITA nanoparticle was formulated as previously described and rehydrated with 10M acetate. 
(A) Size and stability were measured revealing a stable nanoparticle. (B) Encapsulated 
acetate was 0.12mM. 
 
 
 
 
 
A) 
B) 
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2.3.3.2 LITA Characterisation for in vivo application 
Once a formulation was chosen, characterisation of the LITA nanoparticle was carried out. 
Table 2.4 describes the formulation for the five separate liposome formulations applied in the 
studies discussed in this thesis. (A) LITA-Rhd contains Rhodamine (Rhd), a fluorescent lipid 
used for biodistribution via histological investigation using fluorescence microscopy. (B) 
LITA-Gd contains gadolinium (Gd) for use in MRI biodistribution analysis. (C) LITA: 
liposomes conjugation used for the encapsulation of [18F] FDG, acetate or HEPES. (D) LITA-
xenograft, used for in vivo delivery to xenograft tumours, contains increased DSPE-PEG2000. 
(E) LITA-Rhd-xenograft contains Rhd for histological analysis targeted to the xenograft. 
Figure 2.20 is a schematic for the chosen formulation including the lipids used for 
incorporation. 
 
Figure 2.21 A-B shows the reproducibility of liposome in batch-to-bath formulations was 
evaluated, the LITA nanoparticles typically formulated slightly larger in size though there was 
no statically significant difference between groups (control: 93.82 ± 5.642, n=6; LITA: 105.4 
± 5.998, n=6; p=0.1905). The single peak in each graph represents the size distribution of a 
single reading of the liposomes from the Zetasizer. In the example used here, the PDI of 
HEPES was 0.175 (Figure 2.21 C) and the PDI of LITA was 0.475 (Figure 2.21 D). 
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 Table 2.4 Percentage molar components of liposome formulations 
Four separate liposome formulations were conjugated for this study. (A) LITA-Rhd: 
liposomes to contain 1% of Rhodamine (Rhd), a fluorescent lipid used for histology analysis; 
(B) LITA-Gd: liposomes to be conjugated with 1% gadolinium (Gd) for use in MRI bio-
distribution analysis; (C) LITA: liposomes conjugation used for the encapsulation of [18F] 
FDG, acetate or HEPES; (D) LITA-xenograft: liposomes to contain 5% DSPE-PEG2000 for 
increased in vivo circulation; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; CDAN: N1-
cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine; DSPE-PEG2000: 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-methoxy (polyethylene glycol)-2000; DOTA: gadoterate 
meglumine; DSA: digital subtraction angiography; DOPE – Rhodamine B:1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N- (lissamine rhodamine B sulfonyl); (E) LITA-Rhd-
xenograft: liposome contains 1% less cholesterol in order to allow for Rhd incorporation for 
histological analysis targeted to the xenograft. 
 
 
 
 
 
A) LITA-Rhd 32 32 1 34 1 -
B) LITA-Gd 32 32 1 34 - 1
C) LITA 32 32 1 35 - -
D) LITA-xenograft 32 32 5 31 - -
E) LITA-Rhd-xenograft 32 32 5 30 1 -
Gd.DOTA.
DSACholesterol
DSPE- 
PEG2000
 Molar component (%)                     
Application            DSPC CDAN
DOPE-
Rhodamine B
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Figure 2.20 LITA nanoparticle design principles 
 An overview of the nanoparticle formulation process, including chemical structures of the 
key bilayer components. LITA: Liposomal encapsulated acetate; DSPC: 1,2-distearoyl-sn-
glycero-3-phosphocholine; CDAN: N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine; 
DSPE PEG2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy (polyethylene 
glycol)-2000; DOTA: gadoterate meglumine; DOPE - Rhodamine:1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N- (lissamine rhodamine B sulfonyl); DSA: digital subtraction 
angiography. 
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Figure 2.21 Liposomal nanoparticle sizing method after completed formulation 
 The (A) formulated liposome size, data shown as mean ± SEM and (B) size distribution 
between groups showed no statistical significance between groups or batch-to-batch 
formulation (n=6/group). (C) Sizing peaks of control (containing HEPES) and (D) LITA 
(liposome encapsulated acetate) respectively. The x-axis represents the size (nm) of the 
nanoparticle and the y-axis represents the number (%) of liposomes. 
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2.3.4 Study 4: Liposomal Biodistribution and in vivo Optimisation 
 
2.3.4.1  Ex vivo liposomal detection using fluorescence microscopy imaging 
Bio-distribution of LITA-Rhd was achieved by histological investigation using fluorescence 
microscopy to visually identify the bi-layer incorporated lipid, rhodamine (Rhd). For in vivo 
optimisation, a panel of LITA-Rhd was formulated with varying concentrations of acetate 
(control of 0, 1mM, 10mM or 1M) and administered two different routes (i.v. or i.p.) with a 
dosage volume of 200µL. Organs of interest were extracted and observed 2 hours post 
injection (Table 2.5). For all concentrations of loaded acetate and injection methods, no 
visible adverse side effects were observed on the animal during or post injection. The high 
concentration of LITA-Rhd was observed in the liver (Figure 2.22) and spleen (Figure 2.23). 
A much lower visible presence of LITA-Rhd was observed in the kidneys (Figure 2.24) and 
almost no LITA-Rhd was observed in the heart (Figure 2.25).  
 
A control lens was first used to confirm there was no artefact that would generate a false 
positive identification of the LITA-Rhd (Figures 2.22- 2.25 A). A nuclear stain (DAPI) was 
then allied to the microscope slide to ensure the region being observed was tissue (Figures 
2.22- 2.25 B). A rhodamine-specific filter was used to observe the same slide for LITA-Rhd 
visualisation and confirmation of delivery to the tissue of interest (Figures 2.22- 2.25 C). Red 
in images represents the fluorescent rhodamine embedded into the liposome membrane. 
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Figure 2.22 LITA nanoparticle tumour localisation LITA-Rhd identification in the liver 
by histological fluorescence imaging  
Images obtained from the liver of a murine which received LITA-Rhd i.p. administration (A) 
control, (B) nuclear stain (DAPI), (C) rhodamine-specific filter visualisation. Red in images 
represents the fluorescent rhodamine embedded into the liposome membrane. 
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Figure 2.23 LITA nanoparticle tumour localisation LITA-Rhd identification in the 
spleen by histological fluorescence imaging  
Images obtained from the spleen of a murine which received LITA-Rhd i.p. administration 
(A) control, (B) nuclear stain (DAPI), (C) rhodamine-specific filter visualisation. Red in 
images represents the fluorescent rhodamine embedded into the liposome membrane. 
 
 
A
)
B
)
C
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Figure 2. 24 LITA nanoparticle tumour localisation LITA-Rhd identification in the 
kidney by histological fluorescence imaging  
Images obtained from the kidney of a murine which received LITA-Rhd i.p. administration (A) 
control, (B) nuclear stain (DAPI), (C) rhodamine-specific filter visualisation. Red in images 
represents the fluorescent rhodamine embedded into the liposome membrane. 
 
 
A 
B 
C 
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Figure 2.25 A nanoparticle tumour localisation LITA-Rhd identification in the heart by 
histological fluorescence imaging  
Images obtained from the heart of a murine which received LITA-Rhd i.p. administration (A) 
control, (B) nuclear stain (DAPI), (C) rhodamine-specific filter visualisation. Red in images 
represents the fluorescent rhodamine embedded into the liposome membrane. 
 
2
A 
B 
C 
118 
 
 
 
 
 
Table 2.5 Histological evaluation of LITA-Rhd at differing acetate concentrations and 
injection methods 
Histology was carried out in the organs of interest and examined for the presence of LITA-
Rhd, 2 hours after administration of the 200µL dosage volume. A range of acetate 
concentrations was loaded into the liposome and administered either i.v. or i.p. Select 
filtering organs were investigated for LITA-Rhd presence (n=3/group).  
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2.3.4.1.2 Histological evaluation of LITA-Rhd at differing time points after injection 
Animals were assessed at 16, 24 and 48 hours after LITA-Rhd i.p. injection (Table 2.6). 
Following peripheral injection, LITA-Rhd nanoparticles were present in the highest 
concentrations in the liver and spleen with lower concentrations observed in the kidneys at 
the earliest time point, which was consistent with the first histological study. No detectable 
signals from LITA-Rhd were observed in the skeletal muscle or lungs. Signal for LITA-Rhd 
was detected in the brain at all three time points, but not in the heart after the earliest time 
point of 16 hours (Figure 2.25).  
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Table 2.6 Histology time course of LITA-Rhd in selected organs 
Histology was carried out in select filtering organs of interest and examined for the presence 
of LITA-Rhd at 2, 16, 24 and 48 hours post injection (i.p.) of the 200µL dosage volume. The 
table indicated the presence of (ü) or absence (-) of rhodamine at these time points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liv r
Lung Heart Muscle
Kidney Spleen
 Liver Spleen Kidney Lungs Heart Brain Muscle Pancreas 
2h ü ü ü ü ü ü - ü 
16h ü ü ü - ü ü - ü 
24h ü ü ü - - ü - ü 
48h ü ü - - - ü - - 
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2.3.4.2 In vivo liposome detection using MRI and T1 measurements 
This experiment was carried out to profile the accumulation of LITA in vivo with and without 
Gadolinium in respect to tissue delivery over time. Gadolinium (Gd) is an MRI contrast agent 
which when taken up by the tissue decreases the relaxation time of the tissue and therefore 
increasing the T1 signal. Changes in T1 signal were assessed in: brain, liver, subcutaneous 
fat and kidney (Figure 2.26 A-D). At 24 hours the T1 values of the liver with LITA-Gd were 
significantly different from LITA (804.10 ± 81.81 msec; p<0.05). At 48 hours post 
administration of these was significant decreases in the liver T1 (495.90 ± 37.36 and 502.80 
± 65.89msec, respectively) compared to the T1 pre-administration (807.80 ± 76.59 msec; 
p<0.05). No changes in the T1 value were observed in hypothalamus, subcutaneous fat or 
kidney. Results for all T1 measurements can be seen in Table 2.7. 
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Figure 2.26 T1 measurement following administration of LITA nanoparticle conjugated 
with gadolinium (LITA-Gd) 
In vivo assessment of T1 values following peripheral delivery of LITA or LITA-Gd conjugated 
liposomes in the (A) liver, (B) brain, (C) subcutaneous fat and (D) kidney. Measurements 
were taken at 0, 2, 16, 24 and 48 hours post i.p. injection of LITA-Gd or LITA. T1 values in 
the liver were significantly reduced at 24 and 48 hours following LITA-Gd injection. No 
significant differences were observed between LITA-Gd and control groups in any other ROI 
at any time point. Data analysed by two-way ANOVA. Results are shown as mean ± SEM, 
n=4/group. 
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Before  
(mean ± 
sem) 
2 hours 
(mean ± 
sem) 
16 hours 
(mean ± 
sem) 
24 hours 
(mean ± 
sem) 
48 hours 
(mean ± 
sem) 
p 
value 
Liver       
LITA 
802.30  ± 
106.70 
746.80  ± 
99.01 
786.60  ± 
122.50 
804.10  ± 
81.81 
737.70  ± 
80.10 p<0.05 
LITA-Gd 
807.80  ± 
76.59 
755.60  ± 
110.60 
818.00  ± 
90.96 
495. 90  ± 
37.26 
502.80  ± 
65.89 p<0.05 
Brain      
LITA 
941.00 ± 
69.98 
1000.00 ± 
111.70 
1000.00 ± 
91.47 
963.00 ± 
52.99 
952.20 ± 
53.52 NS 
LITA-Gd 
905.70 ± 
49.12 
886.60 ± 
68.42 
884.80 ± 
77.33 
860.40 ± 
44.04 
890.10 ± 
98.50 NS 
Subcut   
LITA 
446.20 ± 
36.09 
451.40 ± 
43.24 
437.60 ± 
35.10 
427.80 ± 
26.44 
449.80 ± 
37.85 NS 
LITA-Gd 
432.30 ± 
16.61 
422.00 ± 
32.26 
442.90 ± 
38.55 
451.90 ± 
38.66 
454. 90 ± 
38.75 NS 
Kidney   
LITA 
902.60 ± 
106.60 
858.90 ± 
84.32 
825.30 ± 
81.07 
836.40 ± 
81.81 
949.50 ± 
93.74 NS 
LITA-Gd 
796.50 ± 
52.88 
873.50 ± 
86.73 
814.40 ± 
78.34 
814.40 ± 
78.43 
930.00 ± 
136.00 NS 
 
Table 2.7 T1 measurements post administration of LITA nanoparticle conjugated with 
gadolinium (LITA-Gd) 
In vivo assessment of T1 values following peripheral delivery of LITA or LITA-Gd conjugated 
liposomes in the liver, brain, subcutaneous fat and kidney. Measurements were taken at 0, 
2, 16, 24 and 48 hours post i.p. injection of LITA-Gd or LITA. No significant differences were 
observed between LITA-Gd and control groups in any other ROI at any time point. Data 
analysed by two-way ANOVA. Results are shown as mean ± SEM, n=4/group. 
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2.3.4.3  Real-time bio distribution assessment by PET/ CT fusion 
Bio distribution of the LITA nanoparticle in real-time was measured by PET/CT. Post 
injection are shown in Figure 2.27. Images are independently acquired during both the (A) 
PET, (B) CT scan and (C) fused PET and CT scans taken over 30 minutes.  
 
For liposomal distribution profiling, the mean intensity of [18F]FDG alone or encapsulated 
within the nanoparticle was taken and standardized uptake values (SUV). To determine 
uptake over time, the area under the curve (AUC) over the 30-minute acquisition time was 
calculated using the previously described SUV values. There was significant uptake of LITA 
encapsulated [18F]FDG when compared to the control [18F]FDG in the muscle (SUV p<0.01; 
AUC: p<0.05) (Figure 2.28), heart (SUV: p<0.01; AUC: p<0.05) (Figure 2.29) and brain 
(SUV: p<0.01; AUC: p<0.001) (Figure 2.30). There was no significant uptake difference in 
[18F]FDG uptake in the liver (Figure 2.31) or kidney (Figure 2.32).  
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Figure 2.27 PET/CT fused image after injection with [18F]FDG conjugated liposomes 
Representative (A) PET, (B) CT and (C) PET/CT fusion imagines 30 minutes after i.v. of 
200µL [18F]FDG conjugated liposomes. The bright regions in the (A) PET and (C) PET/CT 
images represent [18F]FDG uptake. 
 
 
 
1
A) B) C) 
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Figure 2.28 Standard Uptake Value (SUV) and Area under the curve (AUC) from 
muscle for 30min post-injection of [18F]FDG or [18F]FDG conjugated liposomes 
In vivo assessment of bio distribution following peripheral delivery of [18F]FDG or [18F]FDG 
conjugated liposomes over 30 minute acquisition time post i.v. injection in the muscle. (A) 
SUV was significant (*** = p<0.001). Data is presented as mean ± SEM and analysed as 
two-way ANOVA. (B) AUC were significant (p<0.01 vs. control). Data is presented as AUC ± 
SEM and analysed as unpaired t-test; n=4/group. 
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Figure 2.29 Standard Uptake Value (SUV) and Area under the curve (AUC) from heart 
for 30min post-injection of [18F]FDG or [18F]FDG conjugated liposomes 
In vivo assessment of bio distribution following peripheral delivery of [18F]FDG or [18F]FDG 
conjugated liposomes over 30 minute acquisition time post i.v. injection in the heart. (A) SUV 
was significant (* = p<0.05, ** = p<0.01 and *** = p<0.001). Data is presented as mean ± 
SEM and analysed as two-way ANOVA. (B) AUC were significant (p<0.05 vs. control). Data 
is presented as AUC ± SEM and analysed as unpaired t-test; n=4/group. 
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Figure 2.30 Standard Uptake Value (SUV) and Area under the curve (AUC) from brain 
for 30min post-injection of [18F]FDG or [18F]FDG conjugated liposomes 
In vivo assessment of bio distribution following peripheral delivery of [18F]FDG or [18F]FDG 
conjugated liposomes over 30 minute acquisition time post i.v. injection in the brain. (A) SUV 
was significant (* = p<0.05, ** = p<0.01 and *** = p<0.001). Data is presented as mean ± 
SEM and analysed as two-way ANOVA. (B) AUC were significant (p<0.001 vs. control). Data 
is presented as AUC ± SEM and analysed as unpaired t-test; n=4/group. 
Brain
0 5 10 15 20 25 30
0
1
2
3
4
[18F]FDG Lipo+[18F]FDG
*
*
*
**
*
**
*
********
**
*
Time (Minute)
S
ta
nd
ar
d 
 U
pt
ak
e 
V
al
ue
[18F]FDG Lipo+[18F]FDG 
0.0
0.5
1.0
1.5
2.0 ***
A
U
C
A)
B)
129 
 
 
Figure 2. 31 Standard Uptake Value (SUV) and Area under the curve (AUC) from liver 
for 30min post-injection of [18F]FDG or [18F]FDG conjugated liposomes 
In vivo assessment of bio distribution following peripheral delivery of [18F]FDG or [18F]FDG 
conjugated liposomes over 30 minute acquisition time post i.v. injection in the brain. (A) SUV 
did not reach significance. Data is presented as mean ± SEM and analysed as two-way 
ANOVA. (B) AUC did not reach significance. Data is presented as AUC ± SEM and analysed 
as unpaired t-test; n=4/group. 
Liver
0 5 10 15 20 25 30
0
1
2
3
[18F]FDG Lipo+[18F]FDG
Time (Minute)
St
an
da
rd
  U
pt
ak
e 
Va
lu
e
[18F]FDG Lipo+[18F]FDG 
0
10
20
30
40
50
AU
C
A)
B)
130 
 
 
Figure 2.32 Standard Uptake Value (SUV) and Area under the curve (AUC) from 
kidneys for 30min post-injection of [18F]FDG or [18F]FDG conjugated liposomes 
In vivo assessment of bio distribution following peripheral delivery of [18F]FDG or [18F]FDG 
conjugated liposomes over 30 minute acquisition time post i.v. injection in the kidneys. (A) 
SUV did not reach significance. Data is presented as mean ± SEM and analysed as two-way 
ANOVA. (B) AUC did not reach significance. Data is presented as AUC ± SEM and analysed 
as unpaired t-test; n=4/group. 
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2.3.4 Study 5: Liposomal Encapsulation of Butyrate and Propionate 
Once acetate was encapsulated and characterised, butyrate and propionate were 
encapsulated independently. Figure 2.33 show the size of liposomes encapsulated with 
butyrate (1M) and amount of butyrate encapsulated within 200µl of liposome solution. The 
size of the liposome revealed two peaks, one within size range of a normal liposome and 
another peak at too large a size to be a liposome, indicating an excess of lipids which did not 
formulate properly. 1H NMR revealed no amount of butyrate was encapsulated, indicating 
the formulation did not occur properly. 
 
 Figure 2.34 shows the size of liposomes encapsulated with propionate (1M) and amount of 
butyrate encapsulated within 200µl of liposome solution. The size of the liposome revealed 
two peaks, one within range of a normal sized liposome and another peak of similar size, 
though not within range of a formulated liposome. 1H NMR revealed no amount of 
propionate was encapsulated, indicating the formulation did not occur properly. 
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Figure 2.33 Butyrate encapsulated liposomal formulation and characterisation 
Formulation of butyrate encapsulated liposomes was attempted and characterised using the 
LITA formulation. (A) The liposome was sized using a zetasizer which did not form 
liposomes of appropriate size after formulation and dialysis. (B) 1H NMR analysis revealed 
no detection of butyrate was encapsulated within the liposomes.  
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Figure 2.34 Propionate encapsulated liposomal formulation and characterisation 
Formulation of propionate encapsulated liposomes was attempted and characterised using 
the LITA formulation. (A) The liposome was sized using a zetasizer which did not form 
liposomes of appropriate size after formulation and dialysis. (B) 1H NMR analysis revealed 
no detection of propionate was encapsulated within the liposomes. 
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2.4 Chapter Discussion 
 
The chosen method delivery of SCFA, specifically acetate, was a lipid-based nanoparticle 
known as a liposome. Liposomes are a preferential vehicle for therapeutic delivery due to 
the ability to overcome biological barriers to reach a desired organ of interest. In this study, a 
select composition of lipids were incorporated based on their properties to encapsulate and 
deliver such a small molecule, such as acetate, and in parallel act as an imaging agent for in 
vivo monitoring. 
 
One advantage of using the liposome is the modification capabilities and versatile lipids that 
can be incorporated into the formulation to specify the exact purpose. The characteristics of 
liposome formulation, including particle size, surface change properties and encapsulated 
small molecule/lipid ratio possess an influential effect on the cellular uptake. The formulation 
specificity for the LITA nanoparticle was two-fold, one objective was to formulate a particle 
with high payload of a very small molecule and the other was to ensure it reached the organ 
of interest. To achieve both objectives, the lipids of choice were rigid enough to form a tight 
bilayer and have an external environment in order to control circulation time in vivo. The first 
set of experiments was to determine the ideal formulation for a liposome which is stable, a 
functional size, contains contrast agents for in vivo monitoring, encapsulates acetate and 
reaches the organ of interest. From previous work carried out in this lab [216], four main 
lipids were chosen as the foundation lipids: CDAN, DSPC, DSPE-PEG2000 and cholesterol. 
 
 The purpose of the CDAN was to increase uptake within the cell. CDAN are cationic lipids 
which enhance liposomal uptake into the cellular membrane [217]. The isoform, DDAB, did 
not perform as well as the initial CDAN most likely because of the strong cationic properties. 
DSPC is a good building block for liposomes due to a long chain of lipids to encourage a 
higher encapsulation efficiency and stability [218]. The key is the PC (phosphatidylcholine) 
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part; DS stands for di-stearoyl (di-C18 saturated alkanoyl chains). Therefore any PC variants 
being used as alternatives to DSPC, containing the same or different alkanoyl chains 
between C12 and C20 in length, saturated and unsaturated were tested. Length chains 
<C12 and >C20 were proven less likely to formulate stable nanoparticles. Secondly I 
exchange the DSPC with potential alternatives, including DOPE and DLPC, which did not 
formulate as well as the DSPC lipid. There are two components of the DSPE-PEG2000; the 
DSPE is a cholesterol lipid which anchors the PEG lipid securely into the external membrane 
of the liposome. Variation in the size of the molecular weight of the PEG lipid was carried 
out, using PEG of PEG500 to PEG10000. The ideal size of PEG length was confirmed to be 
2000, which is consistent with most PEG literature [219, 220]. The PEG lipid causes a 
negative peripheral charge, which has a ‘stealth-like’ effect of macrophages in the 
bloodstream and therefore increases circulation time of the liposome within the body [191]. 
Cholesterol is an important structural lipid which strengthens the bilayer of the liposome 
increasing the amount of acetate that can be contained within, and also decreasing the rate 
at which acetate leaks out [221]. There are no real structural variations possible here; 
however we have tested the use of Dimethylaminoethane-carbamoyl cholesterol (DC 
cholesterol), to assess if there is any difference compared to normal cholesterol, which did 
inhibit formulation of the liposome.  
 
Again, for each lipid, a formulation was carried out which had a varied molarity of select 
lipids. Based on size and acetate encapsulation, the best formulation of choice was: DSPC 
(32%); Cholesterol (35%); DPSE-Peg2000 (1%); CDAN (32%). The additional lipids used for 
bio distribution studies were used for identification purposes only and did not have any effect 
on the liposome to our knowledge [216, 222]. Liposomes in this study were approximately 
100nm to avoid macrophage uptake and have the ability to fit through the artery walls in 
order to be taken up by organ tissue [223]. 
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 The yielded liposome from this process was shown to indeed encapsulate acetate by 13C 
NMR spectroscopy confirmation. This was achieved by the use of albumin, which is a 
relatively large molecule that has been shown to bind to anionic molecules such as acetate 
[224]. The binding of albumin to acetate causes a reduction in the NMR signal of the 
compound and thus hinders any acetate signal that was not encapsulated within the 
nanoparticle [225].   
 
Addition of albumin to a liposome free acetate solution had a significant effect on the NMR 
signal intensity of the latter, reducing its presence in the spectra significantly and 
demonstrating albumin macrostructure does interact with the acetate molecule. No such 
effect was observed with the liposomes encapsulated acetate solution. Having a remaining 
peak after the addition of albumin to the LITA nanoparticle solution indicates that the acetate 
molecules are protected from albumin interaction within the liposomal structure. These data 
indicate that acetate is encapsulated within the confines of the nanoparticle to which albumin 
does not have access. Once it was confirmed acetate was in fact encapsulated within the 
liposome, the concentration of encapsulated acetate was determined using 1H NMR 
spectroscopy. A known amount of lactate was added to the LITA solution once the 
formulation was complete and the combination of solutions was freeze-died. The released 
acetate from within the liposomes was compared to the concentration of the lactate added 
and by using the ratio between lactate and acetate.   
 
A range of concentrations of acetate was encapsulated into liposomes to determine the 
maximum amount of payload. Five concentrations were attempted, of which the maximum 
acetate was found to be encapsulated when the liposome was formulated with 1M of acetate 
(4.41mM). Concentrations lower than 1M had a concentration dependent gradient of 
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encapsulated acetate. Concentrations higher than 1M did encapsulated only traces of 
acetate, most likely because of the rehydrated solution was overly acidic. 
 
After the LITA nanoparticle was confirmed to formulate appropriately and encapsulate 
acetate, the bio distribution profile came into question. Histology, MRI T1 measurements and 
PET/CT in real time were employed to demonstrate that LITA reach the organs of interest or 
the desired frame of time. Histology was conducted to examine accumulation of the LITA 
embedded within the multiple organs across a panel time points, injection methods and 
acetate concentrations. Though histology is a reliable method for liposomal detection, there 
are limitations regarding the bio distribution over time and the uptake of the material 
encapsulated within the liposome. For these reasons, I turned to two other methods of bio 
distribution to access the LITA nanoparticle: MRI and PET/CT. MRI was used to measure 
LITA accumulation within the tissue over a 24 hour period; however the limitations of 
sensitivity and indication of encapsulated material release encourage me to carrying out 
PET/CT in parallel. The study examining PET/CT allowed me to monitor liposomal bio 
distribution within the first 30 minutes and accumulation of the material encapsulated within 
the liposome, which I was unable to do with either MRI or histology. With these three 
different methods, I was able to determine the bio distribution profile, time frame and 
deposited payload of the LITA nanoparticle.  
 
Histology visually confirmed the presence of liposomes within the tissue and was carried out 
by incorporating the lipid rhodamine into the liposome formulation (LITA-Rh), which is a 
fluorescent lipid easily identifiable by microscopy. Confirmation of LITA-Rhd is a reflection of 
visual identification of a red colour generated by the fluorescent rhodamine lipid. The 
ensuing two images serve as controls eliminating the possibility of any false positive of 
background artifacts and confirming the LITA-Rhd identification is in fact located within the 
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tissue. The fluorescence pattern observed from the liver sections of the LITA-Rhd can be 
explained by the “endothelial massage” theory put forward by Wisee and McCucky [226]. 
This theory describes the movement of fluid and small particles in and out of the Space of 
Disse, which is the area located between the endothelial lining of the hepatic sinusoid and 
the hepatocytes. It has also been shown that Kupffer cells take up far more liposomes per 
cell than other cell types, which may explain the strong fluorescence observed in Figure 2.9.    
 
After histology confirmed the delivery of liposomes, the next step was to investigate the bio 
distribution profile in vivo. MRI was employed to measure T1 of the liposome in circulation. 
Liposomes (LITA-Gd) were formulated containing a gadolinium lipid, which is a 
paramagnetic ion that increases the signal in the tissue it is absorbed into [227, 228]. 
Although histology confirmed the presence of liposomes in multiple organs, T1 change was 
only observed in the liver. This is more likely related to the lower accumulation of liposomes 
in these tissue compare with the liver. A significant T1 reduction was observed in the liver, 16 
and 24 hours post injection of Gd liposomes [213]. 
 
Bio distribution in real time was conducted in vivo using PET/CT with the metabolic tracer 
[18F]FDG to assess whether uptake is altered between [18F]FDG or [18F]FDG conjugated 
liposomes. Previous studies have been carried out using [18F]FDG with liposomes [229], 
however this is the first to my knowledge that encapsulated the tracer instead of 
incorporating it into the bi-lipid membrane of the liposome. This study allowed a number of 
questions to be answered, such as the distribution profile of the liposome, a secondary 
confirmation of encapsulation of a small molecule and the duration of encapsulation. It was 
determined previously that the LITA did have the ability to encapsulate small molecules, 
however we did not have a method to analyse uptake behaviour in real time.  
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The results from this study reveal there a difference uptake profiles between the [18F]FDG 
and [18F]FDG conjugated liposomes, confirming the encapsulation of [18F]FDG within the 
LITA. The distribution pattern fit within our expectations of liposomal uptake, especially with 
the filter organs such as the liver.   
 
 
2.4.3  Conclusion 
In this chapter, a select composition of lipids were incorporated based on their ability to 
encapsulate and deliver such a small molecule, such as acetate, and in parallel act as an 
imaging agent for in vivo monitoring. The formulation specificity for the LITA nanoparticle 
was two-fold, one objective was to formulate a particle with high payload (4mM) of acetate 
and the other was to ensure it reached the organ of interest, which in this case was the liver. 
For this thesis, the desired liposomal size was approximately 100nm and the lipids used had 
specific purposes including a labelling mechanism, a layer to sterically inhibit uptake in the 
plasma, and lipids of rigid formation to ensure the encapsulation of such a small molecule. 
Encapsulated acetate was measured by 1H NMR, which quantitatively confirmed that a 
single treatment of 200µl of LITA would contain 52.9µg of deliverable acetate.  
 
Histology, MRI T1 measurements and PET/CT in real time were employed to demonstrate 
the LITA reach the organs of interest in within the desired frame of time. Histology confirmed 
the presence of the LITA-Rhd nanoparticle in the tissue when examined at varying time, 
injection method and acetate concentrations. All of these methods yielded the biodistribution 
profile of the nanoparticle and confirmed delivery to the liver. 
 
 
140 
 
 
 
 
 
 
 
 
Chapter 3 
 In Vivo Biological Evaluation of 
liposome encapsulated acetate 
nanoparticles (LITA) 
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3.1 Introduction 
As discussed in detail in Chapter 1, the increasing prevalence of obesity has created an 
urgent need to understand its aetiology and that of the metabolic syndrome associated 
morbidities in order to develop effective novel treatments. Relevant here, epidemiological 
studies have indicated that nutritional supplementation with dietary fibre ameliorates several 
features of the metabolic syndrome by promoting reductions in body weight, total body fat 
and blood glucose levels [91, 159, 230, 231]. In fibre, component carbohydrates are 
resistant to amylase digestion in the small intestine, but are subject to fermentation by 
microflora in the large intestine, producing short-chain fatty acids (SCFA) such as acetate, 
propionate and butyrate [159, 232]. Of these SCFAs, acetate in particular has been 
suggested to mediate beneficial effects on features of the metabolic syndrome including 
reductions in fat mass, IHCL, inflammation and improvements in insulin sensitivity, as a 
dietary supplement [90, 230, 233]. 
 
In Chapter 2, I showed the encapsulation of acetate within a liposomal nanoparticle which 
could deliver up to 4.41mM of acetate per injection dose of 200µL. The biodistribution of the 
liposomes through histological evaluation, T1 measurements and PET/CT confirmed the 
potential delivery to organs of interest, specifically the liver. Thus, the acetate encapsulated 
liposomes provide a viable, passively targeted vector for delivering SCFAs to key sites of 
metabolic control.  
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3.1.1 Aims of Studies 
To investigate the metabolic effects of chronic administration of the LITA nanoparticle 
in mice and on a high fat diet. This study will assess the in vivo phenotypic and metabolic 
effects chronically administered liposomes encapsulated with acetate in a high fat model 
environment. A model of obesity will be established by placing mice a high fat diet and once 
an obese state is established, control or LITA nanoparticles will be administered to 
determine if an introduced SCFA will change the obesogenic state or have an effect on liver 
metabolism and assess for phenotypic and molecular changes. 
 
To investigate metabolic effects of LITA nanoparticles using indirect calorimetry in 
mice on a normal fat diet. This will establish the metabolic profile of the LITA in vivo after a 
7 day administration period using the CLAMS cages. This may indicate how the LITA is 
being metabolized and if there are any changing in gas exchange or activity in mice with 
control or LITA nanoparticle treatment. The diet used in this study will be a normal fat diet to 
determine the metabolic effects of LITA in a non-obese environment.  
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3.2 Methods 
3.2.1 Materials 
3.2.1.1 Animals 
Male WT C57BL/6 mice (specific pathogen free (SPF), Harlan, UK) were maintained in 
individually ventilated cages (IVC) under controlled conditions of temperature (21-23°C) and 
light (12 hrs light, 12 hrs dark, lights on at 7am) with access to food and water ad libitum. All 
work with IVC animals was carried out under a ventilated fume hood. All experiments were 
carried out in compliance with Animals (Scientific Procedure) Act 1986 under the project 
licence 70/6656. 
 
3.2.1.2 Diets 
For mice placed on a normal fat diet (NFD), a 16% kCal diet (RM3) was used. For mice 
placed on a high fat diet (HFD), a 60% kCal fat diet (EF D12402) was used. Both diets were 
used independently and in specific models that are outlined in the following text. Dietary 
details are outlined in Table 3.1. Details of each diet were provided by SSNIFF (England, 
UK), the company from which these diets were purchased. 
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Ingredients Normal fat diet High fat diet 
Crude fat 4.25 34.0 
Crude protein 22.39 24.1 
Starch 33.92 2.2 
Sugar 5.75 22.4 
Energy 11.36 MJ/kg 21.4 MJ/kg 
 
Table 3.1 Ingredients of diets used in feeding studies 
The normal fat diet (RM3) used was composted of 4.25% crude fat with a level of energy 
that could be metabolised containing 11.36MJ/kg. The high fat diet (EF D12402) used was 
composed of 34% crude fat. The level of energy that could be metabolised from the high fat 
diet contained 21.4 MJ/kg. 
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3.2.2 Study 1: Chronic LITA Nanoparticle Administration on an Obesogenic 
Background  
Pre-clinical relevance of the liposomal therapy was carried out using an in vivo model over a 
15 week period. At 5 weeks of age, mice were placed on a high fat diet for 5 weeks, during 
which time food intake and weight gained were monitored at least 3 times a week. At 10 
weeks of age the mice underwent a 1H MRS of the liver to establish a baseline for 
intrahepatocellular lipid (IHCL) content prior to liposomal therapy. After which, the mice 
received chronic delivery of either LITA or the control nanoparticles by i.p. injection every 2 
days for 5 weeks. The injection volume was 200µL, which contained approximately 5x108 
liposomes per injection. Mice remained on the high fat diet for the duration of the liposomal 
therapy. At the end of study, MRS was repeated in order to determine the effects of 
liposomal therapy on IHCL. The timeline of the process can be seen in Figure 3.1. 
 
 
 
 
 
 
  
Figure 3.1 Timeline of the model carried out for liposomal therapeutic study 
At 5 weeks of age the mice were placed on a high fat diet, which they consumed for the 
duration of the study. At 10 weeks of age, 1H MRS of the liver was carried out for the pre-
therapy scan prior to the initiation of liposomal injections. At 15 weeks of age, the 1H MRS 
was repeated as a post-study scan before animals were sacrificed.  
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3.2.2.1 Whole body 1H MRS scanning parameters 
Mice were placed on a high fat diet to induce a fatty liver development and localised 1H liver 
MRS scans were performed to access IHCL content before and at the end of treatment. 
Prior to the scans, animals were fasted overnight for 16-18 hours. For the scan, mice were 
anaesthetised with 2 – 3% isoflurane 2/min oxygen, placed prone into the RF coil with the 
liver at the centre of the coil and scanned on a 4.7T Unity Inova MR scanner (Varian Inc, 
USA). During the scan, a breathing pad was used to monitor respiration rate and a rectal 
probe was used to measure core temperature, which was maintained at 37° C with a warm 
air blower.   
 
The field homogeneity was optimised by shimming on the water signal of the whole mouse. 
A three plane scout image was taken in order to plan a series of contiguous axial slices over 
the mouse abdomen to give full liver coverage. Localised 1H liver MRS was performed using 
a PRESS sequence with a voxel 2x2x2mm3 placed using whole body MRI with the following 
parameters: repetition time (TR) 10s, echo delay time (TE) 9ms, averages 64 and spectral 
width 20,000Hz. Total scanning time was approximately 30 minutes per animal. Statistical 
analysis for determining IHCL using 1H liver MRS was carried out using MestRe-C software.  
 
3.2.2.2 Tissue collection and glucose measurement 
Anaesthesia was induced with a 3% oxygen-isofluorane and approximately 1mL of blood 
was collected by cardiac puncture, at which point the animal was then culled and dissected. 
Subcutaneous, epididymal, retroperitoneal and mesenteric white adipose tissue was 
collected, along with brown adipose tissue, liver, pancreas, spleen, kidneys, and heart 
tissues were collected. All tissue samples were frozen in dry ice and kept at -80°C until used 
for further analysis. Glucose was also measured during organ collection by a glucose meter 
(Boots, UK).  
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3.2.2.3 Adipocyte isolation and counting 
During dissection, samples from the epididymal and subcutaneous fat depots collected were 
used to isolate and measure adipocyte numbers and size. Dulbecco's Modified Eagle 
Medium (DMEM) solution (glucose 1g/mL) was prepared with 4% albumin. Collagenase 
solution was made up by adding 1mg/mL of collagenase to the DMEM solution with 4% 
albumin. Wash buffer solution was prepared with trypsin inhibitor 1mg/mL of 4% albumin 
DMEM solution. The tissue was rinsed in DMEM solution 4% albumin and then added to a 
bijou tube along with 1mL of prepared collagenase solution per 0.5g of tissue. The tissue 
was finely minced with scissors and kept in a vibrating water bath at 140 cycles/min and 
37°C for 75-90 minutes. The cell suspension was then filtered through a polypropylene mesh 
(250µm) in order to separate the adipocytes from undigested tissue into a clean bijou tube. 
To stop any further digestion separated adipocytes were washed thoroughly with wash 
buffer. The tube was left out of the water bath till a cell suspension was formed. Then using 
a blunt needle, the wash buffer was sucked up from underneath the cells. More wash buffer 
was added to the tubes and left until the cell suspension was formed again. 
 
After the second wash, the wash buffer was removed and the cells were transferred to a 
universal tube. DMEM solution (5mL DMEM, glucose 1g/mL and 4% albumin) was added to 
the universal tube and this was left in the water bath at 120 cycles/min and 37°C for 30-60 
minutes. The adipocytes were then sized using MultisizerTM 4 Coulter Counter (Beckman 
Coulter, USA). 
 
3.2.2.4 Serum analysis 
Blood was collected via cardiac puncture during dissections and treated with 10% Aprotinin 
(100000KIU) at the collection time, allowed to clot on a rocker for at least 30 minutes and 
then centrifuged at 4000rpm for 10 minutes. Serum was removed and kept at -80°C until 
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used. These samples were used for analysis of cholesterol, triglycerides, HDL and LDL, 
albumin, free fatty acids and adiponectin were measured using 2-site electrochemical 
luminescence immunoassays from MesoScale Discovery (Gaithersburg, USA). Free fatty 
acids were measured using the Non- Esterified Free Fatty Acid kit (Roche). Creatinine, ALT, 
AST, alkaline phosphate, triglyceride, HDL and cholesterol were measured on the 
Dimension RXL autoanalyser (Siemens Healthcare).  
 
3.2.2.5 Protein extraction 
Tissues were weight and placed into an Eppendorf, which contained 250µl per gram of 
tissue of homogenisation buffer (50mM Tris, 5mM sodium pyrophosphate, 50mM sodium 
fluoride, 1mM EDTA and 0.25M Sucrose) supplemented with protease inhibitors (1 tab per 
5mL, Roche). Samples were briefly homogenised while maintaining a constant temperature 
of 4oC and 20µl of 10% Triton X-100 added and left to incubate on ice for 10 minutes, 
centrifuged at 14,000rpm for fifteen minutes at 4oC. From the supernatant aliquot, the 
concentration of protein homogenates was measured immediately with BCA protein assay 
(Thermo Scientific, USA). Protein homogenates were kept at -80oC until the next use and 
precipitated residues were kept at -80oC for histone extraction. Protein expression levels 
were analysed with Western blotting as described in 3.2.3.6. 
 
3.2.2.6 Western blot analysis 
Equal amounts of protein homogenates (50µg) were resolved by SDS-PAGE on a 4-12% 
bis-tris gel (Invitrogen, UK) and transferred to an Immobilon transfer membrane (Millipore, 
UK). After transfer, the membrane was blocked in 5% non-fat dry milk in 1x TBST (50mM 
Tris, 150mM sodium chloride and Tween-20) for 1 hour at room temperature. Following the 
blocking step, the membrane was incubated with purified primary antibodies, targeted to 
various proteins, raised in rabbit or mouse (AbCam, UK) overnight at 4oC on a shaking 
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platform. TBS was diluted from 10X TBS (24.2g Tris base, 80g NaCl in 1 litre H2O, pH was 
adjusted to 7.6 with HCl) and washed in TBS-tween three times, 5 minutes each, and 
incubated in horseradish peroxidase-conjugated secondary anti-mouse antibodies, diluted 
1:2000 in TBST (Santa Cruz Biotechnology, USA), anti-rabbit (1:10000, Sigma-Aldrich) in 
5% non-fat milk in TBS-tween at room temperature for one hour on a shaking platform. The 
secondary antibodies were removed and the membrane was washed with TBST. The 
membrane was further washed three times with 1x phosphate buffered saline (PBS) the 
same way and the proteins were visualised using enhanced chemiluminescence (GE 
Healthcare, UK). Optical densities of individual bands were measured and protein 
expression was standardized to β-actin (mouse monoclonal, 1:10000, Sigma-Aldrich). Image 
acquisitions were carried out by Image J; statistical analysis was carried out by calculating 
the relative intensity using the described housekeeper. 
 
3.2.2.7 RNA isolation and cDNA synthesis 
Total RNA was isolated from 30~100mg of liver tissue and homogenized as described in 
3.2.3.5 and then centrifuged at 12,000 g for 5 minutes at 4oC. The supernatant was 
discarded and pellet was resuspended in 100µL of TE buffer and combined with pre-cooled 
75% (v/v) ethanol. The supernatant and ethanol solution was loaded into a RNA isolation 
column (Sigma-Aldrich, USA) and isolated according to manufactures guidelines. To remove 
the potential genomic DNA all RNA samples were further treated with DNase using TURBO 
DNA-free™ Kit (Ambion, USA) according to manufacturer’s guidelines. All RNA samples 
were measured for concentration and quality on a nanodrop (Thermo Scientific, USA) and 
stored at -80 °C until use. 
 
Total RNA (500ng), 1µL 250ng primer oligo(dT)16 and 1µL 10mM dNTP mix (10 mM each 
dATP, dGTP, dCTP and dTTP at neutral pH) were mixed with dH2O and pre-heated to 70°C 
150 
 
and then cooled on ice for cDNA synthesis. 20µl of reagents, containing 4µl 5X first-strand 
reaction buffer (250mM Tris-HCl, 375mM KCl, 15mM MgCl2), 1µl 0.1M DTT and 1µl of 
Super-script III Reverse Transcriptase (Invitrogen, UK), were incubated at 25ºC for a 5 min 
annealing step, followed by an extension step at 42°C for one hour followed by a final step at 
70ºC for a 15 min heat-inactivate step. 
 
3.2.2.8 Quantitative real-time polymerase chain reaction 
Expression of mRNA was quantified by TaqMan real-time RT-PCR with a GeneAmp 7500 
Fast System (Applied Biosystems, USA). Each reaction mixture contained 1x SYBR Green 
PCR master mix, 1µl cDNA (normalized to represent the equal amount of reverse-
transcribed total RNA in each sample), 0.4µM each TaqMan primer and RNase-free water 
(Qiagen). A 10-fold dilution of RT reaction for each sample was analysed using TaqMan 
Gene Expression Assays (Applied Biosystems, USA) with commercially available specific 
primer-probes. Real-time PCR reactions were set following the manufacture instructions: 
one initial step at 95ºC for 10 minutes for holding, followed by a 40-cycle step, which was 15 
seconds at 95°C for denaturation and one minute at 60°C for annealing or extension. The 
fluorescent dye ROX was used as an internal reference for normalisation of SYBR Green 
fluorescence. A dissociation protocol ranging from 60°C to 90°C was performed to 
investigate the specificity of the primer and the presence of primer dimers after the final 
amplification cycle. Threshold cycle (Ct) values obtained for each gene were converted to 
the linear form using the term 2–▲▲Ct as a value directly proportional to the copy number of 
mRNA 237, where ▲▲Ct was the Ct value normalized to GAPDH and referenced to the 
values obtained for each gene under normoxic conditions. 
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3.2.2.9 Histone extraction 
Tissue residues from protein extraction were washed twice with ice-cold PBS containing 
5mM sodium butyrate to retain levels of histone acetylation. Lysis buffer (10mM Tris 6.5 pH, 
50mM sodium bisulphate, 10mM MgCl2, Sacarose 8.6%, 1% Triton X-100) was added to 
samples on ice and left to incubate on ice for 10 minutes, centrifuged at 14,000rpm for 
fifteen minutes at 4oC. After thorough homogenation, the supernatants were removed and 
the pellets washed with Tris-EDTA (10mM Tris 7.4 pH, 13mM EDTA) and centrifuged at 
14,000rpm for 15 minutes at 4oC. Precipitated nuclei were resuspended in 50µl of ice-cold 
dH2O. 50µl 0.4M sulfuric acid was added to the samples, vortexed, and kept on ice 
overnight. Following centrifuge at 15,000rpm for another one hour, histone was precipitated 
as white pellets in 1mL acetone at -20°C overnight. Dry pellets were resuspended in dH2O 
for measurements of histone concentration with Bradford assay (Bio-Rad, UK). Histone 
expression levels were analysed with Histone acetylation assessment as described in 
3.2.2.9.1. 
 
3.2.2.9.1 Histone acetylation assessment 
Histone acetylation was assessed with Western blotting. Equal amounts of histone extracts 
(10µg) were resolved by SDS-PAGE on a 12% bis-tris gel (Invitrogen, UK) and transferred 
Immobilon transfer membrane (Millipore, UK). After transfer, the membranes were blocked in 
5 % non-fat dry milk in TBS-tween with agitation for one hour and then incubated with 
purified rabbit polyclonal antibodies against human acetyl-histone H3 (1:20000), acetyl-
histone H3 lysine9 (acH3K9, 1:20000), acetyl-histone H4 (1:2000) and acetyl-histone H4 
lysine12 (acH4K12, 1:2000, Millipore) in 5% BSA in TBS-tween overnight at 4°C on a 
shaking platform. After washed in TBS-tween three times, 5 minutes each, they were 
incubated in HRP-conjugated secondary antibodies against rabbit (1:10000, Sigma-Aldrich) 
in 5% non-fat milk in TBS-tween for one hour at room temperature on a shaking platform. 
The membranes were then washed three times again, 5 minutes each, and the proteins 
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were detected by chemiluminescence (Amersham GE Healthcare, UK). Optical densities of 
individual bands were measured and acetyl-histone expression was standardized to total 
histone H3 (rabbit polyclonal, 1:10000, Millipore) or total histone H4 (rabbit polyclonal, 
1:2000, Millipore), which were executed on parallel gels as loading control. The data were 
presented as ratio of acetyl-histone over total histone. 
 
3.2.2.10 Microarray  
A genome wide expression analysis with DNA microarray was carried out on liver samples 
from LITA and control nanoparticle groups at the end of the 10 week study (n=5/group). 
GeneChip Mouse Gene 2.0 ST Array was used to examine the whole-transcript of the liver, 
which contain 35,240 probe sets. Total RNA, was extracted from frozen liver specimens 
using the miRNeasy Mini Kit (Qiagen). RNA quality and integrity was assessed with the RNA 
6000 Nano Assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, USA). Samples 
selected for further analysis had integrity factors (RIN) in the range of 7.0–7.6. Total RNA 
(500ng) was transcribed in vitro with an RNA amplification fit and IVT reagents (Affymetrix, 
USA) to label cDNA synthesis with nucleotides coupled to a fluorescent dye was prepared 
following Alexa Fluor 555 and Alexa Fluor 647 (Invitrogen) Kit protocols. Labelled RNA 
quality was again assessed with an Agilent Bioanalyser. Hybridization and scanning was 
carried out at the MRC microarray centre (Hammersmith Hospital, London, UK). The 
hybridization array was washed and scanned and data was extracted from the scanned 
image using Feature Extraction (FE) version 10.2 (Agilent technologies).  
 
Raw microarray data (cel files) were imported into R using the software package 
Bioconductor (R Development Core Team). An MA plot was carried out in the initial data set 
to determine if there was a need to correct any of the individual samples for differences that 
were not due to the biological data. The MA-plot distributes the intensity ration (M) plotted by 
153 
 
the average intensity (A). One to adjust for differences in labelling intensities and 
hybridization identified from the MA plot, a global normalization was conducted by aligning 
signal intensities of data arrays across the medians. Only probe sets that had a signal 
intensity distribution profile similar to the sample set carried through to analysis; in this case, 
4 arrays were analysed, giving a raw dataset of 16,321 probe sets. Raw data were 
normalized with a log2 transform with median stabilization. Suppression of controls, 
normalization, filtering and expression summary was carried out with the moderate t-test 
Linear Models for MicroArray (LIMMA) in the R-package LIMMA [234]. The parameters m 
and v are treated as known and set equal to the estimated values, and the Bayesian 
modelled t-test. LIMMA provided functions to summarize the results as (log) fold change in a 
linear model. 
 
 
3.2.3 Study 2: Chronic LITA Nanoparticle Administration in Metabolic Cages 
For metabolic chamber experiment, male WT C57BL/6 mice were assigned to a treatment 
group randomly and received i.p. injections of control or LITA nanoparticles (prepared as 
described in Chapter 2), daily for 7 days prior to being placed in the metabolic cages. The 
injection volume was 200µL, which contained approximately 5x108 liposomes per injection. 
Mice were housed 1 per cage with access to normal fat diet food (Table 2.1) and water ad 
libitum (n=8/group).   
 
For metabolic measurements, mice were housed in a climate-controlled metabolic chamber 
designed for mouse studies, the Comprehensive Lab Animal Monitoring System (CLAMS; 
Columbus Instruments, USA). The open-circuit indirect calorimetry system chambers were 
maintained at 2-22°C on a 12-hour light/12-hour dark cycle with lights on at 7am. Mice 
remained on the same food and water as in the week during the nanoparticle administration. 
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Each animal was housed individually in an airtight cage where oxygen consumption (VO2) 
and carbon dioxide expiration (VCO2) was measured by high-speed gas sensors on a 
continuously monitored for 48 hours in a 24 chamber open circuit Oxymax. Mice were 
acclimated to their metabolic cages for 5 hours before data was acquired. Samples were 
obtained electronically hourly and recorded during the 30-second sampling period. Other 
metabolic measurements such as food intake, locomotor activity and core temperature were 
also acquired. 
 
3.2.4 Statistical Analysis 
All the results are presented as mean ± standard error of the mean (SEM) or mean ± 
standard deviation (SD). Statistical analysis was performed by GraphPad Prism version 4 
(GraphPad Software, USA). One-way ANOVA was applied for data of multiple group 
comparisons, whereas Two-way ANOVA was applied for data when there was more than 
one independent variable with multiple observation periods. For comparison between two 
groups, unpaired nonparametric t-test with Mann- Whitney modification was used. Any other 
analysis method is mentioned in the specified text. Significance was accepted at the level of 
p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***). 
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3.3 Results 
 
3.3.1 Study 1: Chronic LITA Nanoparticle Administration on an Obesogenic 
Background 
Liposomes described in Chapter 2 were applied for an in vivo passive targeting system with 
4mM of acetate loaded within the aqueous core of the vesicle. Preliminary biodistribution 
studies confirmed the acetate encapsulated liposomes does reach the circulatory system 
intact. Moving forward, the liposomal encapsulated acetate nanoparticle, or LITA, was 
applied to an in vivo model for observations in an obese state.  
 
3.3.1.1 Food Intake and body weight 
No statistically significant difference in average food intake between groups was observed 
(control: 18.04 ± 0.999; LITA: 15.29 ± 1.216, p=0.6170) (Figure 3.2 A). No statistically 
significant difference in cumulative food intake between groups at any week for the duration 
of the 10 week study was observed (p=0.978) (Figure 3.2 B). 
 
Figure 3.3 shows the weight gain measured weekly over the 10 week study (n=8/group). The 
LITA group show an increase in body weight compared to the control (two-way AONVA, 
p<0.01 vs. Control). Similar changes were observed in cumulative body weight (two-way 
AONVA, p<0.05 vs. Control) for the last four weeks of the study (Figure 3.3 A-B). However 
there was no observed statistically significant difference when we comparing change in body 
weight (Control: 6.586 ± 0.8983; LITA: 7.075 ± 0.6310; unpaired t-test), or cumulative 
change in body weight between groups (two-way ANOVA) (Figure 3.3 C-D). 
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Figure 3. 2 Effects of average and cumulative food intake of chronic i.p. injections of 
control to LITA nanoparticles in ad libitum fed mice on high fat diet 
Food intake of ad libitum fed mice on high fat diet was measured weekly after i.p. injections 
of control or LITA nanoparticles. (A) Average food intake showed no significant difference 
between groups. Data analysed by unpaired t-test. (B) Cumulative food intake showed no 
significant difference between groups. Data analysed by two-way ANOVA. Results are 
shown as mean ± SEM; n=8/group. 
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Figure 3.3 Effects on body weight of chronic i.p. injections of control to LITA 
nanoparticles in mice on high fat diet 
Body weight of mice on high fat diet was measured weekly after i.p. injections of control or 
LITA nanoparticles. (A) Average body weight showed a significant increase in LITA group 
when compared to the control. Data analysed by two-way ANOVA. (B) Cumulative body 
weight showed a significant increase in LITA group when compared to the control. (C) 
Overall change in body weight showed no significant difference between groups (data 
analysed by student t-test) and (D) also showed no significant difference in LITA group when 
compare to the control group. Data analysed by two-way ANOVA. Results are shown as 
mean ± SEM, n=8/group 
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3.3.1.2 Whole body 1H adiposity 
The effect of LITA on whole body adiposity was determined by in vivo magnetic resonance 
spectroscopy (MRS). Whole body adiposity was similar pre-treatment in both the control 
liposomes (0.295 ± 0.041) and LITA treated (0.317 ± 0.041) groups (p=0.781) (Figure 3.4 A). 
Following the 5-week administration (Figure 3.4 B) a reduction in whole body adiposity 
content were observed in the LITA group (0.333 ± 0.033) compared to the control group 
(0.628 ± 0.126) (p=0.0423). Change of whole body adiposity between pre and post 
liposomal administration showed a significant reduction in the LITA group compared to the 
control group (CTRL: 0.400 ± 0.089, LITA: 0.090 ± 0.068; p=0.020), as shown in Figure 3.5 
(n=8/group).    
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Figure 3.4 Whole body adiposity before and after control or LITA administration 
measured in vivo by MRS 
Whole body lipid adiposity relative to water content was measured by MRS in mice to 
measure the effects of control and LITA administration in the obesogenic model. A baseline 
scan was taken (A) before nanoparticle treatment at 10 weeks of age (p= 0.7081) and (B) 
after nanoparticle treatment at 15 weeks of age (p=0.0423). * = p<0.05 vs. control group; 
n=8/group. Data is presented as mean ± SEM and analysed by unpaired t-test.  
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Figure 3.5 Whole body adiposity change after control and LITA administration 
measured in vivo by 1H MRS 
Whole body lipid adiposity relative to water content was measured by MRS in mice before 
and after control and LITA administration and decreased in the LITA treated group 
(p=0.020). * = p<0.05 vs. control group. Data is presented as mean ± SEM and analysed by 
unpaired t-test; n=8/group. 
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3.3.1.3 Whole body adiposity measured ex vivo by dissections 
At the end of the study, white adipose tissue (WAT) was collected by means of dissection. 
Total WAT was calculated by summing the subcutaneous, epididymal, retroperitoneal and 
mesenteric adipose fat depots. There was a slight decrease in total white adipose tissue 
weight in the LITA group (p=0.3726 (Figure 3.6 A)). The regional decrease shown in total 
WAT is itemised in Figure 3.6 B, whereas the epididymal and retroperitoneal fat depots show 
a significant decrease (p<0.05 vs. control) and the subcutaneous (p=0.2874) and mesenteric 
(p=0.3726) shows a trending decrease in the LITA treated group. Results for all white 
adipose tissue recovered from dissections can also be seen in Table 3.2. Continuing on with 
the varying fat depot analysis, when the total WAT to subcutaneous ratio is examined is 
significantly reduced in the LITA group (p<0.05 vs. control (Figure 3.6 C)). However, when 
calculating total WAT over body weight, there is a significant reduction in the LITA group 
(p<0.05 vs. control (Figure 3.6 D)).  
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Figure 3.6 Fat distribution in mice after 10 week study on high fat diet with either 
control or LITA nanoparticle administration 
Mice were dissected at the end of the 10 week study of chronic administration of either 
control or LITA nanoparticles. (A) Total white adipose tissue is decreased in LITA group 
when compared to the control group and (B) differences in fat distribution between the 
control and LITA groups with a statically significant decrease in the retroperitoneal and 
epididymal depots (*p = <0.05). (C) Internal WAT in relation to subcutaneous fat and (D) 
total WAT in relation to body weight. Data is presented as mean ± SEM and analysed by 
unpaired t-test; n=8/group. 
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 Control (mean ± SEM) LITA (mean ± SEM) p value 
Total white adipose tissue 0.376 ± 0.038 0.316 ± 0.0499 0.3726 
Subcutaneous 2.049 ± 0.154 1.795 ± 0.166 0.2874 
Epididymal 1.339 ± 0.123 0.814 ± 0.148 p<0.05 
Retroperitoneal 0.764 ± 0.081 0.437 ± 0.078 p<0.05 
Mesenteric 0.376 ± 0.038 0.316 ± 0.049 0.3726 
 
Table 3.2 Total white adipose tissue extracted by dissection in mice after 10 week 
study on high fat diet with either control or LITA nanoparticle administration 
Mice were dissected at the end of the 10 week study of chronic administration of either 
control or LITA nanoparticles and white adipose tissue was dissected. Total WAT was 
calculated by summing the subcutaneous, epididymal, retroperitoneal and mesenteric 
adipose fat depots. Data is presented as mean ± SEM and analysed by unpaired t-test, 
n=8/group. 
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3.3.1.4 Adipocyte size and number 
Results show the adipocyte isolation from the epididymal and subcutaneous fat depots from 
both the control and LITA treated animals at the end of the 10 week study. The total number 
of cells was measured for a range of 20-120µm to disregard non-cellular debris. The total 
mean number in the subcutaneous (p=0.1801) and in the epididymal (p=0.4417) fat depot 
showed no significant difference between groups (Figure 3.7 A-B). The total cell number of 
cells per gram showed no difference between groups in the subcutaneous (p=0.8997) fat 
depot however there was a slight but not significant decrease in epididymal (p=0.1143) fat 
depot (Figure 3.7 C-D). 
 
Both the mean total cell volume in the epididymal (p=0.4417) fat depot and the 
subcutaneous (p=0.4754) fat depots showed no significant difference between the control 
and LITA groups (Figure 3.8 A-B). Again, the mean surface area showed no different in the 
epididymal (p=0.8119) and the subcutaneous (p=0.1801) showed a non-significant increase 
in the LITA group when compared to the control (Figure 3.8 C-D). Results for all adipocyte 
cell isolation can be seen in Table 3.3.  
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Figure 3.7 Adipocyte cell number in mice after 10 week study with either control or 
LITA nanoparticle administration 
Mice were dissected at the end of the 10 week study of chronic administration of either 
control or LITA nanoparticles and white adipose tissue was dissected out and the adipocytes 
were counted in the epididymal and subcutaneous fat depots. (A) The mean number of cells 
in the subcutaneous tissue had a slight increase in the LITA group and (B) the mean number 
of cells in the epididymal fat depot showed no difference between groups. (C) Total cell 
number per gram of subcutaneous tissue had no difference in cell number between groups 
and (D) Total cell number per gram of epididymal tissue is decreased in LITA group when 
compared to the control group. Data is presented as mean ± SEM and analysed by unpaired 
t-test. 
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Figure 3.8 Adipocyte cell dimensions in mice after 10 week study with either control 
or LITA nanoparticle administration 
Mice were dissected at the end of the 10 week study of chronic administration of either 
control or LITA nanoparticles and white adipose tissue was dissected out and the adipocytes 
were counted in the epididymal and subcutaneous fat depots. Both the (A) total cell volume 
in the epididymal fat depot and (B) the subcutaneous fat depots showed no significant 
difference in cell volume between the control and LITA groups. (C) Surface area showed no 
different in the epididymal and the (D) subcutaneous showed a non-significant increase in 
the LITA group when compared to the control. Data is presented as mean ± SEM and 
analysed by unpaired t-test, n=8/group. 
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Control 
(mean ± SEM) 
LITA 
(mean ± SEM) 
p value 
Mean number Subcutaneous 1007 ± 270.2 1255 ± 183.2 0.4754 
 Epididymal 2537 ± 396.4 2711 ± 1064 0.4417 
Number/ gram Subcutaneous 1681 ± 299.8 1731 ± 161.7 0.8997 
 Epididymal 4597 ± 1335 1335 ± 890.3 0.1143 
Volume (µm3) Subcutaneous 
120700000 ± 
19320000 
151700000 ± 
23650000 
0.3535 
 Epididymal 
319300000 ± 
126900000 
298200000 ± 
199500000 
0.465 
Surface area (µm2) Subcutaneous 
6478000 ± 
1437000 
9665000 ± 1534000 0.1801 
 Epididymal 
15130000 ± 
4009000 
16550000 ± 4110000 0.8199 
 
Table 3.3 Adipocyte cell isolation in mice after 10 week study with either control or 
LITA nanoparticle administration 
Mice were dissected at the end of the 10 week study of chronic administration of either 
control or LITA nanoparticles and white adipose tissue was dissected out and the adipocytes 
were counted in the epididymal and subcutaneous fat depots. Number, number per gram, 
volume and surface are displayed. Data is presented as mean ± SEM and analysed by 
unpaired t-test, n=8/group. 
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3.3.1.5 Intrahepatocelluar lipid content  
1H MRS revealed no significant difference between groups in intrahepatocellular lipid (IHCL) 
content at baseline scans (control: 0.224 ± 0.362, LITA: 0.242 ± 0.037; p= 0.7398) (Figure 
3.9 A). Figure 3.9 B shows the change after the 5-weeks of liposomal administration, there 
was a significant decrease in IHCL in the LITA treat when compared to the control group 
(CTRL: 0.333 ± 0.629, LITA: 0.111 ± 0.024, p=0.0074) (** = p<0.01 vs. control group; 
n=8/group). 
 
IHCL content differences at the end of the 5-week study comparing pre and post IHCL levels 
(Figure 3.10). The control group had an increase in IHCL content (0.236 ± 0.089). Whereas, 
the LITA treated had a significant decrease in IHCL content (-0.106 ± 0.256). The difference 
between the control and LITA treated groups reached statistical significance (*** = p<0.001 
vs. control group; n=8/group).  
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Figure 3.9 Lipid content in the liver before (A) and after (B) control and LITA 
administration as determined by 1H MRS 
Intrahepatocellular lipid content relative to water was measured by 1H MRS in mice. Before 
control or LITA nanoparticle administration baseline MRS scan, the mice had been on a HFD 
for 5 weeks to establish a fatty liver. After LITA or control administration the scan was 
repeated after 5 weeks of administrations and remaining on the HFD. (A) Prior to injections a 
baseline scan was taken of each mouse in both designated treatment groups (p= 0.7398). 
(B) After administration there was a decrease in IHCL when comparing control and LITA 
treated groups (p=0.0074). ** = p<0.01 vs. control group. Data is presented as mean ± SEM 
and analysed by unpaired t-test; n=8/group. 
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Figure 3. 10 Change in lipid content in the liver as an effect to chronic i.p. control or 
LITA administration as determined by 1H MRS 
The change in intrahepatocellular lipid content relative to water was measured by MRS in 
mice. Change shown was calculated from an initial baseline scan with an established fatty 
liver as a result of 5 weeks on a HFD and after 5 weeks of receiving either control or LITA 
nanoparticles whilst remaining on a HFD during injections. The IHCL significantly decreased 
in the LITA group when compared to the control group. *** = p<0.001 vs. control group. Data 
is presented as mean ± SEM and analysed by unpaired t-test; n=8/group. 
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3.3.1.2 Organ size  
Organ weights were recorded upon dissection at the end of the 10 week study (Figure 3.11, 
Table 3.4). A statically significant decrease in liver (*p<0.05 vs. control) and a trending 
decrease in the pancreas (p=0.056) and kidneys (p=0.050) following LITA treatment. An 
increase in the muscle in the LITA treated group was observed but did not reach significance 
(p=0.2394). No other differences were observed between (n=8/group). When examining the 
organ mass in relation as a percentage of body weight, the LITA groups had a significant 
increase in the muscle (**p<0.01 vs. control) and BAT (*p<0.05 vs. control (Figure 3.12, 
Table 3.5)) compared to control.  
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Figure 3.11 Organ weight following chronic i.p. injections of either control or LITA 
nanoparticles during 10 week study 
Organ weight recorded at the of the 10 week study for control and LITA treated groups. The 
liver had a statistically significant decrease in weight (* = p<0.05). The muscles had a 
trending increase in mass but did not reach significance. Results are mean ± SEM and 
analysed by unpaired t-test; n=8/group. 
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Control 
(mean ± SEM) 
LITA 
(mean ± SEM) p value 
Brain 0.434 ± 0.004 0.421 ± 0.003 0.0807 
Liver 1.335 ± 0.080 1.106 ± 0.058 p<0.05 
Spleen 0.097 ± 0.007 0.093 ± 0.006 0.7115 
Heart 0.147 ± 0.007 0.135 ± 0.005 0.2504 
Pancreas 0.228 ± 0.012 0.193 ± 0.012 0.0568 
Lungs 0.177 ± 0.005 0.159 ± 0.013 0.2437 
Kidneys 0.336 ± 0.021 0.291 ± 0.009 0.0503 
Muscle 0.526 ± 0.077 0.649 ± 0.043 0.2394 
Brown Adipose Tissue 0.127 ± 0.240 0.134 ± 0.018 0.6032 
 
Table 3.4 Organ weight following chronic i.p. injections of either control or LITA 
nanoparticles during 10 week study 
Organ weight recorded at the of the 10 week study for control and LITA treated groups. The 
only organ showing a statistically significant different between the control and LITA group 
was the liver. Data is presented as mean ± SEM and analysed by unpaired t-test; n=8/group. 
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Figure 3.12 Organ weight to total body weight ratio in mice following chronic i.p. 
injections of either control or LITA nanoparticles during 10 week study 
Organ weight to total body weight ratio recorded at the of the 10 week study for control and 
LITA treated groups. The muscle and BAT were statistically significant (* = p<0.05, ** = 
p<0.01). Results are mean ± SEM and analysed by unpaired t-test; n=8/group. 
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 Control 
(mean ± SEM) 
LITA 
(mean ± SEM) 
p value 
Brain 1.503 ± 0.061 1.538 ± 0.050 0.715 
Liver 4.458 ± 0.145 4.351 ± 0.127 0.5878 
Spleen 0.341 ± 0.029 0.369 ± 0.027 0.4957 
Heart 0.481 ± 0.015 0.535 ± 0.020 0.0573 
Pancreas 0.789 ± 0.036 0.759 ± 0.032 0.5489 
Lungs 0.622 ± 0.036 0.641 ± 0.063 0.7997 
Kidneys 0.981 ± 0.142 1.149 ± 0.024 0.2686 
Muscle 1.750 ± 0.167 2.560 ± 0.142 p<0.01 
Brown Adipose Tissue 0.335 ± 0.066 0.532 ± 0.062 p<0.05 
 
Table 3. 5 Organ weight to total body weight ratio following chronic i.p. injections of 
either control or LITA nanoparticles during 10 week study 
Organ weight to total body weight recorded at the of the 10 week study for control and LITA 
treated groups. The organs showing a statistically significant different between the control 
and LITA group were the muscle and BAT. Data is presented as mean ± SEM and analysed 
by unpaired t-test; n=8/group. 
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3.3.1.7 Serum analysis 
 
Serum samples were collected via cardiac puncture at the end of the study and in order to 
investigate metabolic markers of obesity. The LITA treatment group showed a significant 
reduction in triglycerides (p<0.05), leptin (p<0.05) and free fatty acids (FFA) (p<0.05) (Figure 
3.7, Table 3.6)). There was a trending increase in adiponectin (p=0.0748) and lipase 
(p=0.0770) levels, although did not reach significance.  
 
Similarly, keratinocyte chemoattractant/ GRO-alpha (KC/GRO) was significantly decreased 
(*p<0.05 vs. control). There was a trending increase of interleukin-2 (p=0.1854), interleukin-4 
(p=0.1342) and interleukin-10 (p=0.265) in the LITA treated group though none were 
significant. Other inflammatory factors such as TNK- α (p=0.678), IFN- γ (0.751), interleukin-
1β (0.996) and interleukin-5 (0.898) had almost no change between control or LITA 
nanoparticle treated groups. (Figure 3.8, Table 3.6)). (n=5-8/group). 
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Figure 3.13 Serum analysis of metabolic marker of obesity in control and LITA groups 
Serum samples were collected via cardiac puncture at the end of the study to investigate the 
effects of LITA and control in obesogenic mice model. A statically significant reduction was 
observed in triglycerides, leptin and free fatty acid (* = p<0.05). Results are mean ± SEM 
and analysed by unpaired t-test; n=5-8/group. 
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Figure 3.14 Serum analysis of inflammatory marker of obesity in control and LITA 
groups 
Serum samples were collected via cardiac puncture at the end of the study to investigate the 
effects of LITA and control in obesogenic mice model. A statically significant reduction was 
observed in KC/GRO (* = p<0.05). Results are mean ± SEM and analysed by unpaired t-
test; n=5-8/group. 
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Control 
(mean ± SEM) 
LITA 
(mean ± SEM) p value 
Metabolic markers Glucose 11.53 ± 1.358 11.26 ± 1.218 0.4416 
 Insulin 0.394 ± 0.054 0.592 ± 0.149 0.3102 
 Triglycerides 1.214 ± 0.254 0.556 ± 0.286 p<0.05 
 Cholesterol 3.300 ± 0.152 3.229 ± 0.0944 0.6978 
 Leptin 23.82 ± 5.617 11.20 ± 2.549 p<0.05 
 Adiponectin 38.26 ± 2.835 43.68 ± 1.944 0.0748 
 Lipase 127.6 ± 11.15 158.7 ± 10.75 0.0770 
 FFA 1138 ± 85.73 896.8 ± 61.41 p<0.05 
Inflammatory markers TNF-α 0.25 ± 0.050 0.284 ± 0.056 0.6785 
 IFN-γ 0.474 ± 0.086 0.430 ± 0.108 0.7513 
 IL-1β 1.859 ± 0.481 1.861 ± 0.203 0.9966 
 IL-2 0.742 ± 0.125 1.025 ± 0.156 0.1854 
 IL-4 0.860 ± 0.199 1.609 ± 0.445 0.1342 
 IL-5 1.963 ± 0.261 2.010 ± 0.240 0.8987 
 IL-10 25.74 ± 3.615 35.44 ± 7.908 0.265 
 KC/GRO 63.87 ± 3.635 48.64 ± 3.284 p<0.05 
 
Table 3.6 Serum analysis from 10 week obesogenic study in mice receiving either 
chronic LITA or control nanoparticles administration 
Results obtained after 10 week chronic control and LITA nanoparticle treated groups on HFD 
from serum samples were collected via cardiac puncture. A significant decreased was 
observed in triglycerides, free fatty acids Data is presented as mean ± SEM and analysed by 
unpaired t-test; n=5-8/group. 
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3.3.1.8 Western blot analysis 
Liver tissue and brown adipose tissue were examined using western blot for proteins of 
interest. Liver was examined for a panel of histone deacetylase proteins and BAT was 
examined for thermogenic activity changes.  
 
 
3.3.1.8.1 Histone deacetylase protein changes in liver tissue 
Analysis of western blotting of liver samples revealed a significant increase in select HDACs 
from class I, HDAC2 (control: 0.7213 ± 0.1106; LITA: 1.257 ± 0.05781, p<0.01) and HDAC3 
(control: 0.8597 ± 0.004951; LITA: 1.316 ± 0.06639, p<0.05). A non-significant decrease 
was seen in HDAC 1. When examining HDACs from class IIA, the only significantly 
decreased protein was HDAC7 (control: 1.427 ± 0.1787; LITA: 0.7555 ± 0.07421, p<0.001) 
in the LITA treated group compared to control groups (Figure 3.26). Other class IIA HDACs 
that did not have a significant difference was HDAC4 with a decrease and an increase in 
HDAC5 in the LITA group when controlled to the control group. Bands from western blot can 
be seen in Figure 3.27 (n=5-6/group). 
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Figure 3.15 Quantitative relative intensity of western blot examining histone 
deacetylase (HDACs) in total proteins isolated from liver tissue after 10 week 
obesogenic study in mice receiving either control or LITA administration 
Western blot determined no change in expression of histone deacetylase total protein in the 
liver tissue in mice at the end of the study between the control and LITA group (n=5-6/ 
group). Significant increase of expression was observed in HDAC 2 and 3 with a reduction in 
HDAC 7. HDAC 1 and 4 had trending decrease of expression and HDAC 5 had a non-
significant increase. Relative intensity was measured and compared to the reference protein 
β-actin. Data is presented as mean ± SEM and analysed by unpaired t-test. 
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Figure 3.16 Western blot bands of histone deacetylase (HDACs) in total proteins 
isolated from liver tissue after 10 week obesogenic study in mice receiving either 
control or LITA administration 
Western blot determined no change in expression of histone deacetylase total protein in the 
liver tissue in mice at the end of the study between the control and LITA group (n=5-6/ 
group). To serve as a control β-actin staining was conducted in parallel. Intensity of staining 
(darkness of band) is related to the amount of protein present.  
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3.3.1.8.2 Uncoupling Protein-1 changes in brown adipose tissue  
 
The protein expression level of uncoupling protein-1 (UCP-1) was examined in the brown 
adipose tissue (BAT) extracted from the mice at the end of the 10 week study. No significant 
difference between the control (14.17 ± 1.998) and the LITA (14.44 ± 3.061) group was 
observed (Figure 3.28).  
 
 
 
 
Figure 3.17 Quantitative relative intensity of western blot examining uncoupling 
protein-1 in brown adipose tissue after 10 week obesogenic study in mice receiving 
either control or LITA administration 
Western blot determined no change in expression of uncoupling protein-1 in the brown 
adipose tissue in mice at the end of the study between the control and LITA group. The 
bands probing for UCP-1 from the western blot can be seen in Figure 3.18 and the analysis 
of relative intensity compared to the control protein β-actin. Data is presented as mean ± 
SEM and analysed by unpaired t-test; n=7/group. 
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Figure 3.18 Western blot bands of uncoupling protein-1 in brown adipose tissue after 
10 week obesogenic study in mice receiving either control or LITA administration 
Western blot was conducted to measure protein levels of uncoupling protein-1 in the brown 
adipose tissue of mice at the end of the study between the control and LITA group (n=7/ 
group). To serve as a control β-actin staining was conducted in parallel. Intensity of staining 
(darkness of band) is related to the amount of protein present. Results show no change in 
UCP-1 expression between groups.  
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3.3.1.9 Microarray analysis 
 
Fluorescence intensity was acquired, normalised and analysed for genes up- and down 
regulated in cDNA extracted from liver tissue in order to compare to the control to the LITA 
nanoparticle treated group. Two preliminary analysis methods were conducted to examine 
the quality of each individual sample, and the range of fluorescence intensity detected; 
firstly, the MA plot showed the non-linear dependence between ratios and fluorescence of 
each sample, showing two samples varied in ratio when compared to the other samples 
(Figure 3.20). When the samples were plotted as a boxplot for signal intensities (Figure 
3.21), it was confirmed that array 05 and array 10 were outliers and were removed from the 
samples in the final analysis.  
 
Analysis parameters removed outlier genes, leaving 2028 genes available for group 
comparison analysis. Colour scheme represents intensity of fluorescence. Data shown is the 
remaining 2028 genes, analysed using LIMMA in R; n=4/group. A heat map was generated 
to give visualization between signal intensities in the most effected genes (x-axis) across the 
8 samples (y-axis) (Figure 3.22).  
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Figure 3.19 MA plots of signal intensity for outlier detection and quality control of 
samples post 10 week chronic study of either LITA or control nanoparticle 
administration for final analysis 
Outlier detection was performed in R by computing Hoeffding's statistic Da on the joint 
distribution of A and M for each array. Shown are the 4 arrays with the highest value of Da 
(top row), and the 4 arrays with the lowest value (bottom row). The value of Da is shown in 
the panel headings. 0 arrays had Da >0.15 and were marked as outliers. Outlier samples 
were identified as array 5 and array 10 and removed from final analysis; n=5/group.  
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Figure 3.20 Microarray intensity distributions of samples post 10 week chronic study 
of either LITA or control nanoparticle administration 
 Boxplots representing signal intensity distributions of the sample arrays. Each box 
corresponds to one array. Outlier detection was performed by computing the Kolmogorov-
Smirnov statistic Ka between each array's distribution and the distribution of the pooled data. 
This confirms array 05 and array 10 are outliers; n=5/group. 
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Figure 3.21 A volcano plot of differentially expressed genes in liver tissue from 10 
week study of chronic i.p. administration of either LITA or control nanoparticles 
Fluorescence intensity is acquired, normalised and analysed for genes up- and down 
regulated when compared to the LITA treated group. Each point represents a gene from the 
microarray experiment. The log2 ratio of expression is shown on the x-axis and the log10 p-
value of the ANOVA significance test is shown on the y-axis. Analysis parameters removed 
outlier genes, leaving 2028 genes available for group comparison analysis. Data shown is 
the remaining 2028 genes, analysed using LIMMA in R; n=4/group. 
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3.3.1.9 Gene expression analysis 
 
Gene expression was carried out to examine a number of genes of interest using qRT-PCR 
to analyse effects of control versus LITA nanoparticles at the end of a 10 week study in liver 
tissue. A statically significant decrease was observed in UCP-2 (***p>0.01 vs. control), 
however no change in PPARα (p= 0.866) (Figure 3.22). When looking at β-oxidation 
changes, ACOX1 (p=0.4423) was up regulated and CPT1A (p=0.0613) was down regulated 
though neither change was significant. The fatty acid synthesis gene, ACC, was slightly 
down regulated when compared to the control group however the difference was not 
significant. The enzyme family of histone deacetylases analysed showed a significant 
decrease in HDAC 1 expression (***p>0.01 vs. control) and a trending decrease in HDAC 2. 
Data is also displayed in Table 3.6.      
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Figure 3.22 qRT-PCR analysis of gene expression fold changes in mRNA isolated 
from the liver as a result of chronic LITA treatment in obesogenic model 
Gene expression changes at the end of a 10 week study of chronic LITA or control 
nanoparticle administration in a HFD model. The mitochondrial function classification of 
genes showed a significant decrease in UCP2 and no change in PPARα. The β-oxidation 
and fatty acid synthesis classification of genes showed no significant changes. There was a 
down regulation of HDAC1, which was not observed in HDAC 2. *** = p<0.001 vs. control 
group. All expression changes were compared to the control nanoparticles set to 1.0 and in 
relation to the housekeeper gene, GAPDH. Data is presented as mean ± SD and analysed 
by unpaired t-test (n=5-8/group). 
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Gene of interest 
LITA 
(mean ± SD) p value 
ACC 0.583 ± 0.583 0.1102 
UCP-2 0.044 ± 0.025 p<0.001 
PPAR-α 1.071 ± 0.805 0.8661 
ACOX1 1.751 ± 1.748 0.4236 
CPT1A 0.475 ± 0.456 0.0613 
HDAC 1 0.083 ± 0.040 p<0.001 
HDAC 2 0.588 ± 0.807 0.4117 
 
Table 3.7 Summary of qRT-PCR analysis of gene expression fold changes in mRNA 
isolated from the liver as a result of chronic LITA treatment in obesogenic model 
Gene expression changes presented as mean ± SD at the end of a 10 week study of chronic 
LITA or control nanoparticle administration in a HFD model. All gene expression changes 
were compared to the control nanoparticles set to 1.0 and in relation to the housekeeper 
gene, GAPDH. *** = p<0.001 vs. control group; n=5-8/group. Data is analysed by unpaired t-
test. 
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3.3.1.10 Histone acetylation assessment  
Histone protein expression was determined ex vivo by western blot at the end of the 10 
week study to analyse effects of control and LITA nanoparticle administration in histones 
isolated from liver tissue (n=4/group). The histone residue acH3K9 showed a decrease in 
the LITA group when compared to the control group (control: 1.349 ± 0.129, LTA: 0.913 ± 
0.109; p=0.0622). Another histone examined, M2H3K9 showed no significant difference 
between treatment groups (control: 0.929 ± 0.158, LITA: 1.271 ± 0.206; p=0.260) group. The 
histone residue acH4K12 did show a significant increase in expression in the control group 
when compared to the LITA treated group (control: 1.291 ± 0.130; LITA: 0.688 ± 0.101, 
p=0.0220), Data in graph format can be seen in Figure 3.23 and blots from experiment can 
be seen in Figure 3.24. (*p<0.05 vs. control, n=4/group). 
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Figure 3.23 Quantitative relative intensity of western blot examining histone residues 
in histones isolated from liver tissue after 10 week obesogenic study in mice 
receiving either control or LITA administration 
Western blot determined a reduction was seen in acH4K12 at the end of the study between 
the control and LITA group (n=4/ group). Relative intensity was measured and compared to 
the reference protein total histone 3 or 4 depending on which target protein of interest was 
being investigated. Both histones acH3K9 and M2H3K9 showed only trending changes, 
however a significant difference was seen in acH4K12. * = p<0.05 vs. control group; data is 
presented as mean ± SEM and analysed by unpaired t-test.  
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Figure 3.24 Western blot bands of histone residue proteins in histones isolated from 
the liver after 10 week obesogenic study in mice receiving either control or LITA 
administration 
Western blot was conducted to measure histone protein levels in the histones isolated from 
the liver of mice at the end of the study between the control and LITA group (n=4/ group). To 
serve as a control either total histone 3 or 4 staining was conducted in parallel depending on 
the target protein of interest. Intensity of staining (darkness of band) is related to the amount 
of protein present.  
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3.3.2 Study 2: Chronic LITA Nanoparticle Administration in Metabolic Cages  
To explain some of the observation made during Study 1, a monitoring of acute motor and 
metabolic activity was investigated. Mice received chronic i.p. injections of either control of 
LITA nanoparticles for 7 days prior to being placed in the metabolic cages for 48 hours. Day/ 
nights are represented in the following figures by the white/black bars along the x-axis of all 
graphs. 
 
 
 Feeding profile while housed in the metabolic cages is shown in Figure 3.25. No significant 
difference in day/night feeding profile (p=0.8550), cumulative food intake (p=0.1941) (Figure 
3.25 B) or cumulative water intake (p=0.8204) (Figure 3.25 C) between groups (Figure 3.25 
A). 
 
 
Gas exchange showed no different between control or LITA groups when specifically looking 
at VO2 (p=0.8614) (Figure 3.26 A) and VCO2 (p=0.8911) (Figure 3.26 B) during the 48 hour 
examination period. Heat was slightly increased however not significant in the LITA group 
when compared to the control group (p=0.8741) (Figure 3.27 A). The respiratory exchange 
ratio (RER) had no significant difference between groups (p=0.9169) (Figure 3.27 B). 
 
 
Motor activity of mice within the metabolic cages showed no statistical significance between 
the control or LITA treated groups in either XAMB (p=0.8948) (Figure 3.28 A) or the XTOT 
(p=0.8471) (Figure 3.28 B) directional movements. There was no significance in the ZTOT 
beam breaks, between the control group and LITA treated group (p=0.5568) (Figure 3.28 C).   
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Figure 3.25 Metabolic cage monitoring of mice after 7 day LITA or control nanoparticle 
administration- Food and drink intake 
The effects of 200µL LITA or control liposomes i.p. daily for 7 days on food and drink intake 
in mice housed in metabolic cages (A) Day/Night feeding profile (p=0.8550), (B) cumulative 
food intake (p=0.1941) and (C) water intake (p=0.8204) during the 48 hour study. White and 
black bars along x-axis indicate day/night cycle. Results are mean ± SEM, statistical 
differences between treatment groups were determined using 2-way ANOVA, n=8/group. 
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Figure 3.26 Metabolic cage monitoring of mice after 7 day LITA or control nanoparticle 
administration- VO2 and VCO2 
The effects of 200µL LITA or control liposomes i.p. daily for 7 days on gas exchange in mice 
housed in metabolic cages. (A) VO2 (p=0.8614) and (B) VCO2 (p=0.8911) were monitored 
during the 48 hour study. White and black bars along x-axis indicate day/night cycle. Results 
are mean, error bars removed from clarity. Statistical differences between treatment groups 
were determined using 2-way ANOVA, n=8/group. 
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Figure 3.27 Metabolic cage monitoring of mice after 7 day LITA or control nanoparticle 
administration- RER and heat 
The effects of 200µL LITA or control liposomes i.p. daily for 7 days on gas exchange in mice 
housed in metabolic cages. (A) RER (p=0.9169) and (B) heat (p=0.8741) was monitored 
during the 48 hour study. White and black bars along x-axis indicate day/night cycle. Results 
are mean, error bars removed from clarity. Statistical differences between treatment groups 
were determined using 2-way ANOVA, n=8/group  
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Figure 3.28 Metabolic cage monitoring of mice after 7 day LITA or control nanoparticle 
administration- XAMB, XTOT and ZTOT 
The effects of 200µL LITA or control liposomes i.p. daily for 7 days on activity in mice 
housed in metabolic cages. (A) XAMB (p=0.8948), (B) XTOT (p=0.8471) and (C) ZTOT 
(p=0.5568) during the 48 hour study. White and black bars along x-axis indicate day/night 
cycle. Results are mean ± SEM, statistical differences between treatment groups were 
determined using 2-way ANOVA, n=8/group. 
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3.4 Chapter Discussion 
Previous studies have shown that fermentable carbohydrates can have a positive effect on 
body composition, weight, and insulin sensitivity [118, 235]. The combination of increased 
food (energy) in the form of a high fat diet provides a complex model of obesity and fatty liver 
syndromes. In the first study, an obesogenic background was established by placing 
C57BL/6 mice on a high fat diet (HFD) for 5 weeks. Mice subsequently received i.p. 
injections of LITA or control (HEPES) nanoparticles (n=8/group) every 3 days for an 
additional 5 weeks, while maintained on a HFD. In the second study, I attempted to monitor 
the metabolic behaviour of the mice based on data reported in Study 1. In order to assess 
the effects of LITA nanoparticle administration on respiratory outcomes, metabolic activity 
and motor behaviour, metabolic cage analysis was performed. Following a week of daily day 
administration of LITA or control injections (n=8/group), mice were monitored over a period 
of 48 hours in CLAMS metabolic cages. 
 
LITA treated animals did not have a significant difference in food intake, however did show a 
significant increase in body weight. No differences in cumulative food intake over the course 
of this study was observed, if anything a minor, though not significant, decrease in 
cumulative food intake was observed in the LITA treated group during week 9 and 10. The 
main increase in body weight in the LITA group occurred in weeks 7, 8, 9 and 10. Studies 
done previous by Kondo et al have shown a decrease in body weight with acetate [125]. 
This difference may be related to the mode of administration, Kondo et al administered 
acetate orally (water), thus none targeted which may contribute to appetite regulation and 
therefore decrease in food intake [125]. In my study the use of LITA may have avoid this 
effect and the changes observed may be related to increase in muscle mass, given that l the 
LITA treated group shows a significant decrease in some body fat depots. Thus acetate may 
have an anabolic effect, a process that may require further investigation. 
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To further investigate the metabolic phenotype of LITA treated animals, I used calorimetric 
cages. In this study, animals were treated for 7 days with either LITA or control nanoparticles 
whilst consuming a normal fat diet and placed in a metabolic cage for 48 hours. Metabolic 
cage studies revealed that LITA nanoparticle treated mice were slightly hyperphagic 
compared with their controls nanoparticle group. In fact they ate a significant amount more 
(p>0.05) when adjusted for total body weight. This is in contrast to what one would expect 
considering it was hypothesized that an energy source would be coming from the acetate 
encapsulated within the nanoparticles. However, the food intake increases the most during 
the last day, potentially after the acetate has been metabolised. There was no difference 
between groups when looking at cumulative drink intake.  
 
Core temperature was considerably higher in LITA treated mice, though not significant. The 
increased heat could be explained in part by the input of acetate causing an increase in 
potential energy. Oxygen consumption showed no significant difference between groups. 
RER levels were similar overall. However, during the first dark period, RER levels were 
increased in LITA treated mice, which may reflect increased carbohydrate utilization. The 
second dark period had a period of symmetry with the control group and later with a 
decrease in RER in the LITA group, which would indicate a difference in carbohydrate-to-
protein ratio utilization difference.  
 
Motor activity was acquired as three different functions; XAMB (horizontal beam breaks) and 
XTOT (total x-axis ambulation) had similar day/night motor patterns between groups. This 
was a surprising result because in Study 1 there was a trending increase in muscle mass in 
the LITA group when compared to the control group. However, 48-hour surveillance did not 
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answer why that was observed. Potentially the monitoring process of Study 2 would require 
a longer observational period to justify the finding in Study 1. 
 
 In general, the metabolic profile of the LITA animals showed an altered response to control 
nanoparticles, showing an increase in caloric intake whilst not changing in motor activity. 
There was a trending increase in heat production, which has previously been shown in 
rodent models on ketogenic diets [236]. A shift away from carbohydrate metabolism might be 
also expected to result in altered respiratory outcomes in LITA-injected animals. However, I 
observed no differences following metabolic cage analysis, with only non-significant trends 
towards reduced RER, and increased oxygen consumption and heat production in LITA-
injected animals. These results are in accord with several papers that demonstrate energy 
expenditure is maintained following acetate infusion, as acetate replaces fat as an oxidative 
fuel [237-239]. Determining the cellular pathways responsible for a compensatory shift from 
fat to acetate metabolism, with a focus on additional aspects of hepatic beta-oxidation, will 
be required to fully elucidate the mechanisms of LITA nanoparticle action. 
 
LITA treatment induced a significant change in total body fat, as measured by MRS. Kondo 
et al., has previously reported a similar decrease in total fat mass as a result of acetate 
administration [240]. However, using dissections to look at different fat depots, a significant 
decrease was only observed in epididymal and retroperitoneal fat, with subcutaneous fat 
depot showing a trend to decrease, while the mesenteric fat depot showed no difference. 
The reason for this discrepancy is unclear, but it may be related to the fact that with in vivo 
MRS all fat can be detected, which cannot be done regularly with MRI or by dissection. The 
localised effect of LITA on epididymal and retroperitoneal fat depots is unclear. The in vivo 
distribution profile of the LITA nanoparticle, as assessed by PET, showed no difference in 
uptake between fat depots, suggesting that other factors, including metabolic susceptibility to 
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acetate may play a role. For example adipose tissue lipase, the enzyme associated lipid 
breakdown [241] , showed a slight increase in the LITA treated group when compared to the 
control group although it did not reach significance. Differential effects on this and other 
process by acetate may lead to differences in fat content in different fat depots. 
 
Size and number of adipocytes are known to be directly associated with adipose tissue 
metabolism, so epididymal and subcutaneous adipocytes were isolated and measured. 
These depots were chosen as they were differentially affected by LITA. The total mean 
number of adipocytes in the subcutaneous and in the epididymal fat depot showed no 
significant difference between groups. The total cell number of cells per gram showed no 
difference between groups in the subcutaneous fat depot however there was a slight but not 
significant decrease in epididymal fat depot. The decrease in the epididymal fat cell number 
per gram of tissue was consistent with the decrease in weight reported during after 
dissections. There was no significant difference in surface area or cell volume between 
groups in the epididymal and subcutaneous adipocytes. This suggests that any effect of 
LITA on these fat depots may be related to lipid oxidation and deposition rather than 
changes in cell number [242, 243]. 
 
Chronic LITA administration significantly reduced IHCL. This was confirmed by a decrease in 
liver weight and size. An increased IHCL level is associated with an increase in overall mass 
of this organ [244]. These changes occurred independently of the potentially confounding 
effects of a reduced food intake or body weight changes. Importantly, more than merely 
slowing accumulation, LITA delivery actively reduced IHCL. Hepatic lipid accumulation 
represents a key intermediary in a succession of increasingly debilitating liver conditions and 
is strongly associated with the development of insulin resistance and diabetes [245, 246]. 
The mechanism by which the effects of LITA on IHCL take place are unclear but may include 
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increases in beta-oxidation and/or decrease TG uptake from the circulation. Indeed, LITA 
treatment leads to a decrease in circulating FFA and triglycerides. These findings are 
consistent with previous studies showing a fall in FFA and triglyceride circulating levels 
following chronic acetate administration [125, 170]. The reduced levels of FFA and 
triglycerides indicate that liver function is being directly targeted by the LITA and not just the 
adipose tissue. Decreased circulating FFA is consistent with other models examining the 
effect of acetate, including those in which animals were fed fermentable carbohydrates. 
Fernandes J., et al recently reported that administered acetate results in a reduction in 
plasma FFA concentrations [247]. Yamashita et al., has also shown a reduction in plasma 
lipids following chronic acetate administration [170]. These changes were attributed to the 
protective behaviour of acetate, causing an inhibition from accumulation of lipids in the liver. 
Thus LITA-induced reduction in IHCL suggests our nanoparticle therapy is not only capable 
of preventing NAFLD, but may also modulate subsequent progression to HCC [246, 248, 
249].  
 
 
Leptin, a sensor of energy storage and regulator of appetite and metabolism at the level of 
the brain, was significantly decreased in the LITA group when compared to the control. 
Circulation levels of leptin have been reported to directly correlate with body fat, which would 
be consistent with the changes in body fat in the LITA group [250]. Glucose is an important 
regulator of leptin in humans and rodents [251, 252], which had no difference between 
groups, thus glucose does not appear to be the catalyst for the decrease in circulating leptin 
levels. A slight increase was observed in circulating adiponectin levels. Adiponectin is 
produced mainly from internal body fat depots and is involved with multiple metabolic 
processes such as regulation of glucose and fatty acid oxidation [253]. Adiponectin levels 
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have been shown to have an inverse correlation with body fat, which again correlates with 
the effects of LITA on this organ 
 
Cytokine balance within the immune system has been correlated with obesity in humans and 
animals [254]. Examination of inflammation markers in the plasma showed a significant 
decrease in KC/GRO in the LITA treated group when compared to the control group. 
KC/GRO (chemokine gro-alpha/ growth-related protein) plays an essential role in the 
phagocytosis and removal of pathogens entering the liver via the portal-venous blood [255, 
256]. KC has a direct hepatotoxic effect and regulating liver inflammation, which would 
indicate a decrease in toxicity in the livers of LITA treated mice [257]. As expected from a 
decrease in KC/GRO, levels of TNF-α and IFN-γ in the LITA treated group were not 
increased, confirming a decreased state of proinflammatory mediators [256]. TNF-α was one 
inflammatory factor of interested, as it increase the risk of cancers including breast and colon 
[258, 259]. However, there were some other inflammatory markers that were non-
significantly increased from the interleukin family, specifically IL-4 and IL-10. IL-4, a 
prominent cytokine released during activation of B-cells [260] and lipoprotein receptor 
pathways [261]. IL-10, an anti-inflammatory cytokine produced by several cell types within 
multiple organs, is an important factor in counteracting inflammatory responses. An increase 
in IL-10 indicates an attempt to inhibit continued proinflammatory cytokine production [262, 
263]. The slight increases in inflammatory markers is thought to be attributed to the obese 
state of the mice and believe that if the LITA administrations continued, the inflammation 
would decrease as the obese state decreased. 
 
In order to investigate identify potential target genes and/or metabolic pathway as a result of 
LITA administration, a microarray analysis of liver tissue was carried out. For quality control 
purposes, a M vs. A plots [264] was carried out to view ratios of fluorescence intensities at 
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the same time. This analysis of the samples is meant to identify spot artefacts and detect 
intensity dependent patters in the log ratios before and after quantitative normalisation. Once 
outliers were removed the quantitative analysis programme of LIMMA was conducted 
revealing a handful of genes affected by LITA treatment, including genes associated with 
detoxification and heat-activated protein and genes whose metabolic functions have not 
been fully identified. The results of the microarray unfortunately did not shed light on one 
specific pathway. This may arise from the fact that acetate may metabolise very fast having 
rather small effect on gene activity levels. Alternatively, the number of samples used is this 
part of the in vivo study was rather limited, thus ‘biological noise’ masking any true change. 
Indeed, cell work with SCFA has shown an extensive number of genes being altered by 
acetate, which I could not reproduce in my study. I therefore carried out qPCR to examine 
genes of interest associated with lipid metabolism. 
 
To investigate the phenotypic changes at the genetic level, a panel of select genes were 
investigated at the mRNA level. The present studies provide in vivo evidence that LITA 
administration decrease uncoupling protein 2 (UCP-2) mRNA expression in hepatocytes. 
Similar effects have been reported previously; the groups conducting the research found that 
acetate administration resulted in a decrease in UCP-2 [125]. Elevated UCP-2 expression 
has been previously reported as an adaption to the obese state, wherein mitochondria 
exhibit an increased rate of proton leakage which disrupts the membrane potential and 
decreases efficiency [265]. The mitochondria are an important component of the metabolic 
landscape due to the adaptive response of oxidation that takes place in hepatic cells [266]. 
Previous studies have shown an increase in UCP-2 expression during obesity due to the 
overly abundant cellular energy supply exceeding hepatocytes requirements [267].  
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Surprisingly no change in mRNA expression was seen in the peroxisome proliferator-
activated receptor alpha (PPARα), a transcription receptor which plays a critical role in the 
control of obesity-induced chronic inflammatory response and regulator of lipid metabolism 
in the liver [267, 268] . Targets genes of PPARα, including peroxisomal acyl-coenzyme A 
oxidase 1 (ACOX1), Carnitine palmitoyltransferase 1 (CPT1) and Acetyl-CoA carboxylase 
(ACC) were investigated. CPT1A, a mitochondrial enzyme associated with the transport of 
long-chain fatty acids across the mitochondrial membrane, had a non-significant decrease in 
mRNA expression. ACC, an enzyme important in the regulation of fatty acid metabolism, 
showed a decrease in mRNA expression however did not reach significance [269]. It has 
been shown that an increase in acetyl-CoA can reduce glycolysis and net hepatic glycogen 
breakdown. One study which supports these findings, reported that rats fed a cholesterol 
rich diet supplemented with acetic acid also had reduced concentrations of in ACC [270]. 
ACC and CPT1A are two of the three main enzymes that regulate the synthesis of malonyl-
CoA, which is the principal inhibitor of fatty-acid entry into the mitochondria for β-oxidation. 
This decrease of activity indicates the potential of decreased lipid uptake into the 
mitochondria and therefore decreasing the rate of β-oxidation. However, ACOX1 which plays 
a key role in the fatty acid β-oxidation pathway was shown to increase following LITA 
treatment. An increase in ACOX1 expression is associated with increased oxidation and lean 
body phenotype. These effect contrasts with those observed with ACC and CPT1A which 
would reduce lipid oxidation. Clearly more work is required to unravel the underlying 
mechanism by which LITA decreases IHCL observed in my study. 
 
In parallel to the above experiment, I looked at the potential effects of LITA HDACs protein 
modification. Butyrate, another of the SCFA produced in the colon is a well-known HDAC 
inhibitor (HDAC) [271, 272]. Moreover, suppression of HDAC (class 2) has been shown in 
murine models of obesity [273, 274]. Thus, I examined HDAC protein level and activity by 
acetate. Inhibition HDAC expression is carried out by the removal the acetyl group from 
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protein substrate, such as histone proteins [165, 275]. Previous studies have suggested that 
acetate contributed minimally to HDAC inhibition [276, 277]. Indeed, I observed a significant 
inhibition in HDAC 7 and trending inhibition in HDAC 1. I also observed an increase in 
expression of the HDAC proteins 2, 3 and 5. The trending decrease in HDAC 1 protein is 
consistent with the decreased mRNA level, confirming HDAC 1 is affected by LITA 
administration. These changes were accompanied by a hypoacetylation of the liver histone 
H4K12. This raises an important question about the epigenetic mechanism by which acetate 
may work as an epigenetic modulator. For example butyrate regulates histone acetylation 
and contributes of the Warburg effect as a by-product of the acetyl-CoA/HAT mechanism 
[278]. This involves the metabolism of butyrate to acetyl-CoA, which in turn stimulates HAT 
activity by functioning as a HAT cofactor and acetyl-group donor, representing an additional 
cascade of regulatory elements [160]. This mechanism of HDAC inhibition is more prevalent 
because studies are now looking into lower doses of butyrate-induces histone acetylation, 
whereas the HDACi is only a by-product rather than a direct effect of acetate arising from 
butyrate. In the case of acetate arising from LITA, it does not require the metabolic process 
seen with butyrate, thus it is likely that acetate is directly shuttle into mitochondria avoiding 
accumulation in the cytoplasm. Much more work is required to clearly define the downstream 
effectors of epigenetic modification. Figure 3.30 shows a global view of LITA administration 
and how HDACs are potentially modified by the introduction of acetate. Interestingly, it 
important to mention that 5mM dose of butyrate in vitro is physiologically relevant because it 
is routinely found at this concentration in the lumen of the colon [115], thus the 
administration of a similar dose via nanoparticle delivery would have the potential for nuclear 
access and for manipulating metabolic pathways epigenetically. I must also point out that the 
production of butyrate-containing liposome is not as straight forward as LITA and further 
work is required to obtain stable nanoparticles with longer SCFAs. 
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Increasing fatty acid availability, as observed in this model by the lack of accumulation in the 
liver, results in the upregulation of fatty acid oxidation while concomitantly reducing 
endogenenous rates of fatty acid oxidation and glucose metabolism, consistent with the 
Randle hypothesis [156, 279]. However, an unresolved question remains how increased 
extracellular fatty acid availability could lead to this “feed-forward” activation of fatty acid 
metabolism. One mechanism to explain the effects of acetate is adenosine monophosphate-
activated protein kinase (AMPK), a crucial sensor of cellular energy status, in particular fatty 
acid circulating levels alike AMP, resulting in allosteric activation leading to the 
phosphorylation and activation by an increase in the AMP/ATP ratio [280]. This multi-
substrate enzyme is considered to be a cell’s “low fuel warning system” since it is activated 
by the low concentrations of ATP (Figure 3.29) [281, 282].  
 
Sakakibara et al. reported activation of AMPK and reduced hyperglycemia after feeding 
acetic acid to obsess mice [283, 284]. Additional studies have reported that in muscle cells 
the “feed-forward” activation of fatty acid oxidation by fatty acids is completely dependent on 
AMPK signalling [285]. This suggests an important mechanism by which muscle responds to 
alterations in substrate availability, which could potentially identify the reason I saw an 
increase in muscle mass dissected from the chronic HFD model. AMPK is also responsible 
for gluconeogenesis via phosphorylation and nuclear exclusion of HDACs 4, 5 and 7 in the 
liver, which coincides with the significant inhibition in HDAC 7 I am reporting [273]. This may 
explain the increase in HDAC 3 I found, due to the heighted recruiting process that occurs 
during AMPK pathway activation in the liver.  
 
Acetyl-CoA leads to an increased formation of AMP, which increases the AMP/ATP ratio and 
causes the phosphorylation of AMPK [170]. AMPK induces transcription of PPARα gene, 
which was slightly increased in expression level when compared to the control group PPARα 
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has downstream effects on two upregulating fatty acid oxidation enzymes examined, CPT-
1A, and UCP-2 [286]. Activation of AMPK has also been shown to suppress the activity of 
lipogenic enzymes, including the transcription of ACC, which is consistent in these findings 
[287]. Other lipogenic enzymes to investigate in my future work will consist of sterol 
regulatory element binding protein (SREBP-1) and downstream of SERBP-1 fatty acid 
synthase (FAS) [288]. However, acetate affects may go beyond direct regulation of 
metabolic signalling. 
 
 
Figure 3.29 Proposed mechanisms on fatty acid synthesis following hepatic delivery 
A proposed mechanism of effect of acetate on fatty acid synthesis in liver is shown in the 
figure. Acetate through activation of AMPK, inhibits fat synthesis in the liver. Fatty acids are 
synthesized from excess glucose in the liver. Glucose is turned into pyruvic acid which goes 
into TCA cycle. Once citrate is formed it generates cytosolic acetyl-CoA and malonyl-CoA 
which then forms fatty acids. Figure from Yamashita et al., 2007. 
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Figure 3.30 Proposed mechanism of global LITA activity following hepatic delivery  
The effects of LITA nanoparticles ( ) on key cellular pathways in the cytoplasm and 
mitochondria of a hepatocyte are shown. LITA nanoparticle administration leads to cellular 
uptake of acetate (blue circles) followed by mitochondrial accumulation of acetyl-CoA. 
Acetyl-CoA then enters the TCA, or Krebs Cycle, to yield citrate. Citrate, an intermediate in 
the TCA cycle, is then transported out of the mitochondria via the citrate shuttle and 
converted to acetyl-CoA. Acetyl-CoA in the cytosol has the availability for lipid biosynthesis. 
Acetyl-CoA is also transported into the nucleus and regulates histone acetylation. This 
model also includes glucose-induced signal transduction that upregulates acetyl-CoA activity 
(via phosphorylation of the enzyme conversion of acetyl-CoA and citrate) which makes it 
susceptible to being regulated by the Warburg effect. Black coloured arrows indicate the up-
regulation effects of LITA delivery. LCFA: Long chain fatty acids; VLDL: very low density 
lipoprotein. 
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3.4.4 Conclusion 
The present work looking at the reparative effects of a HFD with LITA nanoparticle has 
shown to have an improved state of the liver and the overall metabolic profile in vivo. 
 
In both sets of experiments, chronic injections of liposomes did not seem to cause any side 
effects and overall animal behaviour appeared normal. Overall, LITA administration resulted 
in a comprehensive improvement in metabolic profile in animal models of obesity; including 
amelioration of a wide range of metabolic syndrome associated outcomes, including 
reductions in IHCL, body fat, serum insulin, FFA and inflammatory tone. More work will be 
required to fully elucidate the numerous, interconnected metabolic pathways underpinning 
these effects. However, these results present LITA administration as a promising therapy for 
the positive modulation of obesity transformation in vivo. 
 
In conclusion, my results support a mechanism by which the LITA-induced mitochondrial 
accumulation of acetyl-CoA, the end-product of SCFA catabolism, caused changes that are 
consistent with the Randle hypothesis; whereby the availability of acetate as a fuel source 
generates metabolic signals that impair the use of glucose through inhibition of glycolytic and 
gluconeogenic pathways [289]. This shift in substrate oxidation reduced lipid uptake, 
lipogenesis and hepatic glucose uptake, whilst observing no net change in energy balance 
[290]. Further work is required to unravel the full metabolic effects that transpired during 
LITA treatment of metabolic dysfunction. 
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Together, these results support a mechanism by which the LITA-induced mitochondrial 
accumulation of acetyl-CoA, the end-product of SCFA catabolism, inhibits β-oxidation and 
subsequently reduce lipid uptake, lipogenesis and hepatic uptake. Furthermore, the changes 
observed are consistent with the Randle hypothesis; whereby the availability of acetate as a 
fuel source generates metabolic signals that impair the use of glucose through inhibition of 
glycolytic and gluconeogenic pathways [289]. A shift away from carbohydrate metabolism 
might be expected to result in altered respiratory outcomes in LITA-injected animals yet 
observed no differences following metabolic cage analysis. However, these results are in 
accord with several papers that demonstrate energy expenditure is maintained following 
acetate infusion, as acetate replaces fat as an oxidative fuel [237, 239].  
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Chapter 4 
In Vivo Biological Evaluation of LITA-xenograft in 
Tumour Models 
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4.1 Introduction 
As discussed in Chapter 1, impaired cellular energy metabolism is a defining characteristic 
of a number of diseases, including cancer. Supplementation with dietary fibre, or by-products 
of its subsequent colonic breakdown, such as acetate, propionate and butyrate has been 
shown to ameliorate features of the metabolic syndrome and attenuate malignant growth in 
certain cancers [159, 160, 230, 231, 291, 292]. Acetate plays a central role in cellular 
metabolism, functioning as a key intermediate in the synthesis of fatty acids and cholesterol 
in the liver. Furthermore, oxidation of acetate derived from carbohydrates, fats and proteins 
is the initial step in the tricarboxylic acid (TCA) cycle, a fundamental energy producing 
pathway in all aerobic organisms [293]. Oxidative phosphorylation generates the majority of 
energy required for cellular function in normal differentiated cells. In contrast, cancer cells 
rely primarily on aerobic glycolysis, a metabolic shift termed the Warburgh effect that 
comprises attenuation of energy production via mitochondrial beta-oxidation [152]. In 
malignant cells the inhibition of glucose uptake and metabolism by products of SCFA 
breakdown is thought to preferentially inhibit aerobic glycolysis and supress the uncontrolled 
cellular proliferation [162, 294].  
 
In Chapters 2 and 3, I demonstrated that LITA nanoparticles are a viable vector for the non-
targeted delivery of SCFAs to key sites of metabolic control. Liposome based therapeutics 
have found their way to the clinic over the last few decades as drug delivery systems in 
cancer therapy. In this chapter, colorectal cancer (CRC) was examined based on previous 
studies which had a similar metabolic approach of SCFA [295] or acetate isoforms as a CRC 
therapeutic.   
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4.1.1 Aims of Studies 
To optimise and measure LITA-xenograft nanoparticle uptake in an in vivo colorectal 
cancer model. Nanoparticle formulation requires the appropriate ratio of lipids to allow for 
prolonged circulation and tumour accessibility, and a reliable method for detectability post-
delivery. This will develop a delivery system of acetate with the capacity to tailor the design 
of the nanoparticle to reach the xenograft tumour. 
 
To evaluate therapeutic effects of LITA-xenograft nanoparticles in colorectal cancer 
xenograft models in vivo. I will examine the effects of LITA-xenograft nanoparticles on 
tumour growth in three different colorectal cancer cell lines. Longitudinal phenotypic changes 
will be monitoring at a two-fold level, using a standardly used calliper and the activity of the 
tumour by bioluminescent optical imaging. Downstream molecular investigations will also be 
examined for mechanistic changes to mirror any phenotypic changes and determination of 
pathways involved for any growth changes, specifically the Warburg effect and deacetylation 
changes.  
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4.2 Methods 
4.2.1 Materials 
 
4.2.1.1 Animals 
Male Bulb-c nude/nude mice (SPF, Harlan, UK) were housed in IVC cages under the same 
controlled conditions of temperature and light as above. Diet and water was autoclaved (RMI 
diet, Special diet Services, Ltd, Essex, UK) with ad libitum access. All experiments were 
carried out in compliance with Animals (Scientific Procedure) Act 1986 under the project 
licence 70/6656. 
 
4.2.1.2 In vivo cancer cell lines 
Three different cancer cell lines were investigated to explore the therapeutic potential of the 
LITA nanoparticle. A xenograft model of three varying colorectal cancer cell line models 
were independently carried out in vivo with the specified nanoparticle formulation that was 
specific to tumour delivery. Three different CRC cell lines were used in this study with 
different metabolic profiles: HT-29 with a mutated state of p53, HCT 116 with p53 (+/+) and 
HCT 116 without p53 (-/-). 
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4.2.2 Study 1: Liposome Preparation, Formulation and Characterisation for 
Xenograft Model Application 
 
4.2.2.1 LITA-xenograft preparation and formulation 
Liposomes were formulated with a defined molar ratio of individual lipids based on the 
desired in vivo application of delivery to the xenograft tumour in vivo. Liposomes were 
prepared as described in 2.2.2 and 2.2.3 for anticipation of xenograft delivery, therefore 
used formulation LITA-xenograft. To achieve the ‘stealth’ state introduced earlier, the LITA-
xenograft was formulated with a higher percentage molarity of 5% DSPE-PEG2000 (Table 
2.2), rather than the LITA molarity of 1% DSPE-PEG2000, to increase circulation time of the 
particle allocating passive localization within the solid tumour. As shown in the Table 2.2, 4% 
decrease in cholesterol was used in the LITA-xenograft formulation to compensate for the 
increase in DSPE-PEG2000. For in vivo histological analysis, (E) LITA-Rhd-xenograft was 
used for 1% of rhodamine incorporation and 30% cholesterol.  
  
4.2.2.1 Liposome tumour specificity and characterisation 
Xenograft delivery on small animal models of cancer has been made possible through 
specific formulations tailored to the angiogenic environment of a solid tumour. To determine 
delivery of the nanoparticle to the xenograft tumour, ex vivo bio-distribution studies were 
executed using histological studies. Similarly described in 2.2.5.1.1, the LITA-Rhd-xenograft 
formulation was examined for delivery after a single 200µL injection intraperitoneally (i.p.) to 
bulb-c nude/nude mice which had established xenograft tumours from HT-29 cells (n=4).  
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4.2.2 Study 2: LITA effects in a Colorectal Cancer Xenograft Model 
 
4.2.2.1 Cellular  
The desired cells line was seeded at 2.5x105 cells per T-25 flask (Nunc, USA) and grown as 
a monolayer in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-Aldrich, UK), 
supplemented with 10% fetal calf serum (FCS) (Sigma-Aldrich, UK) in an incubator at 37°C 
with 5% CO2. Cells were maintained every 3-5 days while never exceeding 15 passages. 
Once the cells were approximately 80% confluent, the media was removed, they were 
harvested by removal of the media, washing with PBS, and followed by the addition of 
trypsin (Sigma-Aldrich, UK) for approximately 5 minutes. The media was removed and cells 
were washed with PBS three times and re-suspended in serum-free DMEM and centrifuged 
at 1,000 RPM for 5 minutes. The media was removed and cells were counted on a 
haemocytometer.  
 
4.2.2.2 Luciferase-stable CRC cell lines HCTp53+/+ and HCTp53-/- 
HCT 116 wild-type p53 (HCT 116 p53+/+) and HCT 116 isogenic knocked-down p53 (HCT 
116 P53-/-) were maintained at 37°C in Dulbecco’s modified Eagle’s medium (Sigma-
Aldrich, USA) supplemented with 10% fetal bovine serum (FBS; Sigma), 1% L-glutamine, 
1% and penicillin/streptomycin in the presence of 5% CO2. For generating luciferase-stable 
clones from HCT 116 p53+/+ and HCT 116 p53-/-, each cell line was cultured in a 10 cm 
dish until the cells reach 60-70% confluency. The transfection was carried out with 
Polyethylenimine (PEI) polymers mixed with the pGL4.20 [luc2/Puro] Vector from Promega 
in ratio 4:1, and the mixture was completed to 200 µL with Opti-MEM media. Then the 
mixture was dropped over the cells covered with the minimum amount of Dulbecco’s 
modified Eagle’s medium. Two days after the transfection, the stable clones from each cell 
line (HCT 116 p53+/+ and HCT 116 p53-/-) were selected in Puromycin for two weeks. To 
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confirm the success of our stable clones and to check the luciferase expression levels, 
Steady-Glo® Luciferase Assay System (Promega, USA) was used. Cells were finally 
resuspended at 1x107 cells per mL of serum-free DMEM for injections into the mice.  
 
4.2.2.3 In Vivo tumour model development 
Tumourigenicity was achieved by preparing cells as described in 4.2.2.1 and injecting into 
balb/c nude mice subcutaneously into the right flank with 5x106 cells in 100µl of serum-free 
media, using a 25 gauge needle. Mice were divided into groups bearing tumours from three 
cell lines of the colon cancer origin: Group 1 (n=6/group) consisted of mice bearing tumours 
from HT-29; Group 2 (n=6/group) consisted of mice bearing tumours from HCT 116+/+; 
Group 3 (n=6/group) consisted of mice bearing tumours from HCT 116-/-. At the initial 
identification of the xenograft tumour, a baseline measurement was obtained using the two 
growth assessment techniques, described in 4.2.2.4. After baseline measurements, mice 
were stratified into 2 groups. In the first group, mice will be treated with the control HEPES 
liposome. The second group will be treated with the LITA-xenograft nanoparticles in parallel. 
For the duration of the study, injections were administered three times a week i.p. of 200 µl 
per injection. Xenograft tumour growth was monitored on a weekly basis by two different 
methods, the calliper and IVIS Spectrum. 
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4.2.2.4 Tumour growth assessment by size and by bioluminescent imaging luciferase 
For an in-depth assessment of tumour growth and development, a multi-mode approach was 
employed by using both bioluminescence imaging and by calliper. Tumour volume was 
measured by calliper assuming an ellipsoid shape using the following equation: 
 
Volume= length x width x depth x π/6 
 
Equation 4.1 Volume equation used to measure tumour from calliper 
 
 
For visualization by luminescence, the Xenogen IVIS 2000 small-animal in vivo imaging 
system (Xenogen Corp., USA) was used. Briefly, an IVIS 200 cooled CCD camera system 
was used for emitted light acquisition and Living Image software (Xenogen Corp., USA) for 
data analysis as an overlay on IGOR software (Wavemetrics Corporation, USA). Animals 
received a 100uL intraperitoneal injection of D-luciferin (Gold Biotechnology, USA.) at a 
concentration of 15 mg/mL under 1-2% inhaled isoflurane anaesthesia. An average of 10 
kinetic bioluminescent acquisitions will be collected between 0 and 30 minutes after 
substrate injection to confirm a peak photon emission recorded as maximum photon efflux 
per second. Data analyses and background correction was be carried out by using total 
photon flux emission (photons/s) in an ROI covering the entire xenograft tumour region.  
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4.2.2.5 Xenograft mouse tumour tissues processing 
At the end of the study, animals were sacrificed and the tumours were carefully excised, 
making sure that the samples did not contain any surrounding normal tissue. Tumours were 
weighed and portioned to either formalin solution (Sigma-Aldrich, UK) for histological 
evaluation or snap frozen in liquid nitrogen and stored at -80°C for subsequent extraction of 
mRNA. Homogenisation of the tissue was performed as described in 3.2.3.7 and mRNA 
levels were measured as described in 3.3.1.8.   
 
 
4.2.2.6 Statistical analysis 
All statistical analyses were performed using GraphPad Prism (San Diego, CA), unless 
otherwise noted. Data are presented as means ± standard deviation (SD) or standard error 
mean (SEM). Statistical significance was calculated with Student’s t test, two-way ANOVA 
with Bonferroni post-hoc test for multiple comparisons. Significance was accepted at the 
level of * = p<0.05, ** = p< 0.01, *** = p<0.001. 
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4.3 Results 
4.3.1 Study 1: Liposome Preparation, Formulation and Characterisation for Xenograft 
Model Application 
Liposomes formulated in Chapter 2 were applied for an in vivo passive targeting system with 
4mM of acetate loaded within the aqueous core of the vesicle. Preliminary biodistribution 
studies confirmed the acetate encapsulated liposomes does reach the circulatory system 
intact and does have multiple effects on the metabolism of an obesogenic state. Moving 
forward, the question turned to altering the metabolism of cancer in vivo. In order for a 
liposome to reach a xenograft tumour, a longer circulation time of the LITA-xenograft was 
required than the original LITA nanoparticle. These formulation changes were achieved by 
increasing the molarity of the DSPE-PEG2000 lipid from the 1% in the LITA formulation to 5%.  
 
4.3.1.1 Liposome preparation and formulation  
Liposomes were formulated with a defined molar ratio of individual lipids based on the 
desired in vivo application (Table 2.1 D-E). LITA-xenograft: liposomes contain 5% DSPE-
PEG2000 for increased in vivo circulation; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; 
CDAN: N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine; DSPE-PEG2000: 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy (polyethylene glycol)-2000; DOPE 
– Rhodamine B:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- (lissamine rhodamine B 
sulfonyl). LITA-Rhd-xenograft: liposome contains 1% less cholesterol in order to allow for 
Rhd incorporation for histological analysis targeted to the xenograft. 
 
4.3.1.2 Liposome sizing and stability confirmation 
Confirmation of the size of the formulated liposomes was determined by using a Zetasizer 
Nano (Malvern, UK). Size is expressed in nanometers (nm) and the difference in size within 
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the liposome solution is expressed as the poly distribution index (PDI). Figure 4.1 A-B shows 
the reproducibility of liposome in batch-to-bath formulations was evaluated, the LITA 
nanoparticles typically formulated slightly larger in size though there was no statically 
significant difference between groups (control: 100.7 ± 2.071, n=10; LITA-xenograft: 108.2 ± 
3.338, n=10; p=0.0740). The single peak in each graph represents the size distribution of a 
single reading of the liposomes from the Zetasizer. In the example used here, the PDI of 
HEPES was 0.892 (Figure 4.1 C) and the PDI of LITA-xenograft was 0.591 (Figure 4.1 D). 
 
 
 
 
 
225 
 
 
 
Figure 4.1 Liposomal nanoparticle sizing method after completed formulation 
 The (A) formulated liposome size, data shown as mean ± SEM and (B) size distribution 
between groups showed no statistical significance between groups or batch-to-batch 
formulation (n=10/group). (C) Sizing peaks of control (containing HEPES) and (D) LITA-
xenograft respectively. The x-axis represents the size (nm) of the nanoparticle and the y-axis 
represents the number (%) of liposomes.  
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4.3.1.2.1 Liposomal tumour specificity using fluorescence microscopy imaging ex vivo 
Once sizing and stability of the LITA-xenograft was concurrent with the original LITA 
formulation, biodistribution was tested. The specific cell line used for this study was HT-29. 
For in vivo detection of xenograft tumour delivery, LITA-Rhd-xenograft was formulated with 
5% DSPC-PEG2000 encapsulated with 1M acetate and 200µL was administered i.p. Bio-
distribution of LITA-Rhd-xenograft was assessed by histological investigation using 
fluorescence microscopy to visually identify the bi-layer incorporated lipid, rhodamine (Rhd). 
Figure 4.2 shows the xenograft tumour extracted and observed 2 hours post injection. The 
red in Figure 4.2 C confirms presence of LITA-Rhd-xenograft within the tumour tissue. 
 
 A control filter was first used to confirm there was no artefact that would generate a false 
positive identification of the LITA-Rhd-xenograft (Figure 4.2 A). A nuclear stain (DAPI) was 
then allied to the microscope slide to ensure the region being observed was in fast tissue 
(Figure 4.2 B). A rhodamine-specific filter was used to observe the same slide for LITA-Rhd-
xenograft visualisation and confirmation of delivery to the tissue of interest (Figure 4.2 C). 
Red in images represents the fluorescent rhodamine embedded into the liposome 
membrane. 
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Figure 4.2 LITA-Rhd-xenograft nanoparticle tumour localisation LITA-Rhd-xenograft 
identification in the xenograft tumour by histological fluorescence imaging  
Images obtained from xenograft tumour 2 hours post LITA-Rhd-xenograft i.p. administration 
(A) control, (B) nuclear stain (DAPI), (C) rhodamine-specific filter visualisation. Red in 
images represents the fluorescent rhodamine embedded into the liposome membrane. 
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4.3.2 Study 2: LITA-xenograft effects in a Colorectal Cancer Xenograft Models 
4.3.2.1 HT-29 colorectal cancer cell line tumour model  
The HT-29 colorectal cancer cell line was used for the xenograft inoculation, of which tumour 
take up rate was 50% and tumours appeared within the expected time of 14 days. Time 0 
references when the tumour was palpable and large enough to measure by calliper, at which 
point injections of either control or LITA-xenograft nanoparticles were administered. The 
chronic administration of LITA-xenograft nanoparticles led to a significant reduction in growth 
as measured by calliper at the end of the 4 week study (LITA-xenograft: 98.20 ± 25.34mm3, 
Control: 107.2 ± 46.71 mm3, p=0.490) (Figure 4.3 A). During the first 2 weeks, tumour size 
between groups does not have much variability, however going into week 3 showed a rate of 
growth difference that reached significance over the 4 week period. Weekly growth values 
can be seen in Figure 4.3 B and quantitative values in Table 4.1. 
 
At the end of the study, there was a reduction in the LITA group in size of the tumour weight 
(LITA-xenograft: 0.05 ± 0.03mg, Control: 0.33 ± 0.04mg, p<0.01) compared to controls 
(Figure 4.4 A). The image of a xenograft tumour extracted at the end of the study from each 
treatment group, the LITA and the control (Figure 4.4 B).   
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Figure 4.3 Effects of LITA-xenograft nanoparticles in murine HT-29 colorectal tumour 
growth 
Mice were inoculated with HT-29 colorectal cancer cells and were injected every three days 
with either control or LITA-xenograft nanoparticles for 4 weeks, once tumour was confirmed 
palpable. Tumour volume was measured weekly using the standard calliper method. (A) 
Tumour growth over the 4 weeks had a significant decrease in growth in the LITA-xenograft 
treated group, with particular growth difference shown at week 4 (B). Data is presented as 
mean ± SEM and analysed by two-sample t test with Wilcoxon test; n=6/group. 
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Table 4.1 Effects of LITA-xenograft nanoparticles in murine HT-29 colorectal tumour 
growth 
Mice were inoculated with HT-29 colorectal cancer cells and were injected every three days 
with either control or LITA-xenograft nanoparticles for 4 weeks, once tumour was confirmed 
palpable. Tumour volume was measured weekly using the standard calliper method. Tumour 
growth over the 4 weeks had a significant decrease in growth in the LITA-xenograft treated 
group, with particular growth difference shown at week 4. Data is presented as mean ± SEM 
and analysed by two-sample t test with Wilcoxon test; n=6/group. 
 
 
 
 
 
Control  LITA-xenograft 
Week  (mean ± sem)  (mean ± sem) p value
0 00.00 ± 00.00 00.00 ± 00.00 ---
1 39.40 ± 6.467 32.83 ± 9.891 0.7777
2 68.46 ± 8.088 48.79 ± 20.82 0.6525
3 173.8 ± 38.27 254.2 ± 46.80 0.3103
4 108.9 ± 34.54 122.9 ± 53.09 0.2053
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Figure 4.4 Effects of LITA nanoparticles in murine HT-29 colorectal tumours  
Mice were inoculated with HT-29 colorectal cancer cells and were injected every three days 
with either control or LITA-xenograft nanoparticles for 4 weeks. (A) Tumour weight (mg) and 
(B) the represented in the tumour grafts from control on the left side and LITA on the right 
side. Data is presented as mean ± SEM and analysed by unpaired t-test (n=6/group); ** = 
p<0.01. 
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4.3.2.1.1 HT-29 Colorectal Cancer Cell Line Tumour Gene Expression Analysis   
Quantitative RT-PCR was carried out on isolated mRNA from a HT-29 xenograft model, 
chronically treated with either control to LITA-xenograft nanoparticles for 4 weeks. Gene 
expression analysis revealed a significant decrease in Class I of the HDACs genes in LITA-
xenograft injected animals when compared to the control group; HDAC 1 (p<0.05), HDAC 2 
(p<0.05), HDAC 3 (p<0.001) and HDAC 4 (p<0.01). SiRT1 mRNA was also significantly 
reduced in LITA-xenograft injected animals (p<0.05) and SirT2 had an increase in 
expression though did not reach significance (Figure 4.5). All expression changes were 
compared to the control nanoparticles set to 1.0 and in relation to the housekeeper gene, 
GAPDH Data is also displayed in Table 4.2.      
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Figure 4.5 Effects of LITA-xenograft nanoparticles in murine HT-29 colorectal tumours 
at the end of the study  
Mice were inoculated with HT-29 colorectal cancer cells and were injected every three days 
with either control or LITA-xenograft nanoparticles for 4 weeks. Quantitative mRNA changes 
in xenograft tumour after chronic LITA-xenograft administration normalized to control 
liposomes. A significant decrease in expression was observed in all HDACs in class I and 
SirT1, however SirT2 had a non-significant increase. All expression changes were compared 
to the control nanoparticles set to 1.0 and in relation to the housekeeper gene, GAPDH. 
Data is presented as mean ± SD analysed by Student’s t-test (n=6/group); * = p<0.05, ** = 
p<0.01, *** = p<0.001. 
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Table 4.2 Summary of qRT-PCR analysis of gene expression fold changes in mRNA 
isolated from the tumour as a result of chronic LITA-xenograft treatment in HT-29 
colorectal cancer xenograft model 
Gene expression changes presented as mean ± SD at the end of a 4-week study of chronic 
LITA-xenograft or control nanoparticle administration in a CRC xenograft model. All gene 
expression changes were compared to the control nanoparticles set to 1.0 and in relation to 
the housekeeper gene, GAPDH; n=6/group. Data is analysed by unpaired t-test. 
 
 
 
 
 
 
 LITA (mean ± SD) p value 
HDAC 1 .-2.178 ± 1.183 p<0.05 
HDAC 2 .-3.039 ± 1.319 p<0.05 
HDAC 3 .-8.117 ± 1.399 p<0.001 
HDAC 4 .-5.106 ± 1.930 p<0.01 
SirT1 .-5.100 ± 2.937 p<0.05 
SirT2 1.106 ± 0.250 0.8305 
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4.3.2.2 HCT 116 colorectal cancer cell line tumour model 
To examine whether the results from the LITA-xenograft in the HT-29 xenograft model was a 
cell line specific response, the same model was established with another line of CRC, HCT 
116. The difference between the two CRC lines is the active state of p53; in HT-29 the p53 is 
in a mutated form, whereas HCT 116 is functioning without mutation. In order to determine if 
p53 was a determining factor in a tumour growth patterns, a xenograft model was 
established with a p53 knockout HCT 116 cell line. Thus, first a normal functioning HCT 116 
p53+/+ CRC cell line was used followed by a HCT 116 p53-/- using the same model and 
method as carried out before with HT-29. 
 
4.3.2.2.1 HCT 116 p53+/+ colorectal cancer cell lines tumour model 
The HCT 116 p53+/+ colorectal cancer cell line had less than a 50% take rate after 
inoculation and successfully xenotransplanted tumours appeared within the expected time of 
14 days. Time 1 refers to when the tumour was palpable and large enough to measure by 
calliper, at which point injections of either control or LITA-xenograft nanoparticles were 
initiated. Figure 4.6 A-B shows the chronic administration of control or LITA-xenograft 
nanoparticles over the course of 4 weeks led to a trend reduction in tumour size however did 
not reach significance (control: 449.9 ± 211.8, LITA-xenograft: 155.5 ± 87.19; p= 0.1250). 
During the first 2 weeks, tumour size between groups does not have much variability, 
however going into week 3 showed a rate of growth difference that reached significance over 
the 4 week period. Weekly growth values can be seen in Figure 4.6 B and quantitative 
values in Table 4.3. 
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Figure 4.6 Effects of LITA-xenograft nanoparticles in HCT116 p53+/+ colorectal 
tumour growth  
Xenograft tumour volume growth curve in control or LITA-xenograft treated groups for the 
duration of a 4-week study in the colorectal cancer cell line HCT116 p53+/+. (A) Tumour 
growth showed a decreased growth rate in LITA-xenograft treated group when compared to 
the control group, however neither reached significance; a particular growth rate difference 
shown at week 4 (p=0.125) (B) Data is presented as mean ± SEM and analysed by two-
sample t test with Wilcoxon test; n=6/group. 
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 Control LITA-xenograft  
Week (mean ± sem) (mean ± sem) p value 
0 00.00 ± 00.00 00.00 ± 00.00 --- 
1 50.26 ± 18.05 32.59 ± 16.8 0.513 
2 135.7 ± 76.11 94.23 ± 60.05 0.345 
3 269.6 ± 66.38 111.7 ± 70.86 0.179 
4 449.9 ± 211.7 155.5 ± 87.18 0.268 
   	  
Table 4.3 Effects of LITA-xenograft nanoparticles in murine HCT116 p53+/+ colorectal 
tumour growth 
Mice were inoculated with HCT116 p53+/+ colorectal cancer cells and were injected every 
three days with either control or LITA-xenograft nanoparticles for 4 weeks, once tumour was 
confirmed palpable. Tumour volume was measured weekly using the standard calliper 
method. Tumour growth over the 4 weeks had a trending decrease in growth in the LITA-
xenograft treated group, with particular growth difference shown at week 4. Data is 
presented as mean ± SEM and analysed by two-sample t test with Wilcoxon test; n=6/group. 
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4.3.2.2.1.1 Bioluminescence imaging for HCT 116 p53+/+ colorectal cancer cell lines tumour 
model 
For a secondary way to follow tumourigenesis and proliferation activity, luciferase stable cell 
lines HCT 116 p53+/+ was generated and transplanted into nude mice and non-invasive 
spatiotemporal visualization was used based on a bioluminescent molecular imaging 
system. The activity of the tumour groups showed a trending decrease in the LITA-xenograft 
treated groups when compared to the control groups in both cell lines. The images for 
control and LITA treated mice in HCT 116 p53+/+ is represented in Figure 4.7 
(group=6/group). Graph for luminescence output is shown in Figure 4.8 and quantitative 
results Table 4.4. 
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Figure 4.7 Bioluminescence imaging for control or LITA-xenograft treated HCT 116 
p53+/+ colorectal cancer cell lines tumour model  
Images of the murine xenograft model of HCT 116 p53+/+ after 3 weeks of having chronic 
control nanoparticle i.p. injections. (A) Control and (B) LITA-xenograft treated groups 
represent the luciferase activity quantified by the bioluminescent imaging system. Colour 
indicates luciferase activity which is correlated in counts given in the scale.   
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Figure 4.8 Bioluminescence imaging for control or LITA-xenograft treated HCT 116 
p53+/+ colorectal cancer cell lines tumour model 
Mice were inoculated with HCT 116 p53+/+ colorectal cancer cells. Once tumours were 
confirmed palpable, mice were injected every three days with either control or LITA-
xenograft nanoparticles for 4 weeks. Data is presented as mean ± SEM and analysed by 
two-sample t test with Wilcoxon test; n=6/group. 
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 Control LITA-xenograft  
Week (mean ± sem) (mean ± sem) p value 
0 00.00 ± 00.00 00.00 ± 00.00 --- 
1 6139 ± 2422.8 13697.5 ± 11250.5 0.578 
2 4458.1 ± 1652.4 3864.7 ± 161.6 0.755 
3 7602.8 ± 1152.6 27038.8 ± 13730.8 0.293 
4 5100.2 ± 2643.4 3476.6 ± 1934.4 0.669 
 
Table 4.4 Bioluminescence imaging for HCT 116 p53+/+ colorectal cancer cell lines 
tumour model 
Mice were inoculated with HCT116 p53+/+colorectal cancer cells and were injected every 
three days with either control or LITA-xenograft nanoparticles for 4 weeks, once tumour was 
confirmed palpable. Tumour metabolic activity was measured weekly using the standard 
calliper method. Tumour growth over the 4 weeks had a trending decrease in growth in the 
LITA-xenograft treated group, with particular growth difference shown at week 3. Data is 
presented as mean ± SEM and analysed by two-sample t test with Wilcoxon test; n=6/group. 
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4.3.2.2.2 HCT 116 p53-/- colorectal cancer cell lines tumour model 
The HCT 116 p53-/- colorectal cancer cell line had less than a 50% take rate after 
inoculation and successfully xenotransplanted tumours appeared within the expected time of 
14 days. Time 0 refers to when the tumour was palpable and large enough to measure by 
calliper, at which point injections of either control or LITA-xenograft nanoparticles were 
initiated. Figure 4.9 shows the chronic administration of control or LITA-xenograft 
nanoparticles over the course of 4 weeks led to a trend reduction in tumour size however did 
not reach significance (control: 216.1 ± 75.47, LITA-xenograft: 132.9 ± 48.06, p= 0.2500). 
During the first 3 weeks, tumour size between groups does not have much variability, 
however going into week 4 showed a rate of growth difference that reached significance over 
the 4 week period. Weekly growth values can be seen in Figure 4.9 B and quantitative 
values in Table 4.5. 
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Figure 4.9 Effects of LITA-xenograft nanoparticles in HCT116 p53-/- colorectal tumour 
growth  
Xenograft tumour volume growth curve in control and LITA-xenograft treated groups for the 
duration of a 4-week study in HCT116 p53-/- colorectal cancer cell lines. (A) Xenograft cell 
line growth showed a decrease in LITA-xenograft treated group, however neither reached 
significance. (B) Tumour growth over the 4 weeks had a trending decrease in growth over 
the 4 week period, with particular growth difference shown at week 4 (p=0.250). Data is 
presented as mean ± SEM and analysed by two-sample t test with Wilcoxon test or student’s 
unpaired t-test; n=6/group. 
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 Control LITA-xenograft  
Week (mean ± sem) (mean ± sem) p value 
0 00.00 ± 00.00 00.00 ± 00.00 --- 
1 22.58 ± 6.338 35.25 ± 20.34 0.584 
2 141.6 ± 11.7 100.3 ± 52.19 0.483 
3 171.7 ± 60.74 157 ± 65.39 0.877 
4 216 ± 75.46 132.8 ± 48.05 0.405 
 
Table 4.5 Effects of LITA-xenograft nanoparticles in murine HCT116 p53-/- colorectal 
tumour growth 
Mice were inoculated with HCT116 p53-/- colorectal cancer cells and were injected every 
three days with either control or LITA-xenograft nanoparticles for 4 weeks, once tumour was 
confirmed palpable. Tumour volume was measured weekly using the standard calliper 
method. Tumour growth over the 4 weeks had a trending decrease in growth in the LITA-
xenograft treated group, with particular growth difference shown at week 4. Data is 
presented as mean ± SEM and analysed by two-sample t test with Wilcoxon test; n=6/group. 
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4.3.2.2.2.1 Bioluminescence imaging for HCT 116 p53-/- colorectal cancer cell lines tumour 
model 
For a secondary way to follow tumourigenesis and cellular proliferation, luciferase stable cell 
line HCT 116 p53-/- was generated and transplanted into nude mice and non-invasive 
spatiotemporal visualization was used based on a bioluminescent molecular imaging 
system. The activity of the tumour groups showed a trending decrease in the LITA-xenograft 
treated groups when compared to the control groups in both cell lines. The images for 
control and LITA treated mice in HCT 116 p53-/- is represented in Figure 4.10 (n=6/group). 
Graph for luminescence output is shown in Figure 4.11 and quantitative results Table 4.6 
. 
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Figure 4.10 Bioluminescence imaging for control or LITA-xenograft treated HCT 116 
p53-/- colorectal cancer cell lines tumour model 
Images of the murine xenograft model of HCT 116 p53-/- after 3 weeks of having chronic 
control nanoparticle i.p. injections. (A) Control and (B) LITA-xenograft treated groups 
represent the luciferase activity quantified by the bioluminescent imaging system. Colour 
indicates luciferase activity which is correlated in counts given in the scale.   
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Figure 4.11 Bioluminescence imaging for control or LITA-xenograft treated HCT 116 
p53-/- colorectal cancer cell lines tumour model 
Mice were inoculated with HCT 116 p53-/- colorectal cancer cells. Once tumours were 
confirmed palpable, mice were injected every three days with either control or LITA-
xenograft nanoparticles for 4 weeks. (A) Luciferase activity had no significance difference 
between control or LTIA-xenograft treated groups (p=0.25), (B) despite having a difference 
in luciferase activity at week 3. Data is presented as mean ± SEM and analysed by two-
sample t test with Wilcoxon test or student’s t-test; n=6/group. 
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 Control LITA-xenograft  
Week (mean ± sem) (mean ± sem) p value 
0 00.00 ± 00.00 00.00 ± 00.00 --- 
1 34562.5 ± 3815.3 24949.2 ± 2414.3 0.164 
2 27418.9 ± 7800.6 35295.5 ± 7879.5 0.547 
3 337165 ± 167318.1 177838.5 ± 133426.5 0.550 
4 19274 ± 14065.9 3818.5 ± 1592.5 0.458 
 
Table 4.6 Bioluminescence imaging for HCT 116 p53-/- colorectal cancer cell lines 
tumour model 
Mice were inoculated with HCT116 p53-/- colorectal cancer cells and were injected every 
three days with either control or LITA-xenograft nanoparticles for 4 weeks, once tumour was 
confirmed palpable. Tumour metabolic activity was measured weekly using the standard 
calliper method. Tumour growth over the 4 weeks had a trending decrease in growth in the 
LITA-xenograft treated group, with particular growth difference shown at week 3. Data is 
presented as mean ± SEM and analysed by two-sample t test with Wilcoxon test or student’s 
t-test; n=6/group. 
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4.4  Discussion 
In this Chapter I have designed a tumour-directed LITA particle for the uptake and treatment 
to three murine xenograph models of colorectal cancer in vivo, HT-29, HCT116 -/- and 
HCT116 +/+. HT-29 xenograft tumour showed a decreased growth rate and a decreased 
mRNA expression in HDAC 1, 2, 3 and 4 and Sirtuin 1 with an increase in Sirtuin 2. LITA 
administration caused a decrease in growth in HCT116 -/- and HCT116 +/+ by calliper 
measurements, however not by bioluminescent imaging.  
 
An important factor in the design of a drug delivery system is the efficiency with which it 
comes in contact with the desired tissue, in this case the tumour tissue. The LITA 
nanoparticle formulated and tested in this study is categorised as a passively targeted, 
cationic liposome. This formulation was chosen as positively charged lipids lead to 
favourable interaction with surfaces of cells which are normally negatively charged. 
Liposome-tumour endothelial cells interactions is strongly governed by the degree of surface 
cationic charge, which is in turn determined by the amount of cationic lipid used in the 
formulation of the liposomal bilayer [213, 217]. Thus in the case of my LITA formulation the 
cationic lipid content was 32%mol. Krasnici et al. have previously shown that intravenously 
applied cationic liposomes preferentially accumulated in a xenograft tumour in vivo, in 
comparison with normal surrounding tissue [296]. Interestingly, this preferential accumulation 
of cationic liposomes in the solid tumour is thought to cause binding of the liposomes to 
angiogenic tumour microvessels. It would therefore be interesting to assess if the LITA 
nanoparticles develop here undergo a similar binding process. 
 
Many studies have focused on elucidating the optimal concentration of the polymer 
polyethylene-glycol (PEG) that should be incorporated in the liposomal membrane to provide 
liposomes with long-circulating characteristics. Abu Lila et al. showed that PEG-coated 
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cationic liposomes had a 2-3 fold higher accumulation in tumour tissue than PEG-coated 
neutral liposomes [297]. Levchenko et al demonstrated that for a xenograft model in vivo, 
PEG concentrations of ≥6 mol% shield the electric surface of potential cationic liposomes, 
while higher concentrations (≥15%mol) were found to cause unfavourable structural changes 
in the liposome bilayer that enhanced the rapid clearance of liposomes from circulation[186]. 
In agreement, Cambell et al proposed a concentration range of PEG-lipid incorporation to be 
approximately 4-9% for ideal xenograft delivery [298] . This is also in accordance with my 
previous work [216], with an increased molarity percentage of DSPE-PEG2000 in the 
liposome membrane led to a preferential accumulation of liposomes in tumour tissue. Here, 
5%mol of PEG lipid was incorporated into the liposome bilayer and created a long-circulating 
characteristic and allowed accumulation within the xenograft tumour.   
 
As a verification of accumulation of LITA within the tumour, ex vivo fluorescence microscopy 
was performed. As with the previously validated LITA-Rhd nanoparticles in Chapter 3, the 
inclusion of the fluorescent DOPE-Rhodamine lipid in the liposome formulation allowed for 
post-mortem analysis. Confirmation of the LITA-Rhd is based on visual identification to 
determine presence of liposome and comparison of uptake between organs. The 
fluorescence pattern observed for the LITA-Rhd-xenograft nanoparticles appear to be more 
localised within the tissue than in previous histological evaluations carried out in the HFD 
model. The distribution profile of the nanoparticle was different in tumours versus organs; 
passively targeted tumours have a high accumulation in filter organs such as the liver or 
kidneys, thus the LITA-Rhd allowed visualisation of the vascular structure as well as tissue 
distribution (Chapter 3, Figures 2.9-2.12). Tumour growth does not have this vascular 
organisation and so the LITA-Rhd-xenograft appears bright in only one location within the 
histology slice as a result of liquid accumulation. It is also a factor of distribution over time, 
and the initial 2-hour time point does not allow for such cross organ comparison. Nomure et 
al. have previously demonstrated that tumour accumulation of liposomes tended to increase 
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up to 24 hours after injection and remained at this level for 48 hours [299]. The time point of 
2 hours was merely used to confirm the delivery of the LITA nanoparticles to the tumour and 
therefore does not fully reflect the overall uptake of these nanoparticles by the tumour. This 
clearly needs further investigation. Fluorescence microscopy was carried out ex vivo in 
HCT116 cells lines, however with a different panel of small molecules thus is not included in 
this thesis, however it was confirmed liposomal delivery in achievable all cell lines used in 
this study.   
 
Following the renewed interest in the ‘Warburg effect’, it has become clear that alterations in 
metabolism should be included among the essential characteristics of tumour cells, as 
described earlier. To investigate cancer dysregulated metabolism, acetate encapsulated 
nanoparticles were chronically delivered to xenograft inoculated mice, investigating 
colorectal cancer (CRC) cell lines with varying metabolic profiles. These CRC cell lines were 
HT-29 and HCT116 derived from two widely used colon carcinoma models. The latter 
consisted of a wild-type p53 (HCT116 3 (+/+)) and a p53-knockout (HCT116 without p53 (-/-
)). Furthermore, HT-29 bears a mutation in one allele of p53 and is therefore characterised 
by altered p53 protein [300, 301]. The tumour suppressor p53 integrates intracellular signals 
and induces the transcription of target genes and interacts with a wide array of pathways to 
help determine cell fate and promote cell arrest, senescence or apoptosis. Indeed, p53 has 
been recently associated with the control of cancer cell metabolism [302, 303]. 
 
All cell lines underwent to same inoculation and treatment protocol leading to visible 
xenographs. HT-29 cell lines were only measure by calliper as no luciferase cloned cell line 
was available. HT-29 showed a decrease in tumour volume in the LITA group by the end of 
the study. However, both groups had similar growth patterns for the first two weeks. This 
apparent discrepancy could be due to the lack of acetate reaching the tumour and/or the fact 
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that acetate requires to be present for a significant period of time before cellular response 
can take place. Thus, the increase in acetate delivery over time may have curved the 
metabolism by saturating the tumour environment. Consistent with the decrease in the 
tumour growth curve, the volume and mass were also both significantly decreased in the 
LITA-xenograft treated group. A noticeable difference in tumour volume versus tumour mass 
was observed at the end of the study. One potential confounding factor could be the dense 
microenvironment of the tumour, which is included in the calliper measurement but is 
dissected out when removing and isolating the tumour itself. Another factor that could 
contribute to the discrepancy between volume and mass changes may be the growth pattern 
of the tumours; some tumour appeared to have significant necrosis, being hollowed centre 
filled with liquid instead of cellular tissue. 
 
Calliper based measurements were also carried out for HCT116 p53+/+ and HCT116 p53-/- 
cell lines, which showed a reduction in tumour volume in the LITA-xenograft group, though 
neither reached significance. The growth rate of HCT116 p53+/+ appeared much more 
aggressive than HCT116 p53-/- and the HT-29, though they all showed a reduction when 
treated with the LITA nanoparticle. Interestingly, the protocol of treatment was the same for 
all models, yet the growth response was different between cell lines. It has been previously 
shown in vitro that HCT116 p53+/+ grows at a higher rate than HT-29 cells, but both are 
faster than the HCT116 p53-/- [304, 305]. Furthermore, the HT-29 and HCT116+/+ had a 
more pronounced response to the LITA administrations than HCT116-/-, possibly indicating 
a role for p53 in the mechanism of action of acetate [306].  
 
Bioluminescence imaging is a broadly applicable technology for assessing biological process 
in vivo. Luciferase activity provides a read-out of increases or decreases in transcription of 
the reporter gene in vivo. Thus, bioluminescent imaging was carried out in addition to calliper 
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to measure tumour activity. It is important to point out; the intensity of the signal measured 
by in vivo may depend on various factors, including D-luciferin absorption through the 
peritoneum, cell membrane permeability, availability of co-factors, blood flow, intracellular pH 
and transparency of overlying tissue, in addition to the amount of luciferase that is able to 
reach the location of interest [307]. Luciferase activity and calliper measurements did not 
appear to correlate at any point over the 4 week study in the HCT 116+/+ cell line. Calliper 
measurements showed an increase over the 4 week study; however the luciferase activity 
did follow the same pattern. Indeed, luciferase activity and calliper measurement only 
correlated in the HCT 116-/- tumour growth at week 3. While in the first two weeks the 
calliper measured group showed tumour growth in both groups at relatively the same rate, 
the luciferase groups appears to have no change over time or between groups. Week 2 in 
particular had low luciferase activity which most likely was a result of the assay more than 
the tumour. This inconsistency between methods may arise from the fact that changes in 
tumour architecture may limit the supply of either substrate or enzyme activity, thus leading 
to a diminished bioluminescence despite having tumour growth. Moreover, at the alter stage 
of the study; tumour necrosis may play a significant role in the bioluminescence 
measurements. Thus, although the luciferase activity could have delivered important data on 
tumour activity in vivo the more accurate and consistent measurements from calliper will be 
referred to when discussing growth rates.  
 
The discrepancy between calliper and bioluminescence presented a difference in recorded 
observations. According to the tumour measurements by calliper and weight, I observed a 
decrease in tumour growth in the LITA group; however according to the bioluminescence 
pattern, I saw no difference in either group. The lack of agreement was a surprising result 
since this method is widely reliable. It is assumed that bioluminescence signal increases as 
tumour volume increases, but the relationship might have been disrupted due to hypoxia, 
necrosis or pH of the tumour microenvironment or the location of transplantation of the 
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xenograft tumour [307]. The tumour decreased in size, thus it can be assumed some portion 
of the LITA-xenograft nanoparticle was reaching the tumour, however the hypoxic conditions 
might have hindered the signal of the bioluminescence substrate that reached the tumour 
tissue, and impacting the interpretation.       
 
The mechanism behind the effects of LITA-xenograft results is unclear but may take place 
by altering genetic or metabolic processes. SCFA have previously been investigated for 
activity in cell differentiation, growth arrest and/or apoptosis [308, 309]. Valproic acid, phenyl 
acetate and butyrate have been shown to have antigrowth properties [310, 311] . These anti-
proliferation effects attributed to SCFAs have been linked to changes in activity of many 
enzymes and transcription factors, including HDAC enzymes, important markers that play a 
key role in cellular gene expression [173, 312].  
 
LITA-xenograft treatment of HT-29 xenograft showed a reduction in tissue mRNA expression 
of HDACs 1, 2, 3 and 4. This would suggest a potential decrease in HDAC activity following 
LITA-xenograft treatment. A potential model to understand this effect would be butyrate, a 
well-known HDC inhibitor. It was initially proposed that butyrate inhibited HDAC activity by its 
accumulation in the cytoplasm, leading to its transport into the nucleus and directly affected 
HDAC transcription. However, Donohoe et al., have shown that butyrate might induce 
histone acetylation by an alternative mechanism. Metabolism of butyrate to acetyl-CoA 
appears to stimulate HAT activity by functioning as a HAT cofactor and acetyl-group donor. 
In this model, butyrate undergoes β-oxidation to acetyl-CoA inside of the mitochondria, 
followed by the first step of the TCA cycle to yield citrate. Citrate is then transported out of 
the mitochondria via the citrate shuttle and converted by the enzyme ATP citrate lyase (ACL) 
to acetyl-CoA and oxaloacetate, thus the butyrate is active as a result of conversation to 
acetyl-CoA. This model also potentially includes glucose-induced signal transduction that 
255 
 
upregulates ACL activity (via phosphorylation of ACL by AKT [313]), which makes it 
susceptible to being regulated by the Warburg effect [160]. If this is the case, then acetate 
may not be functioning as direct HDACi, but may be causing a decrease in expression of the 
same family of genes through other mechanisms.  
 
Wellen et al also showed that post-translational modification of proteins, particularly 
histones, through acetylation requires acetyl-CoA, and inhibition of acetyl-CoA production 
can affect histone acetylation in response to growth-factor stimulation [314]. One example of 
this effect is the sirtuins, a class of NAD+-dependent protein deacetylases, which are 
important regulators of energy metabolism and stress resistance. The decreased expression 
of the histone deacetylase, SirT1, is of note given its established role as an inhibitor of 
apoptosis and promoter for tumourigenesis [315]. However, more work is required to clearly 
define the downstream effectors of epigenetic modification. 
 
Dicholoracetate (DCA), an analogue of acetate, has been shown to have significant anti-
tumour effects [316]. DCA appears to inhibit pyruvate dehydrogenase kinase (PDK), which 
leads to a shift in metabolism from glycolysis to oxidative phosphorylation, thus diminishing 
the ‘Warburg effect’ [316]. This in turn will create a substantial increase in ROS production, 
and subsequent cell death. Clearly the acetate from the LITA-xenograft particles would not 
affect PDK directly but would increase the influx of acetyl-CoA molecules into the 
mitochondria, thus inducing elevated ROS production and apoptosis of cancer cells. 
However, it is important to point out that DCA has not been universally reported to enhance 
apoptosis in tumour cells. Shahrzad et al (2010) showed that DCA had no effect on the 
apoptotic rate in tumours [317]. Interestingly, Babu et al has recently shown that DCA also 
act as an HDAC inhibitor when examined under identical in vitro conditions of 1mM [318]. 
This is an interest parallel to my findings where a decrease in HDAC activity, including SirT1, 
was observed in the HT-29 xenograft model. The lack of change in SirT2 in my model was 
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not surprising as in vitro studies also by Babu showed that after an incubation of acetate and 
DCA a significant decrease was only seen in SirT1 and no change to SirT2 [318]. Future 
work is required to clearly define the downstream effectors of the LITA-xenograft in relation 
to these Sirtuins. 
 
 
Figure 4.12 Mitochondrial responses to dichloroacetate administration  
Dichloroacetate (DCA) inhibits the function of pyruvate dehydrogenase kinase (PDK) in 
mitochondria which in turn releases the inhibition of pyruvate dehydrogenase (PDH). PDH 
catalyses the conversion of pyruvate to acetyl-CoA and consequently causing hypoxia and 
in turn causes lethality to the tumour cell. Figure from Chan & Giaccia, 2011. 
 
Thus, acetate may parallel the DCA mechanism when administered in vivo. This represents 
a diverse molecular abnormality in cancer that has the potential be exploited in future 
treatments. The Warburg Effect does explain the altered metabolism in cancer cells, though 
it does not define the only source or metabolic targeting. Since acetate plays a ubiquitous 
role in metabolism and alterations, a number of cellular pathways could feasibly contribute to 
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the decrease in tumour growth. A theme that is consistent amongst the proposed models of 
mechanism for the LITA-xenograft nanoparticle, with the mitochondria playing a pivotal role. 
In regards to the conflicting literature cited here, the novel approach of acetate delivery via a 
carrier system introduces a number of parameters that have not been examined before; the 
system described here was in vivo, whereas most data referenced was carried out in vitro. In 
addition, acetate delivery was chronically over a time course of weeks, whereas most data 
referenced was one single administration.  
 
Finally, many cellular processes are highly dependent on the availability of metabolites, so 
metabolic reprogramming may have even more of a marked effect in cancer cells [319-321]. 
Cancer cells reprogram their metabolism in order to satisfy their bioenergetic and 
biosynthetic requirements [322-324]. Increased aerobic glycolysis has been linked to 
therapeutic resistance in cancer and the deregulated cancer metabolism promotes cell 
proliferation through increased energy production and metabolite synthesis. It is possible 
that the phenotypic changes observed in these cancer models may have been induced by 
metabolic changes brought about by the influx of excess acetate. The formation of acetyl-
CoA from acetate requires ATP, thus activating AMPK [284]. This acetyl-CoA can then enter 
the TCA cycle modifying the generation of lactate from pyruvate [325] or by utilised for FA 
synthesis. These processes can in turn change the bioenergetics balance of the cell, 
increase ROS production leading accelerated cell death. Additionally, tumour development 
and progression are both accompanied by marked changes in expression and activity of 
pivotal enzymes in lipid metabolism including fatty acid synthesis FAS [326] . FAS catalyses 
do novo synthesis of fatty acids from acetyl-CoA, Malonyl-CoA and NADPH [327]. 
Furthermore, ACC is a determining factor for FAS activity can significantly affect cancer cell 
metabolism. Genetic manipulation of the two isoforms of ACC, ACC1 or ACC2, in cancer 
cells have been shown to yield different outcomes in terms of FAS and β-oxidation [328]. 
Based on this, one would predict that accumulation of acetate in the tumour tissue may 
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affect the functions of these enzymes. Once acetate is converted into acetyl-CoA, and 
depending on its cellular location, will activate ACC1 or ACC2 [329]. However, activation of 
AMPK will inhibit ACC isoforms, which would lead to a decrease in FA synthesis. This is 
clearly a paradox which requires further investigation, regardless, the presence of acetate in 
cancer cell leads to increase cell death and a reduction in tumour size Figure 4.12 gives a 
schematic diagram for a potential mechanism for acetate metabolism within tumour cells. 
 
Figure 4.13 Effect of LITA-xenograft on Cancer Cell Metabolism 
A schematic representation of the metabolic routes interconnected with β-oxidation. The 
LITA-xenograft enters the tumour tissue and is converted to Acetyl-CoA via Acetyl-
Coenzyme A synthase 1 (ACS1). Central metabolism processes are depicted such as 
glycolysis, the TCA cycle, oxidative phosphorylation, and β-oxidation. Acetyl-CoA enters the 
TCA cycle, one effect of that is the production of citrate, which is exported to the cytoplasm. 
Dashed arrows represent indirect effects or serial reactions.   
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4.5 Conclusion  
The combined results from my studies support the hypothesis that chronic administration of 
LITA-xenograft nanoparticles specifically engineered for tumour uptake leads to a reduction 
in tumour growth across three independent studies of colorectal cancer: HT-29, HCT116+/+ 
and HCT116-/-. Much of cancer treatment depends not only on the drug itself, but dosage 
and delivery. This study has aimed to tailor the delivery aspect in order to reach the 
xenograft tumour itself. Literature cited here has carried out research either in vitro or 
achieved SCFA delivery through diet, which would incorporate a system-wide change 
incorporating many different elements of effect on tumour growth. The data presented here 
is the starting point for the potential use of SCFA via liposome delivery for in vivo 
therapeutics. 
 
 
 
 
 
 
 
 
 
 
260 
 
 
 
 
Chapter 5 
Final Discussion 
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5.1 Final conclusions  
The intertwining developmental trajectories of cancer and obesity have a shared origin in 
impaired cellular metabolism, with mitochondrial dysfunction at their core. In order to correct 
the aberrant pathways associated with these conditions I have manufactured and evaluated 
an acetate carrying liposomal-based vector that is preferentially delivered to key sites of 
metabolic control. Dietary supplementation with fibre ameliorates features of the metabolic 
syndrome and inhibits malignant growth in certain cancer types, effects attributed to the 
production of short-chain fatty acids (SCFA), such as acetate. My results presented here 
indicate that nanoparticle encapsulated acetate acts as a multifunctional active 
pharmaceutical ingredient (API), capable of altering the development of pathogenic 
signatures indicative of both obesity and cancer. 
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5.2 Discussion of Methods Used  
Chapter 3 
Mircroarray analysis was used to investigate the profile of how acetate may change the 
metabolic system in a way that would be recognisable to this particular assay. Data analysis 
was done in conjunction of a bioinformatics platform in order to obviate any computer coding 
issues or misinterpretations in results. While the data does not indicate any specific 
mechanism or pathway, it did exploit the difficultly of using wild-type C57/BL6 mice on a HFD 
as a background to this assay. A more sensitive analysis method may be desirable, 
including qPCR. 
 
Chapter 4 
In Chapter 4, assessment of xenograft tumour in vivo was conducted with a two-pronged 
approach: calliper and bioluminescence. The use of bioluminescence was concluded to be 
an unreliable measurement tool in this setting. Xenograft tumour models are well-accepted 
methods; however my study had difficulties correlating the results between the calliper and 
bioluminescence. The reason for this is unclear, but growth pattern of xenograft tumours are 
known to have interrupted blood flow, necrosis, and varying microenvironments. These 
factors make longitudinal studies difficult and require further optimising. Possible 
improvements to the design could include an increased sample size, shorter experimental 
duration and potentially bi-weekly measurements instead of weekly.  
 
While the xenograft tumour model is a widely used and accepted technique, there are many 
limitations to take into consideration. As previously stated, the method used for statistical 
analysis was the two-sample t test using a generalised Wilcoxon test. This selection was 
done with the following challenging problems in mind: 1) the numbers of animals per group 
were quite low, approximately 6, which introduces a wide variability between the animals as 
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far as tumour growth and response to treatment. 2) The loss of data from animal morbidity 
did occur, which causes a drop out in n number. 3) The growth behaviour of the tumour such 
as necrosis and tumours receding internally will impede measurements recorded. 
 
 
5.3 Limitations to studies 
Chapter 3 
A number of interesting results were obtained with acetate encapsulated in liposomal 
nanoparticles. The results could have been enhanced with a prolonged treatment period 
beyond the 5 weeks tested here. The serum data presented here was carried out by an 
external company which had an unfortunate incident of corruption for assays intended for my 
study. This caused a decrease in n numbers, which has a potential affect to statistical power. 
Also, this cause a truncated selection of serum markers intended to be measured. However, 
the results obtained from these studies gave a good insight into the positive effects of 
acetate, the mechanism by which it causes these effects. 
 
Chapter 4 
While the xenograft tumour model is a widely used and accepted technique, there are many 
limitations to take into consideration. The selection of cell type needs to be expanded, as 
well as the rate of tumour growth needs to be controlled. Furthermore, different techniques 
to assess tumour size, activity and viability are required, including MRI and PET. The growth 
behaviour of the tumour is also an important issue, including necrosis and tumours receding 
internally which can impede proper assessment[330]. 
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5.4 future studies 
Here I have shown that LITA can be utilised to re-engineer the metabolism of dysfunctional 
tissues in obesity and cancer. Future work will require validating and expanding on these 
findings, including a larger cohort of animals, cell lines and further in vivo work to unravel the 
underlying mechanism underpinning the effect of LITA, both in obesity and cancer. Future 
work also includes the use of different obesogenic models, including ob/ob and other 
knockouts to have an better insight as to the extent of the LITA effect on the metabolic 
syndrome. In addition, further experiments could include comparisons with control clinically 
used agents such as metformin, which has been shown to reduce plasma glucose levels and 
improve insulin sensitivity through activation of AMPK [288]. 
 
To answer some of the multiple questions arising over the course of this research, I wanted 
to investigate how acetate was affecting cellular metabolism and specifically mitochondrial 
respiration and ATP production. Some preliminary results are shown below. Using HEPG2 
cells (liver hepatocellular carcinoma); I measured the metabolic flux between oxygen 
consumption rate (OCR) and acid efflux (ECAR) through catabolic pathways used to 
generate ATP. Acetate (5mM) was found to increase ATP production (p<0.01) with no 
significant different in spare respiration between the acetate or control group (Figure 5.1). 
Further work is clearly required to assess the metabolism of acetate and its flux through the 
mitochondria and intact cells. 
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Figure 5.1 Mitochondrial calorimetry  
HT-29 cells were treated with acetate (5mM) or without (Control) and assessed for ATP 
production by the Seahorse assay in vitro. (A) ATP production; (B) Spare respiration; (C) 
overall mitochondrial respiration profile; n=4/group; **=p<0.01; data analysed using student 
t-test (GraphPad Prism); OCR: Oxygen consumption rate. 
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Appendix I- Lipid structures 
Lipids used in liposome formulations used in Chapter 2 in attempts to encapsulate acetate: 
(A) DOPE, (B) DLPC C12, (C) DLPC C20, (D) DDAB, (E) DC cholesterol. 
(A) DOPE 
 
(B) DLPC C12 
 
(C) DLPC C20 
 
(D) DDAB 
 
 
(E) DC cholesterol 
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SUMMARY 
 
Dietary supplementation with fibre ameliorates features of the metabolic syndrome and 
inhibits malignant growth in certain cancer types, effects attributed to the production of short-
chain fatty acids (SCFA), such as acetate. However, the ubiquitous role of SCFAs in 
metabolism, combined with a short tissue half-life and the non-targeted nature of oral and 
peripheral administrations limit their therapeutic potential. PEGylated liposomal vectors 
overcome these issues by protecting against degradation, increasing circulation time and 
passively targeting both the liver and tumour tissue. Here, we employ a SCFA encapsulated 
vector in animal models of both obesity and malignancy. Chronic administration of liposome 
encapsulated acetate (LITA) nanoparticles led to a significant reduction in adiposity, 
intrahepatocellular lipid, inflammatory tone and improvements in liver function, as well as an 
inhibition of tumour growth in a murine colorectal cancer xenograft model. These results 
indicate that LITA nanoparticles can be used to improve multiple metabolic pathways, in 
vivo. 
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INTRODUCTION 
 
Impaired cellular energy metabolism is a defining characteristic of cancer and the metabolic 
syndrome. Dysfunctional pathways common to both disorders underpin their co-morbidity 
and represent a potential target for therapeutic intervention at a molecular level. Obesity, 
arising from an imbalance between surplus energy intake and decreased energy 
expenditure, leads to excess triglyceride synthesis and hepatic lipid accumulation (Eriksson 
et al., 1986). The consequences of “fatty liver” are increased mitochondrial fat oxidation 
without compensatory electron transport chain activity, leading to “stressed” mitochondria 
and the production of reactive oxygen species (Begriche et al., 2013). These events are 
thought to play a pivotal role in the subsequent development of inflammation and lipotoxicity, 
creating an aberrant cellular environment which contributes to non-alcoholic steatohepatitis 
(NASH), hepatic fibrosis and cirrhosis (Neuschwander-Tetri, 2010; Park et al., 2010). In turn, 
these disorders are strongly associated with the progression of specific cancers, including 
colorectal cancer and hepatocellular carcinoma (HCC) (Caldwell et al., 2004; Muhidin et al., 
2012).  
 
Supplementation with dietary fibre has been shown to ameliorate features of the metabolic 
syndrome and attenuate malignant growth in certain cancers (Donohoe et al., 2012; Higgins, 
2004). Component carbohydrates are fermented by the microflora of the large intestine, 
producing short-chain fatty acids (SCFA), such as acetate, proprionate and butyrate 
(Higgins, 2004). Acetate plays a central role in cellular metabolism, functioning as a key 
intermediate in the tricarboxylic acid (TCA) cycle and synthesis of fatty acids and cholesterol 
in the liver. Furthermore, oxidation of acetate is the initial step in the TCA cycle, a 
fundamental energy producing pathway in all aerobic organisms. Oxidative phosphorylation 
generates the majority of energy required for cellular function in normal differentiated cells. 
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In contrast, cancer cells rely primarily on aerobic glycolysis; a metabolic shift termed the 
Warburgh effect that comprises attenuation of energy production via mitochondrial beta-
oxidation (Vander Heiden et al., 2009). In malignant cells, the inhibition of glucose uptake 
and metabolism by products of SCFA breakdown is thought to preferentially inhibit aerobic 
glycolysis and supress the uncontrolled cellular proliferation (Roden, 2004; Seyfried and 
Shelton, 2010). 
 
Reductions in fat mass, inflammation and improvements in insulin sensitivity have also been 
attributed to acetate administration in animal studies (Kondo et al., 2009; Vinolo et al., 2011; 
Yamashita et al., 2007; Yamashita et al., 2009). However, current evidence regarding the 
underlying mechanisms is unclear, with exogenous acetate delivery demonstrating 
inconsistent effects on weight gain, mitochondrial function and markers of lipogenic and 
lipolytic activity. This ambiguity may arise from the ubiquitous role acetate plays in cellular 
metabolism, combined with the non-targeted nature of oral and peripheral administration. In 
addition, the adversely low pH of acetate and its rapid clearance from the circulation limit its 
therapeutic potential when administered systemically (Cummings, 1981). The therapeutic 
limitations of SCFA also extend to cancer models, where reductions in tumour growth, 
mediated by butyrate inhibition of histone deacetylase (HDAC) enzymes that control 
transcriptional regulation, are thwarted by a short half-life and first-pass hepatic clearance 
(Steliou et al., 2012).  
 
Liposomal encapsulation of therapeutic agents addresses a number of these issues by 
improving bio-availability, extending treatment effects and reducing dosing (Allison, 2007). 
Liposomes are also preferentially delivered to the liver, an organ central to the control of 
whole body metabolism and a primary target for treatments and therapies aiming to correct 
the metabolic deregulation associated with obesity and the metabolic syndrome (Dardevet et 
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al., 2006). In addition, the enhanced permeability and retention (EPR) effect; comprising 
increased liposomal uptake through leaky tumour microvasculature and prolonged retention 
due to reduced lymphatic drainage, is an efficient means of passively targeting malignant 
tissue (Maruyama, 2011). Here, we hypothesise that preferential delivery of liposome 
encapsulated acetate (LITA) nanoparticles to key sites of metabolic control will provide 
beneficial therapeutic effects in animal models of both obesity and cancer. 
 
RESULTS AND DISCUSSION 
 
Nanoparticle preparation and bio-distribution 
 
Various imaging modalities were employed to confirm the passive, non-targeted delivery of 
our liposomal vector to both the liver and malignant tissue. Liposomal conjugations were 
distinguished by their encapsulated products or moieties introduced into the lipid bilayer 
(Supplementary Figure 1). Short term biodistribution was assessed in C57BL/6 mice 
following intraperitoneal (i.p.) injection with 18F-FDG encapsulated liposomes (LIP-FDG) or 
18F-FDG. Representative PET, CT and PET/CT fusion images from the LIP-FDG group 
acquired 30min post-injection are shown in Figure 1A. Increased liposomal uptake was 
observed in the heart and muscle for the initial 30min post-injection as measured by area 
under the curve (AUC) (Figure 1B). Tissue-specific accumulation of liposomes conjugated 
with rhodamine (LIP-Rhd) was examined using histological techniques; representative 
images from the liver, heart and muscle at 2h post-injection are shown in Figure 1C-G. The 
highest concentrations of LIP-Rhd were observed in the liver and spleen, with lower 
quantities in the kidneys, brain and heart (Supplementary Figure 2). 
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Xenograft uptake of nanoparticles formulated for enhanced delivery to malignant tissue (LIP-
XG) is shown in Figure 1H. Long-term nanoparticle accumulation was assessed by tracking 
biodistribution of liposomes formulated with gadolinium embedded into the lipid membrane 
(LIP-Gd, Supplementary Figure 1) using magnetic resonance imaging (MRI). Following a 
baseline scan, mice received an i.p. injection of either LIP-Gd or control and were scanned 
at 24h and 48h post-injection. T1 signal intensity recorded in the liver, kidney, and 
subcutaneous fat are shown in Figure 1I-K, respectively. Nanoparticles accumulated 
preferentially in the liver, indicated by the significant reduction in T1 signal, at 24h and 48h 
post-injection (Liver T1 24h: LIP-Gd: 495.9 ± 37.4msec, Control: 804.1 ± 81.8msec; p<0.05; 
Liver T1 48h: LITA-Gd: 503 ± 66msec, Control: 738 ± 80msec; p<0.05).  
 
 
Liposomal encapsulated acetate (LITA) formulation and quantification 
 
Following the confirmation of preferential uptake in target tissues, liposomes were prepared, 
encapsulated with either acetate (LITA), or low ionic strength buffer (HEPES) for use as a 
control. 1H-NMR spectroscopy was performed to quantify acetate concentrations and 
assess nanoparticle integrity. LITA formulations and a liposome-free control solution were 
both scanned with and without the addition of albumin, which binds to acetate in free solution 
reducing its NMR signal (Chatham and Forder, 1999). Albumin suppressed the NMR signal 
for acetate in free solution, whereas no reduction was observed in LITA nanoparticle solution 
(Supplementary Figure 3A-D); indicating acetate is successfully encapsulated within the 
liposome. To enable quantification of liposomal acetate, LITA formulations were scanned 
with a known concentration of lactate, for use as an internal standard. Liposomal acetate 
concentration was calculated to be 52.9µg (4.4mM) per 200µl (Supplementary Figure 3E-F) 
and was used in all subsequent studies. The concentration of acetate per LITA injection was 
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2.6mg/kg, an order of magnitude lower than previously used for intragastric or oral delivery 
in murine models (Kondo et al., 2009; Yamashita et al., 2007). There was no difference in 
liposome size (LITA: 102.3 ± 7.5nm; Control: 95.9 ± 9.0nm, p=0.6, Supplementary Figure 
3G-I), indicating uptake would not differ between groups. 
 
 
The in vitro effects of acetate on mitochondrial respiration 
In vitro mitochondrial respiration was assessed to determine if acetate was used as an 
energy source, at a concentration comparable to the dosage used in all subsequent chronic 
injection protocols (4.4mM per 200µl injection). Acetate (5mM) was found to increase ATP 
production (p<0.01) with no significant different in spare respiration between the acetate or 
control group (Supplementary Figure 4).   
 
 
The reparative effects of chronic LITA nanoparticle administration in C57BL/6 mice placed 
on a high fat diet 
The metabolic potential of LITA nanoparticles was assessed in multiple in vivo models, 
examining a wide range of metabolic outcomes. In the first model, an obesogenic 
background was established by placing mice on a high fat diet (HFD) for 5 weeks. Mice 
subsequently received i.p. injection of LITA or control nanoparticles every 3 days for an 
additional 5 weeks, while maintained on a HFD. No differences in body weight (Figure 2A) or 
cumulative food intake (Figure 2B) were observed between groups. Whole body 1H MRS 
and localised 1H liver MRS were performed after the initial 5 weeks of HFD, and again 
following 5 weeks of chronic injection. The change in whole body adiposity (LITA: 9.0 ± 
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16.7%; Control: 40 ± 21.8%, p=0.02) (Figure 2C) and IHCL (LITA: -0.11 ± 0.06, Control: 2.4 
± 0.9, p<0.0001) (Figure 1D) were significantly reduced in LITA injected animals. White 
adipose tissue (WAT) was also reduced (LITA: 3.4 ± 1.2g, Control: 4.3 ± 1.2g, p<0.01) 
(Supplementary Figure 5A). No changes were observed in circulating levels of glucose, 
insulin or lipids (Figure 2E). However, LITA injected animals did demonstrate a reduction in 
serum levels of the chemokine KC/GRO (p<0.05), signifying reduced inflammatory tone 
(Stefanovic et al., 2005), and increased levels of IL-10 (p<0.05) (Figure 2F), a marker for the 
inhibition of pro-inflammatory cytokine production (Esposito et al., 2003). Quantitative RT-
PCR of liver mRNA also revealed a significant reduction in the expression of UCP-2 in LITA 
injected animals (Figure 2G). 
 
RT-PCR analysis demonstrated a LITA-induced reduction in HDAC1 expression (p<0.001) 
(Figure 2G), while western blot analysis of liver samples showed a significant differences in 
HDAC2 (p<0.01) and HDAC7 (p<0.001) in LITA injected animals (Figure 2H). Normalisation 
of histone lysine proteins to total histone protein expression revealed a reduction in residue 
acH4K12 in LITA compared to control samples (Figure 2I). Microarray analysis also 
confirmed significant changes in the expression of metabolic related genes of interest, 
including the HDAC class 1 (Supplementary Figure 5B).  
 
 
The preventative effects of chronic LITA nanoparticle administration in C57BL/6 mice placed 
on a high fat diet 
In the second dietary model, we assessed the potential of LITA nanoparticles to prevent the 
development of outcomes associated with an obesogenic diet. C57BL/6 mice placed on a 
HFD received i.p. injections of LITA or control nanoparticles every 3 days for 6 weeks. No 
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differences were observed in body weight (Figure 3A) or weekly food intake (Supplementary 
Figure 6A). However, in accord with the previous model, chronic LITA injection was found to 
significantly reduce the change in both whole body adiposity (LITA: 24.1 ± 9.7%; Control: 
30.8 ± 9.7%, p=0.03) (Figure 3B) and IHCL (LITA: -0.01 ± 0.7, Control: 0.03 ± 0.05, p=0.05) 
(Figure 3C). LITA injection resulted in reduced fed serum levels of insulin (LITA: 0.6 ± 
0.3ng/ml, Control: 1.1 ± 0.7ng/ml, p<0.05), while fasting glucose levels were elevated (LITA: 
8.6 ± 1.8mmol/L, Control: 7.4 ± 1.5mmol/L, p=0.02) (Figure 3D). A non-significant trend 
towards reduced glucose clearance was seen in LITA-injected mice following a glucose 
tolerance test (GTT) (Supplementary Figure 6B). No differences in insulin sensitivity were 
recorded when assessed using the homeostatic model assessment (HOMA) index (LITA: 6.1 
± 2.5, Control: 6.7 ± 2.3, p=NS). 
 
Additional serum analysis revealed a non-significant trend toward reduced levels of 
inflammatory markers in LITA-injected animals (TNF-α: LITA: 5.4 ± 3.4pg/ml, Control: 10.6 ± 
8.5pg/ml, p=0.06; IL-6: LITA: 17.4 ± 17.6pg/ml, Control: 39.7 ± 35.5pg/ml, p=0.06), with no 
differences in leptin, ghrelin or adiponectin (Supplementary Figure 6C). There were no 
differences in serum lipid concentrations (Figure 3E), despite LITA-injected mice presenting 
reduced subcutaneous adipose tissue (SAT) mRNA expression of adipose triglyceride lipase 
(ATGL) (p<0.01) (Figure 3F), suggestive of a reduced mobilisation of peripheral lipids 
(Zechner et al., 2012). No differences in the weight of individual fat depots or mean 
adipocyte number and size were recorded between groups (data not shown). However, 
there was a notable decrease in serum free fatty acids (FFA) in LITA-injected animals (LITA: 
0.36 ± 0.08nmol/L, Control: 0.75 ± 0.2nmol/L, p<0.05), while serum concentrations of the 
ketone, 3-hydroxybutyrate, were increased (LITA: 0.29 ± 0.1nmol/L, Control: 0.18 ± 
0.03nmol/L, p<0.05) (Figure 3E). 
 
306 
 
Hepatic function was assessed via standard liver function tests and quantitative RT-PCR of 
mRNA. A decrease in serum levels of the liver function markers AST and ALP was observed 
in LITA-injected animals (AST: LITA: 106 ± 26U/L, Control: 201 ± 87U/L, p=0.02 and ALP: 
LITA: 57.5 ± 14U/L, Control: 76.9 ± 20U/L, p=0.02) (Supplementary Figure 6D). Chronic 
LITA injection also led to a significant reduction in mRNA expression of genes involved in 
fatty acid synthesis (FAS); including sterol regulatory element-binding protein-1 (SREBP1), 
acetyl coenzyme-A carboxylase (ACC) and fatty acid synthase gene (FASN) (Figure 3G). 
LITA administration also led to a significant reduction in mRNA expression of genes 
responsible for both β-oxidation; carnitine palmitoyltransferase-1 (CPT1), acyl coenzyme-A 
oxidase-1 (ACOX1), and VLDL synthesis; microsomal triglyceride transfer protein (Mttp) 
(Figure 3G). In accord with the previous HFD model, LITA-injected mice demonstrated 
reduced levels of UCP-2 (Figure 3G). Furthermore, LITA treated mice demonstrated reduced 
microvacuolation in the liver compared control treated mice (Figure 3H). Transmission 
electron microscopy analysis of hepatic mitochondrial morphology revealed no difference in 
mitochondrial number and a trend towards increased cristae / perimeter length in LITA-
injected mice (p=0.07, Supplementary Figure 7D). No differences in oxidative 
phosphorylation complex I, III or V activity were observed between LITA and control animals 
(Supplementary Figure 7E). Chronic LITA injection led to a reduction in hepatic expression in 
forkhead box protein O1 (FOXO1) mRNA (Figure 3G), indicative of reduced 
gluconeogenesis (Gross et al., 2008). Furthermore, a reduction in hepatic uptake of glucose 
was also observed following LITA administration, as revealed by a reduction in glucose 
transporter 2 (GLUT2) mRNA (Figure 3G), and the increased fasting levels of glucose 
(Figure 3D), without a concomitant difference in food intake.  
 
 
307 
 
The preventative effects of chronic LITA nanoparticle administration in C57BL/6 mice placed 
on a normal fat diet 
The next model assessed the effects of LITA delivery on a normal dietary background. Mice 
placed on a normal fat diet (NFD) received i.p. injections of LITA or control nanoparticles 
every 3 days for 6 weeks. There were no differences in body weight change (Figure 4A) or 
weekly food intake (Supplementary Figure 8A). Unlike previous HFD models, no difference 
was observed in whole body adiposity (LITA: 3.9 ± 4.4%, Control: 6.6 ± 9.1%, p=NS) (Figure 
4B). However, a significant reduction in IHCL was again seen in LITA injected mice (LITA: -
0.01 ± 0.08, Control: 0.05 ± 0.05, p<0.05) (Figure 4C). No differences were recorded 
regarding fed or fasted levels of insulin or glucose (Figure 4D), or following a GTT performed 
after 5 weeks of chronic injection (Supplementary Figure 8B). However, a significant 
reduction in the HOMA-IR index was recorded in LITA injected animals, suggesting 
improved insulin sensitivity (LITA: 1.9 ± 1.4; Control: 3.6 ± 1.5, p=0.03). 
 
Serum inflammatory markers resistin and TNF-α were significantly reduced in mice that 
received LITA injection (Resistin: LITA: 13.6 ± 1.8ng/ml, Control: 17.2 ± 4.8ng/ml, p<0.05; 
TNF-α: LITA: 14.8 ± 8.5pg/ml, Control: 46.9 ± 33.1pg/ml, p<0.01). Serum levels of 
triglycerides (LITA: 0.79 ± 0.09mmol/L, Control: 1.03 ± 0.22mmol/L, p=0.05) (Figure 4E) and 
leptin (LITA: 1921 ± 935pg/ml, Control: 2889 ± 1209pg/ml, p<0.001) (Supplementary Figure 
8C) were also significantly decreased in LITA injected animals, with no differences were 
observed in cholesterol, HDL or LDL (Figure 4E). Total white fat (TWF) and mesenteric 
adipose tissue were significantly reduced following LITA administration (TWF: LITA: 1.36 ± 
0.24g, Control: 1.5 ± 0.17g, p<0.05; mesenteric: LITA: 0.16 ± 0.04g, Control: 0.19 ± 0.01g, 
p<0.05) (Supplementary Figure 8D). Isolated adipocytes from epididymal and subcutaneous 
depots revealed no differences in mean number, volume or surface area between groups 
(data not shown). However, AT isolated from LITA-injected animals demonstrated reduced 
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expression of hormone sensitive lipase (HSL) mRNA (Fold change in compared to control: 
0.05 ± 0.08, p<0.001) (Figure 4F), reflecting a reduced mobilisation of peripheral lipids 
(Zechner et al., 2012). 
 
Similar to the results of the preventative HFD model, quantitative RT-PCR of liver mRNA 
samples revealed a LITA-induced reduction in expression of genes involved in VLDL 
metabolism (Apo-B, Mttp), β- oxidation (ACOX-1, CPT-1), mitochondrial oxidation (PPARγ, 
PGC-1), glucose metabolism (GLUT-2, IRS-1, IRS-2) and inflammation (TNFα) (Figure 4G). 
Histological examination revealed normal liver architecture for all mice on a NFD, with LITA 
injected mice revealing less microvacuolation compared controls (Figure 4H), indicative of 
reduced inflammation. Similar to the previous HFD model, no differences in mitochondrial 
oxidative phosphorylation complex activity were seen between groups (Supplementary 
Figure 7F).  
 
The respiratory effects of LITA nanoparticles in mice as measured by metabolic cages  
Following a week of daily day administration of LITA or control injections, mice were 
monitored over a period of 48 hours in CLAMS metabolic cages. No differences were seen 
in food intake or cumulative food intake between groups (data not shown). While the 
expected diurnal variations in ambulatory activity, VCO2, VO2 and RER were observed, no 
significant differences between LITA and control injected animals were recorded in any of 
these parameters (Supplementary Figure 9).  
 
The metabolic effects of LITA nanoparticle administration on xenograft tumour metastasis 
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The administration of LITA-XG nanoparticles led to a significant reduction in tumour size 
(LITA: 107 ± 113mm2, Control: 270 ± 87mm2, p=0.04) and tumour weight (0.05 ± 0.03mg, 
Control: 0.33 ± 0.04mg, p=0.003) compared to controls (Figure 5A-C). Progression of 
tumour volume was significantly reduced in LITA-XG injected animals (Tumour volume 
(week 4): LITA: 123 ± 119mm3, Control: 254 ± 93 mm3, p<0.05) (Figure 5D). Quantitative 
RT-PCR of xenograft mRNA revealed a significant decrease in expression of Class I 
HDACs; HDAC 1 (p<0.05), HDAC 2 (p<0.05), HDAC 3 (p<0.001) and HDAC 4 (p<0.01) in 
LITA-XG injected animals (Figure 5E). In addition, the expression of “silent mating type 
information regulation homologues” or SirT proteins, responsible for epigenetic silencing 
mRNA, was also significantly reduced in LITA-XG injected animals (SirT1, p<0.05) (Figure 
5E). 
 
Discussion 
The intertwining developmental trajectories of cancer and obesity have a shared origin in 
impaired cellular metabolism, with mitochondrial dysfunction at their core. In order to correct 
the aberrant pathways associated with these conditions we have manufactured and 
evaluated an acetate carrying liposomal-based vector that is preferentially delivered to key 
sites of metabolic control. Our results indicate that nanoparticle encapsulated acetate acts 
as a potent multifunctional active pharmaceutical ingredient (API), capable of preventing and 
reversing the development of pathogenic signatures indicative of both obesity and cancer. 
Assessment of the bio-distribution of FDG, rhodamine and gadolinium conjugated liposomes 
using histological and imaging techniques confirmed that LITA nanoparticles are naturally 
liver tropic. In accordance with our previous work (Kenny et al., 2011), the increased molarity 
percentage of DSPE-PEG2000 in the liposome membrane led to a preferential accumulation 
of liposomes in tumour tissue. 
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In all dietary models examined chronic LITA administration significantly reduced IHCL, and 
reduced whole body adiposity and white adipose tissue in both reparative and preventative 
HFD paradigms. These changes occurred independently of the potentially confounding 
effects of a reduced food intake or body weight. Importantly, more than merely slowing 
accumulation, LITA delivery actively reduced IHCL. Hepatic lipid accumulation represents a 
key intermediary in a succession of increasingly debilitating liver conditions and is strongly 
associated with the development of insulin resistance and diabetes (Powell et al., 1990; Sun 
and Karin, 2012). The LITA-induced reduction in IHCL suggests our nanoparticle is not only 
capable of preventing NAFLD, but may also modulate subsequent progression to HCC.  
 
Consistent with previous studies showing a fall in plasma lipids following chronic acetate 
administration (Kondo et al., 2009; Yamashita et al., 2007), LITA injection was found to 
reduce circulating levels of FFA and triglycerides, in HFD and NFD models respectively. 
Data indicating LITA administration decreases the expression of proteins involved in 
peripheral mobilisation of lipids, hepatic lipogenesis and lipid uptake, provide a prospective 
mechanism for the robust reduction in IHCL. In addition to the reductions in body fat and 
IHCL, further investigation of liver function revealed a number of additional beneficial effects 
following LITA delivery. The reduction in UCP-2 expression, observed in both HFD and NFD 
models, reflects reduced proton leakage across the mitochondrial membrane, less disruption 
in electrochemical potential and increased organelle efficiency (Chavin et al., 1999). 
Furthermore, the LITA-induced reduction in serum levels of AST and ALP, and the trend 
toward an increase in the number of cristae per perimeter length are also indicative of 
improved function (Wu et al., 2011). 
 
In accord with previous studies demonstrating a reduction in inflammatory markers following 
acetate administration (Reisenauer et al., 2011; Vinolo et al., 2011), LITA delivery led to the 
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reduced expression of TNF-α in liver in both NFD and HFD models, with a trend towards 
lower serum concentrations of TNF-α, IL-6 and resistin. Furthermore, were LITA 
administration to continue, the reductions in fat mass and IHCL observed in all dietary 
paradigms would be expected to contribute to an additional long-term improvement in 
inflammatory tone (Eckel et al., 2005). It should be noted that the range of effects following 
LITA administration were not consistent across all dietary models, with reductions in fatty 
acid synthesis, circulating FFA, insulin and serum markers of inflammation and liver function, 
limited to HFD paradigms. Under normal dietary conditions an increase in hepatic acetate is 
associated with the up-regulation of fatty acid oxidation that occurs during prolonged fasting 
(Seufert et al., 1974). It is conceivable that compensatory homeostatic mechanisms 
interpreting the elevated level of hepatic acetate as a starvation signal led to the muted 
metabolic response to LITA administration on a NFD background; a hypothesis supported by 
trend towards increased food intake and bodyweight seen in the LITA-injected animals on a 
NFD.  
Acetate supplementation leads to an increase in the production of acetyl Co-A in the liver, 
(Reisenauer et al., 2011), which following mitochondrial uptake, can enter either the TCA 
cycle, increasing ATP production as we observe in in vitro cultured cell analysis, or enter 
ketogenic pathways, as seen in the preventative HFD model. As ketogenesis occurs 
exclusively in liver mitochondrion, the LITA-induced increase in serum concentrations of the 
ketone body, hydroxybutyrate, is an important finding, indirectly confirming in vivo delivery of 
acetate to hepatic mitochondria. Given the apparent absence of expression of the 
mitochondrial form of acetyl-CoA synthetase (AceCS2) in the liver (Fujino et al., 2001), we 
predict that acetate from LITA nanoparticles is converted to acetyl-CoA by the cytosolic form 
of the enzyme (AceCS1), which subsequently enters the mitochondria. Previous studies 
have reported that systemic acetate delivery leads to an increase in hepatic fatty acid β-
oxidation (Kondo et al., 2009; Yamashita et al., 2009). However, our data indicates the 
reverse, with chronic LITA injection reducing expression of genes controlling β-oxidative 
312 
 
pathways in both NFD and HFD models. The manner and rate of acetate metabolism may 
account for these differences, with the comparatively stable and predominantly hepatic 
delivery afforded by liposomal nanoparticles, contrasting with the more immediate, global 
uptake following bolus injection or oral gavage (Henriksen-Lacey et al., 2011).  
 
Together, our results support a mechanism by which the LITA-induced mitochondrial 
accumulation of acetyl-CoA, the end-product of SCFA catabolism, inhibits β-oxidation and 
subsequently reduce lipid uptake, lipogenesis and hepatic uptake (Supplementary Figure 
10). Furthermore, the changes we observe are consistent with the Randle hypothesis; 
whereby the availability of acetate as a fuel source generates metabolic signals that impair 
the use of glucose through inhibition of glycolytic and gluconeogenic pathways (Hue and 
Taegtmeyer, 2009). A shift away from carbohydrate metabolism might be expected to result 
in altered respiratory outcomes in LITA-injected animals yet we observed no differences 
following metabolic cage analysis. However, these results are in accord with several papers 
that demonstrate energy expenditure is maintained following acetate infusion, as acetate 
replaces fat as an oxidative fuel (Akanji et al., 1989; Smith et al., 2007). 
 
The anti-tumorigenic effects attributed to SCFAs have been linked to changes in expression 
of HDAC enzymes, important epigenetic markers that play a key role in cellular gene 
expression (Soliman et al., 2012; Steliou et al., 2012). The ineffectual metabolism of SCFA 
in cancer cells is thought to lead to the accumulation of acetyl-CoA in the nucleus, where it 
functions as an HDAC inhibitor altering the expression of genes involved in cellular 
proliferation, apoptosis, and differentiation (Waldecker et al., 2008). Previous studies have 
attempted to target and disrupt the altered cellular metabolism in colonic cancer cells via 
supplementation with the SCFA, butyrate (Donohoe et al., 2012; Hamer et al., 2008). Our 
results support this hypothesis; chronic administration of LITA nanoparticles led to a 
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significant reduction in tumour growth and decreased mRNA expression in several classes 
of HDACs. We predict LITA supplementation induces a switch in fuel selection, from aerobic 
glycolysis to mitochondrial beta-oxidation, representing a metabolic reprogramming of 
cancer cells towards a normal, non-proliferative state. The decreased expression of the 
histone deacetylase, SirT1, is of note given its established role as an inhibitor of apoptosis 
and promoter for tumorigenesis (Qu et al., 2012). However, more work is required to clearly 
define the downstream effectors of epigenetic modification. Indeed, recent data indicates 
SCFA are also able to upregulate specific classes of histone acetylase (HAT) proteins, 
representing an additional cascade of regulatory elements (Donohoe et al., 2012). The 
inconsistencies we see in LITA effects on HDAC expression between xenograft and 
reparative HFD models serves to highlight that the metabolic state of the cell further 
influences how exogenous signals are interpreted. 
 
Overall, LITA administration resulted in a comprehensive improvement in metabolic profile in 
animal models of both obesity and cancer; including reductions in tumour growth and 
amelioration of a wide range of metabolic syndrome associated outcomes, including 
reductions in IHCL, body fat, serum insulin, FFA and inflammatory tone. More work will be 
required to fully elucidate the numerous, interconnected metabolic pathways underpinning 
these effects. However, these results present LITA nanoparticles as a novel approach for the 
positive modulation of both obesity and malignant transformation in vivo. 
 
Material and methods 
Materials and experimental animals 
All in vivo experiments were carried out in compliance with the Animals (Scientific 
Procedure) Act 1986. Mice were supplied by Harlan, UK. Mice were housed 4 per cage, in a 
temperature controlled room at approximately 25°C with alternating 12h periods of light and 
314 
 
dark (light: 8:00-20:00) in filter-topped cages with ad libitum access to water. Normal fat diet 
(NFD) was the RM3 diet supplied by Special Diet Services (Essex, UK). 60% of the caloric 
content of the HFD was fat (EF D12402; Special Diet Services). 
 
Preparation of liposome nanoparticles 
Nanoparticle design was based upon our previous studies, where PEGylated liposomes 
were formulated for labelling and visualization of cells (Oliver et al., 2006), or specifically 
designed for preferential uptake in xenograft tumours (Kenny et al., 2011). Liposomes were 
prepared by the thin film hydration method (Bhalerao and Raje Harshal, 2003). Design 
principles and molar components are shown in Supplementary Figure 1. 
 
Bio-distribution of liposome nanoparticles 
Nanoparticles were formulated and encapsulated with 160mBq fluorodeoxyglucose 
[18F]FDG. Nanoparticles (200µl) containing encapsulated [18F]FDG (10MBq) were injected 
intraperitoneally (i.p.) into C57/BL6 black mice (n=4/group). Images were acquired and 
analysed using IRW (Siemens Medical solutions). The intensity of [18F]FDG uptake was 
quantified for organ specific regions-of-interest (ROI) for 30min following injection. Area 
under the curve (AUC) data for each ROI was calculated. 
 
Formulation of LITA nanoparticles 
Liposomes were prepared with either acetate (1M, pH 2.3) to form liposome encapsulated 
acetate (LITA) nanoparticles or HEPES for use as a control. Particle size was determined 
using a Malvern Zetasizer (Malvern Instruments, UK). 
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Quantification of acetate encapsulated within LITA nanoparticles 
The presence and concentration of acetate within liposomes was determined using 1H NMR 
spectroscopy. 200µl of LITA formulation was scanned with addition of albumin, which binds 
to acetate in free solution reducing the NMR signal for the compound (Chatham and Forder, 
1999). A liposome free control solution containing an equivalent concentration of acetate 
(4mM) was also scanned with and without the addition of albumin (2g). LITA solution was 
scanned following the addition of lactate (5.2mg sodium lactate) to act as a quantitative 
control. Spectra were obtained using a Bruker DRX 11.74T NMR spectrometer. Spectra 
were analysed using MestRe-C NMR spectroscopy software (Santiago de Compostela, 
Spain). 
 
Ex vivo histology of nanoparticle distribution 
C57BL/6 mice were injected i.p. with 200µL of LITA-Rhd (n=12). Animals were euthanized at 
2, 16, 24 and 48h post administration (n=3/time point). Tissue samples were collected and 
frozen at -80°C and sliced (7µm) using a cryostat (Leica, Milton Keynes, UK) then stained 
with DAPI. Images were obtained using an Olympus IX71 microscope (Olympus, U.S.A). 
 
Long-term nanoparticle bio-distribution as measured by contrast-enhanced MRI 
Mice were anesthetized with 2-3% isofluorane 1/min oxygen and placed in a birdcage coil. A 
fast-spin echo sequence was performed. A fast-spin echo sequence (TR 8500 msec, TEeff 
20msec, ETL 8, k zero at 2, FOV 50 x 50 mm, matrix 256 x 256, one average, 40 slices of 2 
mm thickness) was performed at various TI values. After the baseline scan, animals 
received an i.p. injection of either LITA or LITA-Gd solution (n=4/group) and were scanned 
again at 2, 16, 24 and 48h post-injection. Signal intensity was measured in each ROI using 
ImageJ software. 
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The in vitro effects of acetate on mitochondrial metabolism 
HT-29 cells were obtained from the American Tissue Culture Collection (Rockville, USA). 
Cells were maintained in standard culture conditions at 37°C in a humidified atmosphere 
containing 5% CO2. The metabolic profile of HT-29 cells was determined using a Seahorse 
XF24 Extracellular Flux Analyser (Seahorse Biosciences, Billerica, MA). Cells were treated 
with a concentration of acetate (5mM) comparable to the amount delivered per injection in 
our LITA nanoparticle. 
 
The reparative effects of chronic LITA nanoparticle administration in C57BL/6 mice placed 
on a high fat diet 
After 5 weeks on a high fat diet (HFD) C56BL/6 mice (n=16) received an i.p. injection (200µl) 
of either LITA (n=8) or control (n=8) every 3 days, for an additional 5 weeks while maintained 
on a HFD. Food intake and body weight were measured weekly. Whole body 1H MRS and 
localised liver 1H MRS were performed after the initial 5 weeks of HFD and at the end of 
study. Following scanning organs and serum were collected and stored at -80°C. 
 
The preventative effects of chronic LITA nanoparticle administration in C57BL/6 mice placed 
on a HFD or NFD 
C57BL/6 mice were placed on either a HFD (n=48) or NFD (n=48) for 6 weeks. Within each 
dietary group mice received an i.p. injection of either LITA nanoparticles (n=24) or control 
(HEPES) (n=24) three times per week. Whole body 1H MRS and liver 1H MRS were 
performed prior to dietary intervention and after 4 weeks of the study. At the start of week 5, 
a fasted GTT was performed, (n=10-12/group). After week 6 animals were euthanized; blood 
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samples and organs, including the liver, epididymal, mesenteric and subcutaneous fat 
depots were collected and stored at -80°C. The homeostatic model assessment method was 
used to quantify insulin resistance (HOMA-IR) (Matthews et al., 1985).  
 
Serum analysis  
Serum samples were analysed for a panel of clinical biomarkers; ghrelin, total GLP-1 and 
adiponectin were measured using 2-site electrochemical luminescence immunoassays from 
MesoScale Discovery (Gaithersburg, USA). FFA: using the Non-Esterified Free Fatty Acid kit 
(Roche). 3-OH butyrate was measured using a Liquicolour Beta Hydroxybutyrate kit 
(Stanbio, USA). Creatinine, ALT, AST, alkaline phosphate, triglyceride, high density 
lipoprotein (HDL) and cholesterol were measured on the Dimension RXL autoanalyser 
(Siemens Healthcare). Low density lipoprotein (LDL) was calculated using the Friedwald 
formula. C-Peptide, Ghrelin, GIP, interleukin-6 (IL-6), glucagon, insulin, leptin, MCP-1, 
Tumour necrosis factor- α (TNF-α) and resistin were measured by Mouse Metabolic 
Magnetic Bead Panel (Millipore, UK). Additional markers of inflammation (IL-1, IL-2, IL-4, IL-
5, IL-10, KC/GRO, IFN-γ) were measured with Mouse ELISA kit (Abcam, USA). Fasting 
levels of insulin were measured by using Ultrasentive Mouse Insulin Elisa (Mercodia AB, 
Sweden). 
 
Whole body lipid and intrahepatocellular lipid 
Animals were fasted overnight for 16-18h prior to scanning on a 4.7T Unity Inova MR 
scanner (Varian Inc, USA). Whole body 1H MRS was carried out using the SPULS 
sequence (TR 10s, Pulse angle 45°, 4 averages and spectral width (SW) 20,000Hz). 
Localised 1H liver MRS was performed using a PRESS sequence with a 2x2x2mm voxel 
placed using liver MRI (TR 10s, TE 9ms, averages 64 and SW 20,000Hz) (So et al., 2007). 
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Adipocyte Isolation and Counting 
Adipocyte number and size were measured in epididymal and subcutaneous fat depots of 
LITA and control animals (n=8-10/group) from Experiment 3B and Experiment 3C as in 
(Frost et al., 1996). The adipocytes sized using a Multisizer™ 4 Coulter Counter (Beckman 
Coulter, USA). 
 
Hepatic histology, immunohistochemistry, and immunofluorescence 
Liver tissue was fixed in 10% formalin or embedded in Tissue-Tek OCT compound for frozen 
block preparation. Paraffin-embedded liver tissue was stained with haemotoxylin and eosin 
(H&E), TUNEL (Roche), and bromodeoxyuridine (Marik et al., 2007). TUNEL and BrdU-
positive cells were quantified using Image tool. Frozen tissue sections were stained with oil-
red O (ORO) for lipid detection (Oliver et al., 2006). 
 
Electron microscopy of the liver mitochondrial 
Liver slices were prepared using a cryostat (70-90nm) and stained. Sections were examined 
on a FEI Tecnai 12 transmission microscope operated at 120 kV. Images were acquired with 
an AMT 16000M digital camera. For each 36 random and different images with magnification 
1400x were acquired where the number of mitochondria was counted per image. Images 
were also obtained with magnification 4800x (12/liver) with the perimeter of cross-sectional 
view of mitochondria and number of cristae in the mitochondria recorded. 
 
Hepatic expression of oxidative phosphorylation complexes I, III and V 
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Mitochondrial oxidative phosphorylation was investigated by using Rat/Mouse Oxidative 
Phosphorylation Magnetic Bead Panel (Millipore, USA), according to manufacturer’s 
instructions using 20ug of total liver protein. 
 
Hepatic and adipose tissue mRNA expression assessed via quantitative RT-PCR and 
microarray 
Total mRNA was isolated from mouse liver using RNeasy (Qiagen, USA) following the 
manufacturer’s instructions. Mouse Gene 1.0ST microarrays were performed on mRNA 
isolated from LITA (n=5) and control (n=5) animals and analysed using linear model for 
microarray (LIMMA) (Smyth et al., 2005). Total mRNA was isolated from subcutaneous and 
mesenteric fat depots of animals from HFD models using RNeasy Lipid Tissue Mini Kit 
(Qiagen, USA). RT reactions for all tissues were performed using a SuperScript II RT Kit 
(Invitrogen) and used in both RT-PCR and microarray analysis. Quantitative PCR reactions 
were performed using Assays-on-Demand FAM-MGB primer/probe sets Taqman Universal 
PCR Master Mix (Applied Biosystems, USA) (n=6-8 per group).  
 
Hepatic histone deacetylase expression 
Western blotting was performed on liver samples from LITA and control animals from the 
preventative HFD (n=8/group) to examine the expression of HDAC proteins in classes I, II 
and IV. Raw signals for each protein target of interest were quantified and background 
subtracted using the Li-COR Odyssey software and normalised to β-actin. Quantification of 
protein expression was performed using ImageJ software (NIH, Bethesda, MA). 
 
The respiratory effects of LITA nanoparticles in mice as measured by metabolic cages  
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C57BL/6 mice were injected daily with either the control or LITA nanoparticles (n=8/group) 
for seven days and placed individually into the Comprehensive laboratory animal monitoring 
systems (CLAMS) cages (Columbus Instruments, USA) for 48 hours. Parameter data 
recorded and analysed as in (Semjonous et al., 2009). 
 
The metabolic effects of LITA nanoparticle administration on xenograft tumour metastasis 
Tumourigenicity was initiated by injecting 2.5x105 colon cancer cell line of HT-29, 
subcutaneously into the left flank of 6-8 week-old nude mice (BALB/C nu/nu). For staining 
LITA-Rhd was injected (i.p.) and animals euthanized at 2 hours post administration 
(n=3/group). For chronic analysis, i.p. injections of LITA or Control nanoparticles were given 
every three days for 4 weeks (n=6/group). Tumour volume was monitored every 2-4d by 
calliper to determine the volume estimated assuming an ellipsoid shape using the following 
equation: V= L x W x D x π/6. After 4 weeks animals were euthanized with tumour tissue 
isolated and stored at -80°C for subsequent extraction of mRNA as previously described 
above. 
 
Statistical Analysis 
All statistical analyses were performed using GraphPad Prism (San Diego, CA), unless 
otherwise noted. Data are presented as means ± standard deviation (SD). Statistical 
significance was calculated with Student’s t test, two-way ANOVA with Bonferroni post-hoc 
test for multiple comparisons and generalised estimating equation (GEE) analysis where 
appropriate. Metabolic cage data was analysed by the Mann-Whitney U test and presented 
as mean ± sem. Significance was accepted at the level of * = p<0.05, ** = p< 0.01, *** = 
p<0.001. 
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Supplementary Figure 1 – LITA nanoparticle design principles and percentage molar 
component of formulations. (1) LIP: Standard liposome conjugation used for the 
encapsulation of 18F-FDG, acetate and HEPES; (2) LIP-XG: Liposomes conjugated with a 
higher DSPE PEG2000 percentage to increase tumour uptake in animal models of 
malignancy; (3) LIP-Rhd: Liposomes contained 1% of rhodamine (Rhd), a fluorescent lipid 
used for histological analysis; (4) LIP-XG-Rhd: LIP-XG contained an additional 1% of 
rhodamine for histological analysis. (5) LIP-Gd: Liposomes conjugated with gadolinium (Gd) 
for use in MRI bio-distribution analysis; LIP: Liposome; LITA: Liposome encapsulated 
acetate; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; CDAN: N1-
cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine; DSPE PEG2000: 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-methoxy (polyethylene glycol)-2000; DOTA: gadoterate 
meglumine; DOPE - Rhodamine:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- 
(lissamine rhodamine B sulfonyl); DSA: digital subtraction angiography. 
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Figure 1 Bio-distribution of liposomal conjugations. (A) Representative PET, CT and 
PET/CT fusion images at 2h post injection in C57BL/6 mice injected with LIP-FDG 
nanoparticles (10 MBq of encapsulated 18F-FDG) (B) Area under the curve (AUC) data 
recorded from regions of interest (ROI) at 30min post-injection of 18F-FDG (Control) or LIP-
FDG (n=4/group). (C-G) are representative histological images from C57BL/6 mice, 
collected 2h post i.p. injection of LIP-Rhd; (C) Liver, (D) Heart, (E) Muscle, (F) Spleen and 
(G) Lung. (H) Representative histological image of xenograft tumour collected 2h post i.p. 
injection of LIP-XG-Rhd. (I-K) are T1 values recorded at 0, 24 and 48 hours in ROI post i.p. 
injection of LITA-Gd or LITA (Control) nanoparticles (n=4/group); (I) Liver, (J) Kidney and (K) 
Subcutaneous fat. Results are displayed as mean ± SD. Data analysed by student’s t-test; * 
= p<0.05, *** =p<0.001.  
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Supplementary Figure 2 - Bio-distribution of rhodamine conjugated LIP nanoparticles. 
Mice were injected i.p. with 200µl of LIP-Rhd nanoparticle solution. Organs were collected 
and stained for rhodamine at 2, 16, 24 and 48h post injection (n=3/time point); indicates the 
presence (ü) or absence (-) of rhodamine at these time points. 
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Supplementary Figure 3 – Acetate encapsulation and quantification. 1H NMR spectra 
from 4.5ppm to -0.5ppm of (A) 4mM acetate solution, (B) 4mM acetate solution with 
albumin, (C) LITA solution with albumin (2g); (D) LITA solution with albumin (4g). 
Trimethylsilyl propionate (TSP) provides a reference at 0ppm. The peak for acetate is 
normally observed at 2.03ppm. The NMR spectra of LITA nanoparticles without lactate (E) 
and with lactate (5.2mg sodium lactate) (F) are shown. The size of liposome preparations 
was measured using a Zetasizer Nano (Malvern, UK), (G) and (H) show the size distribution 
of control (containing HEPES) and LITA (liposome encapsulated acetate) respectively, (I) 
average size of control and LITA liposomes.  
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Supplementary Figure 4 - Mitochondrial calorimetry HT-29 cells were treated with 
acetate (5mM) or without (Control) and assessed for ATP production by the Seahorse assay 
in vitro. (A) ATP production; (B) Spare respiration; n=4/group; **=p<0.01; data analysed 
using student t-test (GraphPad Prism); OCR: Oxygen consumption rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
331 
 
 
Figure 2 - The reparative effects of LITA nanoparticles in mice placed on a HFD diet. 
After 5 weeks placed on a high fat diet (HFD) mice were injected every three days with either 
liposome encapsulated acetate (LITA) nanoparticles or control (HEPES) for an additional 5 
weeks. (A) Change in body weight (g); (B) Cumulative food intake (g/week); (C) Whole body 
adiposity (%); (D) IHCL; (E) Plasma lipids and additional circulating peptides (glucose 
(mmol/L), insulin, triglycerides (mmol/L), triglycerides (mmol/L), Leptin (ng/ml), Adiponectin 
(ng/ml), Lipase (U/L), Free fatty acids (FFA) (µmol/L); (F) Serum levels of inflammatory 
markers; (G) The fold change in hepatic mRNA levels in LITA compared to control groups; 
(H) Expression of HDAC proteins (normalised to β-actin); (I) Expression of histone residues 
(normalised to total histone). Data analysed by Student’s t-test or two-way ANOVA with 
Bonferroni post hoc test; n=8/group; * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Supplementary Figure 5 - The reparative effects of LITA nanoparticles in mice placed 
on a HFD diet. Mice were placed on a high fat diet (HFD) for 5 weeks. Chronic injections 
then began every three days with either liposome encapsulated acetate (LITA) nanoparticles 
or control (HEPES) for an additional 5 weeks (n=8/group). (A) Organ weight, (B) Microarray 
data; n=8/group; *=p<0.05, **=p<0.01, ***=p<0.001. Data analysed by 2-way ANOVA with 
Bonferroni post-hoc test (GraphPad Prism).  
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Figure 3 - The preventative effects of LITA nanoparticles in mice placed on a HFD diet. 
Mice were placed on a high fat diet (HFD) and injected every three days with either liposome 
encapsulated acetate (LITA) nanoparticles or control (HEPES) for 6 weeks. Overall change 
in; (A) Body weight (g), (B) Whole body adiposity, (C) IHCL. Fed and fasted levels of plasma 
(D) Plasma lipids (mmol/L) (n=12/group), (E) Fed and fasted levels of serum glucose and 
insulin (n=18/group), (F) Fold change in adipose tissue mRNA expression in LITA compared 
to control animals (n=6-8/group) (G) Fold change in hepatic mRNA expression in LITA 
compared to control animals (n=6-8/group), genes grouped by function. (H) H&E staining of 
liver cross-section. Data analysed by 2 way ANOVA with Bonferroni test for multiple 
comparisons (GraphPad Prism); n=24/group; * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Supplementary Figure 6 - The preventative effects of LITA nanoparticles in mice 
placed on a HFD diet. Mice were placed on a high fat diet (HFD) and injected every three 
days with either liposome encapsulated acetate (LITA) nanoparticles or control (HEPES) for 
6 weeks. (A) Average weekly food intake (g), (B) A glucose tolerance test (GTT) was 
performed following an overnight fast at the start of week 5 (n=10/group). (C) Additional 
circulating peptides (Adiponectin (ng/ml), ghrelin (ng/ml) and GIP (ng/ml) (n=6/group), Leptin 
(pg/ml), and interleukin-6 (pg/ml) (n=18/group), (D) Serum concentrations of 3 markers of 
liver function: Alanine transaminase (ALT), Aspartate transaminase (AST) and Alkaline 
phosphatase (ALP) (all U/L) (n=12/group); n=24/group; **=p<0.01; Data analysed by 2 way 
ANOVA with Bonferroni post-hoc test (GraphPad Prism).  
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Supplementary Figure 7 - The effects of chronic LITA nanoparticle administration on 
mitochondrial morphology and oxidative phosphorylation. Mitochondrial morphology of 
mice placed on a HFD and injected with either LITA or control nanoparticles for 6 weeks, (A) 
A representative transmission electron microscopy image (TEM) obtained at 1200x 
magnification used to calculate the number mitochondria, (B) A representative TEM image at 
4800x magnification used to calculate the number cristae per mitochondrion, (C) Number of 
mitochondria per image, (D) Number of cristae per perimeter length of mitochondrion 
(n=4/group); The mean fluorescence intensity (MFI) of oxidative phosphorylation complexes 
1, III and V in control and LITA injected mice from (E) Preventative HFD and (F) Preventative 
NFD studies; n=12/group; data analysed by 2-way ANOVA.  
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Figure 4 - The preventative effects of LITA nanoparticles in mice placed on a NFD diet. 
Mice were placed on a normal fat diet (NFD) and injected every three days with either 
liposome encapsulated acetate (LITA) nanoparticles or control (HEPES) for 6 weeks. Overall 
change in(A) Body weight (g), (B) Whole body adiposity, (C) IHCL. Fed and fasted levels of 
plasma (D) Plasma lipids (mmol/L) (n=6/group), (E) Fed and fasted levels of serum glucose 
and insulin (n=8/group), (F) Fold change in adipose tissue mRNA expression in LITA 
compared to control animals (n=6/group) (G) Fold change in hepatic mRNA expression in 
LITA compared to control animals (n=6/group), genes grouped by function. (H) H&E staining 
of liver cross-section. Data analysed by 2 way ANOVA with Bonferroni test for multiple 
comparisons (GraphPad Prism); n=24/group; * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Supplementary Figure 8 - The preventative effects of LITA nanoparticles in mice 
placed on a NFD diet. Mice were placed on a normal fat diet (NFD) and injected every three 
days with either LITA nanoparticles or control (HEPES) for 6 weeks. (A) Average weekly 
food intake (g) (n=24/group), (B) A glucose tolerance test (GTT) was performed following an 
overnight fast at the start of week 5 (n=10/group). (C) Additional circulating peptides 
(Adiponectin (ng/ml) (n=6/group), C-peptide (pg/ml), ghrelin (pg/ml), GIP (pg/ml), glucagon 
(pg/ml), insulin (pg/ml), Leptin (pg/ml), MCP-1 (pg/ml), Resistin (ng/ml), interleukin-6 (pg/ml) 
and TNF-α (pg/ml) (n=12/group), (D) Serum concentrations of 3 markers of liver function: 
Alanine transaminase (ALT), Aspartate transaminase (AST) and Alkaline phosphatase (ALP) 
(all U/L) (n=6/group). (E) Weights of adipose tissue depots (n=12/group). **=p<0.01; Data 
analysed by 2 way ANOVA with Bonferroni post-hoc test (GraphPad Prism). 
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Supplementary Figure 9 - The subsequent effects of LITA nanoparticles on respiratory 
and ambulatory parameters as measured by CLAMS metabolic cages. C57BL/6 mice 
were injected daily with either control liposomes or LITA nanoparticles for seven days and 
then individually housed in CLAMS metabolic cages for 48 hours. (A) VO2, (B) VO2, (C) 
RER, (D) Heat, (E) XAMB, (F) ZTOT. The 12-hour light/dark cycle is indicated by the open 
(light) and black (dark) bars below each graph. Results are mean ± sem; data analysed by 
the Mann-Whitney U test; n=8/group; *=p<0.05. 
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Figure 5 - The effects of LITA nanoparticles in murine HT-29 colorectal tumours. Mice 
were inoculated with HT-29 colorectal cancer cells and were injected every three days with 
either LITA nanoparticles or control (HEPES) nanoparticles for 4 weeks, once tumour was 
confirmed palpable. (A) Representative tumour grafts from LITA and Control injected 
animals, (B) Tumour size (mm2), (C) Tumour weight (mg), (D) Tumour volume (mm3) during 
the 4 week protocol, (E) Quantitative mRNA changes in xenograft tumour after chronic LITA 
administration normalized to control HEPES liposomes. Data analysed by Student’s t-test or 
two-way ANOVA with Bonferroni post hoc test (GraphPad Prism); n=6/group; * = p<0.05, ** 
= p<0.01, *** = p<0.001. 
 
 
 
Control LITA
0
50
100
150
200
250
300
350
*
Tu
m
ou
r s
iz
e 
(m
m
2 )
Control LITA
0.0
0.1
0.2
0.3
0.4
**
Tu
m
ou
r w
ei
gh
t (
m
g)
0 1 2 3 4
0
50
100
150
200
250
300
350
LITA
Control
Time (week)
Tu
m
ou
r V
ol
um
e 
(m
m
3 )
LITAControl
A B C
D
HD
AC
1
HD
AC
2
HD
AC
3
HD
AC
4
Sir
T1
Sir
T2
-16
-12
-8
-4
0
4
8
* * *** ** *
Fo
ld
 c
ha
ng
e 
in
m
R
N
A 
ex
pr
es
si
on
E
340 
 
 
Supplementary Figure 10 – Proposed mechanism of LITA action following hepatic 
delivery. The effects of LITA nanoparticles on key cellular pathways in the cytoplasm and 
mitochondria are shown. LITA nanoparticle administration leads to cellular uptake of acetate 
(grey circles) followed by mitochondrial accumulation of acetyl-CoA. Colour coded arrows 
represent the effects of LITA delivery; white arrows indicate down-regulation, black arrows 
indicate up-regulation. FAS: fatty acid synthesis; LCFA: Long chain fatty acids; VLDL: very 
low density lipoprotein	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